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Scope of the Series
Biochemistry, the study of chemical transformations occurring within living organ-
isms, impacts all of life sciences, from molecular crystallography and genetics, to 
ecology, medicine and population biology. Biochemistry studies macromolecules - 
proteins, nucleic acids, carbohydrates and lipids –their building blocks, structures, 
functions and interactions. Much of biochemistry is devoted to enzymes, proteins 
that catalyze chemical reactions, enzyme structures, mechanisms of action and 
their roles within cells. Biochemistry also studies small signaling molecules, co-
enzymes, inhibitors, vitamins and hormones, which play roles in the life process. 
Biochemical experimentation, besides coopting the methods of classical chemistry, 
e.g., chromatography, adopted new techniques, e.g., X-ray diffraction, electron 
microscopy, NMR, radioisotopes, and developed sophisticated microbial genetic 
tools, e.g., auxotroph mutants and their revertants, fermentation etc. More recently, 
biochemistry embraced the ‘big data’ omics systems.
Initial biochemical studies have been exclusively analytic: dissecting, purifying and 
examining individual components of a biological system; in exemplary words of 
Efraim Racker, (1913 –1991) “Don’t waste clean thinking on dirty enzymes.” Today 
however, biochemistry is becoming more agglomerative and comprehensive, setting 
out to integrate and describe fully a particular biological system. The ‘big data’ me-
tabolomics can define the complement of small molecules, e.g., in a soil or biofilm 
sample; proteomics can distinguish all the proteins comprising e.g., serum; metage-
nomics can identify all the genes in a complex environment e.g., bovine rumen. This 
Biochemistry Series will address both the current research on biomolecules, and the 
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Preface
This book provides an overview of the analysis of blood, serum, plasma, urine,
and tissues for a wide variety of substances such as substrates, enzymes, and
hormones, and their use in diagnosis and monitoring of disease. The content
provides qualitative and quantitative analysis of these biological fluids with their
specific chemical constituents or physiologic processes.
The first chapter by Drs. Satish Ramanathan and Chakravarthy Narasimhachar
Srinivas emphasizes the use of electrophoresis as an aid in diagnosing clinical
conditions such as acute and chronic inflammations and various other diseases.
Serum protein electrophoresis, which separates serum proteins into various frac-
tions based on their molecular weight and electric charges, can provide specific
measurements of various serum proteins such as alpha-1 antitrypsin (AT), alpha-
1-chymotrypsin, thyroid-binding globulin, alpha-2 macroglobulin, haptoglobin,
ceruloplasmin, transferrin, low-density lipoprotein, and immunoglobulins (IgG,
IgA, IgM, IgD, and IgE) for diagnostic purposes.
The chapter by Husniza Hussain, Rusidah Selamat, Lim Kuang Kuay, Fuziah Md 
Zain, and Muhammad Yazid Jalaludin highlights the importance of urinary iodine
measurement in diagnosing disease related to this marker.
The chapter by Khushaboo Pandey and Om Prakash Mishra Apart discusses
sample analysis, collection, storage, and preparation. It also discusses various
spectrophotometry, sensors, and chromatographic techniques.
The chapter by Nataša Gros covers the quality of blood collection tubes and examines
the differences in tube characteristics of different brands and different lots. Because
the tubes’ attributes change over their shelf life, the author suggests fast, easy-to-
perform testing procedures using purified water and low-cost equipment.
The chapter by Samreen Riaz and Muhamamd Sohail examines the use of extra
virgin olive oil in reducing lipid profile in diabetes. It reports that this activity may
be due to the oil’s antioxidants. The authors use in silico bioinformatic analysis to
screen and check the therapeutic potential of this plant.
The chapter by Zilton Vasconcelos, Renata Campos Azevedo, Andrea Zin, Luiza
Neves, and Daniela Prado Cunha explores the advancement of serological diagnostic
tools for Zika virus. Reverse transcriptase real-time PCR is suggested as the most
reliable tool for Zika virus infection diagnosis. It detects viral RNA in both biological
fluids and tissues and contributes to clinical case classification for initial description
of developmental changes observed in neonates exposed congenitally to Zika virus.
A detail protocol of standardized hemolytic assay AP100 was elaborated in a chapter
on Semi-Solid Phase Assay for Alternative Pathway Activity Assessment. The
authors aimed to assist laboratories in the developing and low incomes countries by
using this assay. The procedure is essentially the same as AP50 except the two items
mentioned in the book chapter. The chapter by Kheir Eddine Kerboua emphasizes
II
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the many advantages of AP100 over AH50, where AP100 has at least nine applica-
tions in disease diagnosis and follow-up.
The chapter by Yana Sandlers gives an overview of amino acid metabolism-related 
inherited disorders. It presents amino acid analysis for the diagnosis and routine 
monitoring of this category of inborn errors of metabolism.
Finally, the chapter by Wojciech Smętek, Jacek Węgrzyk, Agnieszka Klama-Baryła, 
Wojciech Łabuś, Małgorzata Kraut, Michał Szapski, Mariusz Nowak, and Diana 
Kitala discusses the importance of performing good quality control in accordance to 
good manufacturing practice to produce high-quality, advanced therapy medicinal 
products.
The Editors would like to acknowledge all chapter contributors for their excellent 





Department of Clinical Laboratory Sciences,
College of Applied Medical Sciences,
King Khalid University,
Abha, Kingdom of Saudi Arabia





Serum Protein Electrophoresis and 
Its Clinical Applications
Satish Ramanathan and Chakravarthy Narasimhachar Srinivas
Abstract
This chapter focuses on the principle of electrophoresis and its utilization in
a clinical laboratory. A sincere attempt has been made to discuss about clinical 
applications of serum protein electrophoresis, throwing light on the significance of
serum protein electrophoresis in the management of multiple myeloma. Emphasis
has been made on quality assurance in terms of accuracy and precision in elec-
trophoresis to ensure reliability of patient results. A note on issues with lack of
standardization of reporting of electrophoresis and an insight into global efforts to
standardize the reporting of the assay has been included in this chapter.
Keywords: electrophoresis, gamma globulins, polyclonal, oligoclonal, biclonal,
myeloma
1. Introduction
Serum protein electrophoresis is an electrophoretic method of separating 
proteins present in the serum to various fractions based on their molecular weight
and electric charges. Electrophoresis had been widely used in clinical medicine for
aiding in diagnosis of various clinical conditions like acute and chronic inflamma-
tions, monoclonal gammopathies, nephropathy, liver diseases, etc. This chapter
discusses the clinical applications of serum protein electrophoresis [1] including the
quality control practices and its implications [2].
2. Principle
The separation of proteins by electrophoresis is based on the fact that charged 
molecules usually migrate through a matrix/medium upon application of an electri-
cal field [3]. The rate at which proteins move in an electric field is determined by a
number of factors of the electrophoretic system and the nature of proteins itself. 
Some factors to mention are the strength of the electric field, temperature of the
system, pH of the ions, concentration of buffer etc. [4]. Proteins vary in their size
and shape and have the charges determined by the dissociation contents of their
amino acids. Smaller proteins usually migrate faster, and larger proteins take a
longer time. This physical property of proteins is exploited for its separation by
employing the electrophoretic technique.
The most commonly employed variant of electrophoresis for serum protein sepa-
ration is zone electrophoresis in which the serum proteins are separated into zones or
1
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fractions and interpreted accordingly [5]. There are several support mediums avail-
able for separation of serum proteins including agarose, cellulose acetate, capillary 
medium etc. [6]; when a capillary medium is used, the technique is known as capil-
lary zone electrophoresis (CZE). Capillary electrophoresis is the preferred method 
when compared to its competitors including agarose gel electrophoresis due to the 
following reasons. CZE provides an improved resolution due to the following factors:
a. The use of “electroendosmosis” principle which improves the resolution of 
separation
b. Employing a “high-voltage” electric current which aids in improving the 
throughput (the processing time) and the resolution of protein separation.
Below is an illustration of capillary electrophoresis (Sebia Minicap Flex Piercing) 
(Figure 1). Sebia Minicap Flex Piercing capillary electrophoresis works on the 
principle of capillary electroendosmosis under high-voltage electric current. The Flex 
Piercing model of Sebia CZE aids in testing of human blood with capped tubes which 
in turn eliminates the biohazard xassociated with handling of uncapped samples.
3. Revisiting the basics: an insight into the protein family
Serum proteins are a family of albumin and globulins. Albumin is the major 
fraction synthesized from human liver endogenously and available through various 
dietary sources exogenously including egg, meat, pulses, milk etc. Globulins are a 
group of proteins subclassified into alpha-1, alpha-2, beta-1, beta-2, and gamma 
globulins based on the electrophoretic mobility (Figure 2). The normal biological 
interval of serum total proteins in a healthy adult ranges between 6 and 8 g/dl which 
includes Serum Albumin: 3.5–4.5 g/dl and Globulins: 2.5–3.5 g/dl.
3.1 Albumin
Albumin is a 69 kDa protein. It is the most abundant protein in serum. Albumin 
is synthesized in the liver and functions as a transport protein of various substances 
like bilirubin, enzymes, hormones, drugs etc. It also maintains fluid volume within 
the vascular space. Albumin is the first protein fraction to appear near the anode in 
Figure 1. 
Sebia Minicap flex piercing capillary electrophoresis.
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SPE. Altered levels of serum albumin are associated with various clinical conditions. 
Low levels of albumin are clinically significant and are termed as hypoalbuminemia.
Decreased concentration of serum albumin (hypoalbuminemia) indicates either 
a poor dietary intake (malnutrition) or a decreased production or an increased loss. 
Chronic liver disease is a common clinical condition associated with decreased albu-
min production, and chronic kidney disease (CKD) is the most common disease 
associated with an increased loss of albumin in urine (proteinuria). This clinical 
condition is otherwise known as nephropathy. Other causes of hypoalbuminemia 
include acute and chronic inflammation, critical illness, pregnancy etc.
Apart from hypoalbuminemia which is commonly observed in an electrophoreto-
gram, there are a few variations which can be observed in the in albumin peak including:
a. Bilirubin, Triglycerides if present in high levels in serum may appear as a blunt 
peak which is seen adjacent to the cathode near the albumin peak.
b. Prealbumin (transthyretin)—increased levels of pre albumin, if present due to 
various clinical conditions including several inflammatory diseases is seen as a 
blunt anodal peak distinctly separated from the peak of albumin.
c. A rare variant observed in the albumin peak is bisalbuminemia which is a rare 
condition, with no clinical features, in which the serum contains two albumin 
variants of different electrophoretic mobilities, usually in equal concentra-
tions, though the total concentration of albumin is normal. Bisalbuminemia 
may be hereditary or acquired. The acquired type has been more frequently 
reported in chronic renal disease and pancreatitis and in patient with chronic 
renal disease. Two (rather than one) albumin bands may represent bisalbu-
minemia. Hereditary condition is a rare anomaly caused by a genetic lesion in 
the albumin gene usually a point mutation.
d. Analbuminemia (absence of albumin) is another genetically inherited meta-
bolic disorder and was first described in 1954. This disorder is rare and affects 
less than 1 in 1 million births.
The most important aspect of such albumin variants lies in quantification of an 
albumin peak in such scenarios followed by interpretation and clinical correlation 
(Figure 3).
Figure 2. 
Serum protein family with fractions.
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3.2 Alpha fraction
As electrophoresis proceeds toward the negative portion of the gel (cathode), 
the alpha zone is the next band after albumin. The alpha zone is subdivided into two 
zones: the alpha-1 peak and alpha-2 peak.
The alpha-1 peak consists of alpha-1 antitrypsin (AT), alpha-1-chymotrypsin, 
and thyroid-binding globulin. Alpha-1 antitrypsin is an acute-phase reactant. The 
concentration of alpha-1 antitrypsin increases in conditions of inflammation and 
is usually decreased in patients with alpha-1 antitrypsin deficiency or decreased 
production of globulin in patients with severe liver disease. A rare variant of alpha-1 
antitrypsin is encountered occasionally characterized by a split peak pattern of 
alpha-1 globulins.
The alpha-2 peak consists of alpha-2 macroglobulin, haptoglobin, and cerulo-
plasmin. Alpha-2 macroglobulin accounts for about 3% of the total protein in the 
serum. Because of the variable migration of the haptoglobin types, a2-macroglobu-
lin is often adjacent to, or co migrating with, haptoglobin and is therefore not seen 
as a discrete band.
A distorted pattern of alpha-2 region in electrophoresis is seen commonly in 
conditions of hemolysis, including in vivo and in vitro. The pathophysiology behind 
this pattern is the formation of hemoglobin-haptoglobin complexes in these condi-
tions. This is a physiological adaptive response by human physiology to conserve 
hemoglobin released as a result of RBC breakdown into circulation and hemoglobin 
being a smaller globular protein is bound to be lost in urine. Hence to preserve it, 
haptoglobin is consumed to form complex with hemoglobin which results in the 
formation of a macromolecular protein which is retained in circulation making 
hemoglobin available for the production of RBCs and prevention of anemia.
Haptoglobin and ceruloplasmin are acute-phase reactants, and hence increased 
in acute inflammatory states.
Alpha-2-macroglobulin is increased in nephrotic syndrome and cirrhosis of the 
liver. The elevation of alpha-2 macroglobulin is distinctly evident in nephritic syn-
drome, since it is a bulky molecule, and hence retained in circulation to compensate 
Figure 3. 
Abnormal electrophoretic patterns of albumin zone.
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for the loss of other proteins in urine which is evident in form of proteinuria in 
urine microscopic examination.
Ceruloplasmin is an important copper-binding transport protein produced by 
the liver. Ceruloplasmin concentrations are markedly decreased in conditions of 
Wilson’s disease. The disadvantage of serum protein electrophoresis is that it will 
not aid in the detection of a decreased ceruloplasmin.
3.3 Beta fraction
The beta zone usually is subdivided into two peaks, beta-1 and beta-2 in 
CZE. Beta-1 zone comprises proteins like transferrin and low-density lipoprotein 
(LDL).
Transferrin functions to transport non-heme ferric iron from the gastroin-
testinal tract. Each Transferrin molecule can bind two molecules of free iron. An 
increased beta-1 band is observed in iron deficiency anemia due to an increased 
level of free transferrin and also in pregnancy. Determinations of the transferrin 
levels are useful in distinguishing between iron deficiency anemia (inadequate 
intake or chronic hemorrhage with loss of iron stores) and hemolytic anemia, 
in which transferrin levels are low resulting in a beta-1 peak of low amplitude. 
Transferrin is usually decreased in alcoholic cirrhosis. Transferrin is also decreased 
during renal disease and thermal injuries.
The beta-2 band is mostly composed of complement proteins, C3 and C4. 
Elevated beta-2 zone can be caused in inflammatory states due to activation of 
complement cascade which include C3 and C4 too.
A reduced beta-2 peak intensity can be encountered in an aged sample, since 
the immune complexes are used up and low serum levels of complements are 
evidenced.
Fibrinogen is a protein with molecular weight of 340 kDa protein. Sometimes a 
small fibrinogen band can be seen in serum protein electrophoresis due to the insuffi-
cient clotting or failure to remove the serum from the clot. This fibrinogen band is seen 
between beta-1 and beta-2 regions. This band is also seen in patients who are receiving 
heparin therapy. It is also an important indicator of the sample type being analyzed. 
When plasma is used in the place of serum for protein electrophoresis, fibrinogen 
present in plasma appears in the beta-2 region, and this has the potentiality to interfere 
with the detection of monoclonal gammopathies in such patients (Figure 4).
3.4 Gamma fraction
One of the main clinical implications of serum protein electrophoresis is to aid 
diagnosis of disorders associated with alterations of gamma globulins. Gamma region 
comprises mainly of serum immunoglobulins. The five major classes of immunoglob-
ulins are IgG, IgA, IgM, IgD, and IgE. The immunoglobulins are characterized by the 
presence of two protein moieties named as heavy chain and light chain. The classifica-
tion of immunoglobulin had been made based on the composition of heavy chains, 
while the light chains are of two types including kappa or lambda. Physiologically, 
kappa forms the major light chain fraction among the two.
Various clinical conditions are associated with alteration of gamma globulins 
including:
a. Hypergammaglobinemia (increased serum gamma globulin levels)
b. Hypogammaglobinemia (decreased serum gamma globulin levels)
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Hypergammaglobinemia (gammopathies):
Gammopathy is defined as abnormal proliferation of the lymphoid cells produc-
ing immunoglobulins. There are four types of gammopathies: polyclonal, monoclo-
nal, biclonal, and oligoclonal.
Polyclonal gammopathies are defined as heterogeneous increase in immu-
noglobulins involving more than one cell line, commonly caused by a variety of 
inflammatory conditions (chronic inflammation), infections, chronic liver diseases 
(cirrhosis), chronic kidney diseases, etc.
Monoclonal gammopathies are characterized by a homogenous increase 
produced by clonal population of mature B cells, most commonly plasma cells. 
Monoclonal immunoglobulins seen in these conditions are also known as Para 
proteins. The classic interpretative terminology used in clinical laboratory medicine 
for describing a monoclonal immunoglobulin in SPE is “M” band where M stands 
for monoclonal. Common clinical disorders producing “M” Band in SPE include 
multiple myeloma and plasmacytoma in usually 60% of cases and Waldenströms 
Macroglobulinemia, lymphomas, and leukemia in approximately 10% of cases. 
Certain monoclonal gammopathies produce “M” band in electrophoretic regions 
other than in gamma regions, commonly being beta region especially in case of IgA 
and IgG myeloma.
Biclonal gammopathies are characterized by a double peak in the gamma region. 
This electrophoretic pattern is seen when there is a biclonal proliferation of immu-
noglobulins encountered in multiple myeloma. A biclonal pattern is also seen in 
monoclonal gammopathies associated with IgA and IgG. In such scenarios, these 
immunoglobulins appear as polymerized and monomerized forms which elute as 
biclonal peaks in gamma region or in beta region, respectively (Figure 5).
The oligoclonal pattern of gamma region is characterized by more than two 
peaks evident in the gamma region. This pattern is commonly seen in autoimmune 
disorders, light chain myelomas (characterized by clonal proliferation of light 
chains), amyloidosis, etc. (Figure 5).
Apart from serum immunoglobulin, C-reactive protein (CRP) also is evident in 
the gamma region. C-reactive proteins levels usually increase during inflammatory 
responses.
Apart from the common causes of altered electrophoresis picture specific to the 
particular zones, a sharp distinct peak when evident especially in beta or alpha region 
Figure 4. 
Fibrinogen producing a peak in beta 2 region (from a plasma sample).
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should raise a high index of diagnostic suspicion of multiple myeloma since a few 
monoclonal immunoglobulins shall migrate in these zones too, in contrary to the clas-
sical gamma zone M protein pattern, which is commonly reported in these conditions.
4. Role of SPE in multiple myeloma work-up
According to the International Myeloma Foundation, plasma cell dyscrasias are 
group of plasma cell disorders involving a wide spectrum of pathologies including:
1. MGUS—monoclonal gammopathy of undetermined significance
2. MGRS—monoclonal gammopathy of renal significance
3. Smoldering myeloma
4. Multiple myeloma (which includes various subtypes including nonsecretory 
myeloma (NSMM), light chain myeloma, secretory multiple myeloma)
Criteria for diagnosis and differentiation of the plasma cell disorders based on 
International Myeloma Working Group (IMWG) criteria:
1. Monoclonal gammopathy of undetermined significance (MGUS)
• M protein (Monoclonal band)—<3 g/dl
• Bone marrow biopsy—<10% plasma cells seen
Figure 5. 
Abnormal electrophoretic patterns of gamma zone.
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Figure 5. 
Abnormal electrophoretic patterns of gamma zone.
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• No clinical symptoms/signs
• Normbal free light chain ratio in serum
2. Monoclonal gammopathy of renal significance (MGRS)
• M protein (monoclonal band)—<3 g/dl
• Bone marrow biopsy—<10% plasma cells seen
• Renal disease with elevated serum creatinine
• Normal Free light chain ratio in serum
3. Smoldering myeloma
• M protein (monoclonal band)—<3 g/dl
• Bone marrow biopsy—>10% plasma cells seen
• Abnormal free light chain ratio in serum
• Clinically significant. Clinical diagnosis includes a tetrad of “ÇRAB” 
which stands for (one of the four shall be present):
 ○ C—hypercalcemia
 ○ R—renal abnormalities (elevated creatinine)
 ○ A—anemia
 ○ B—bone lesions
4. Multiple myeloma
• M protein (monoclonal band)—>3 g/dl
• Bone marrow biopsy—>10% plasma cells seen
• Abnormal free light chain ratio in serum
• Clinical diagnosis includes a tetrad of “ÇRAB” which stands for (one of 
the four shall be present):
 ○ C—hypercalcemia
 ○ R—renal abnormalities (elevated creatinine)
 ○ A —anemia
 ○ B—bone lesions
There are exceptions in SPE findings in certain cases of multiple myeloma 
wherein the SPE does not reveal any significant alteration or a clue toward the 
diagnosis.
These variants of multiple myeloma characterized by an abnormal bone marrow 
(increased plasma cells) but a normal SPE are termed as nonsecretory myelomas 
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which account to 1–2% of multiple myelomas. In such cases, an immunoassay of 
free light chains (FLC) in serum provides a diagnostic clue toward NSMM which 
show a significant disproportionate elevation of usually a clone of light chains 
(kappa or lambda) with an alteration in kappa/lambda ratio (normal Ratio is 
between 0.60 and 1.65). A commonly encountered phenomenon with laboratory 
testing of FLC includes “prozone” effect or “hook” effect which occurs due to 
antigen excess and requires appropriate dilution to obtain reliable results.
Bence-Jones protein estimation in urine is an antique piece of laboratory evi-
dence toward multiple myeloma, which is characterized by detection of light chains 
in urine. But since the methodology of testing is manual and does not provide stan-
dardization, this has been replaced by urine FLC analysis in laboratories practicing 
good clinical laboratory practices (GCLP).
One more valiant laboratory investigation which is an essential requisite for 
multiple myeloma work-up includes immunoelectrophoresis.
One common principle employed in immunoelectrophoretic technique involves 
the use of specific antihuman immunoglobulins (e.g., Anti-IgG, Anti-IgA, Anti-
Kappa, etc.) as a preprocessing step which results in precipitation of immunoglobu-
lins if present and disappearance of the band/peak contributed by that specific 
immunoglobulin. Hence this technique is also known as immunosubtraction. This 
technique aids in typing the specific type of immunoglobulin (including the type of 
light chain) contributing to myeloma. This technique is supplemented by quantifi-
cation of serum immunoglobulins by an immunoassay.
4.1 SPE and its clinical significance
SPE is a semiquantitative investigation which involves technical expertise to 
recognize the specific electrophoretic patterns and associate with various clinical 
conditions. This requires a laboratory practice integrated across various divisions of 
laboratory and with respective clinical and ancillary divisions of clinical medicine [1].
With respect to SPE, the laboratory professionals shall act as consultants to 
the clinical consultants. This is possible in scenarios where the clinician does not 
arrive at a provisional diagnosis of a gammopathy and the laboratory picks up the 
diagnostic clue toward gammopathy through an increased serum total protein 
level (<8 g/dl) and an altered serum albumin globulin (AG) ratio (which is usually 
altered in gammopathy). A normal AG ratio ranges between 1.2 and 1.8, while 
there is a significant reduction in the ratio in patients with gammopathy. This 
becomes an incidental finding which leads to a concept of “reflex” testing for 
multiple myeloma work-up including SPE, upon consent from the treating clini-
cian and the patient.
These are some of the common SPE patterns associated with various clinical 
conditions:
• Inflammation: Increased intensity of alpha-1 and alpha-2 with a sharp leading 
edge of alpha-1 may be observed, but with chronic inflammation the albumin 
band may be decreased with increased gamma zone due to the polyclonal 
gammopathy.
• Nephrotic syndrome: The albumin band is decreased due to hypoalbumin-
emia. In addition, the alpha-2 band may be more distinct.
• Cirrhosis or chronic liver disease: A low albumin band due to significant 
hypoalbuminemia with a prominent beta-2 band and beta-gamma bridging 
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is a characteristic feature. In addition, polyclonal hypogammaglobinemia is 
observed.
• Malnutrition: Decreased albumin levels [1].
• Alpha-1 antitrypsin deficiency: Inflammatory condition, pregnancy.
• Hemolysis: Altered electrophoretic pattern of small indistinct peaks in alpha-2 
region.
4.2 Quality assurance in SPE
Quality assurance in SPE is an essential prerequisite to ensure reliability of an 
SPE result [2]. There are two major aspects of analytical quality including precision 
(measure of precision) and accuracy (measure of trueness).
Good clinical laboratory practices demand processing of an internal quality 
control (IQC) for assessment of precision and external quality assurance (EQA)/
proficiency testing (PT testing) for accuracy assessment. IQC is a material which 
can be prepared in house (patient sample) or available commercially and is to be 
processed before a patient sample is taken up for processing.
The clinical laboratory has its responsibility to select and use an IQC which has 
a matrix comparable to patient sample, preferably covering the clinical decision 
point (cut off value that differentiates between a normal and abnormal result). 
EQA is an external assessment of the analytical quality wherein the laboratory 
processes a blinded sample and the results are compared against a reference 
method and/or against the consensus value of other participant laboratories for 
that specific sample.
The laboratory has to hold responsibility in selecting a suitable EQA provider 
who shall preferably be accredited to ISO 17043. If an EQA program is not available, 
the laboratories shall participate in exchange of samples with referral laboratories 
with a similar methodology and a comparable quality of testing standard.
5. Reporting of results and its standardization
Reporting SPE requires interpretation of the electrophoretic pattern which is 
followed by comments of such an interpretation along with the piece of advice to 
the clinician if indicated. There is a big lacuna in the format of reporting of SPE, 
each laboratorian using his/her own means of interpreting and communicating. It 
is the need of the hour to have a standardized format of reporting SPE for ensuring 
patient safety and clinician follow-up. There are no international guidelines, though 
the working party on standardized reporting of protein electrophoresis which is an 
initiative of the Australasian Association of Clinical Biochemists has come out with 
a standardized format of reporting SPE.
6. Conclusion
In the current scenario, it becomes the responsibility of each and every laboratory 
to ensure that all relevant information is available in a SPE report, easily read, under-
stood, and interpreted by a clinician. This becomes the core of a clinical laboratory 
practice.
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Abstract
Many reports or manuals had focused on the implementation of iodine deficiency 
disorder (IDD) elimination programme from the point of view of the programme 
managers. In this chapter, we will focus on the importance of urinary iodine testing, 
its related diagnosis and further biomarker testing suggested for further diagnosis 
related to thyroid health. This chapter will be relevant for the respondents to the 
monitoring programme, particularly the 8–10-year-old schoolchildren and pregnant 
women, i.e., the vulnerable targeted groups from either the iodine-deficient areas 
or the Universal Salt Iodization (USI) gazetted areas. USI has been proposed by the 
World Health Organization (WHO) as the most cost-effective programme to elimi-
nate IDD, and it is also a way to increase the intelligent quotient (IQ ) of the world 
population for the future. This chapter had been laid out so that the readers will know 
briefly the rationale behind the testing of urinary iodine among schoolchildren and 
pregnant women under the implementation of the USI programmes in their countries 
and their benefits, especially the utilisation of urinary iodine as the biomarker to por-
tray the population iodine status. Diagnosis including iodine-induced thyroid diseases 
and further biomarkers measurement besides urinary iodine is also discussed briefly.
Keywords: urinary iodine, biomarker, iodine nutrition, population, thyroid status
1. Introduction
1.1 Importance of urinary iodine testing to determine population iodine nutrition
All iodine in the blood is in the iodide form either it is taken up by the thyroid 
and converted into thyroid hormone or being excreted in the urine. Almost 90% of 
the ingested iodine is excreted in the urine. Therefore, urinary iodine excretion is 
a good biomarker of very recent dietary iodine intake [1]. On an individual basis, 
24-hour urine sample is necessary for the assessment of iodine intake as the level is 
more consistent in iodine-deficient populations than in those with adequate iodine 
intake (Figure 1). On a population basis, the median urinary iodine concentration 
(mUIC) of spot urine from sufficiently large randomly selected 8–10-year-old chil-
dren or adults has been shown to provide useful information on the average iodine 
intake or status of a community. On an individual basis, urinary iodine varies from 
day to day and even within a given day. However, this variation tends to even out 
among population [2]. Most of the epidemiological IDD studies had emphasised on 
rapid inexpensive methods of urinary iodine determination that could be applied to 
a large number of samples [3].
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The main biochemical indicator that is widely used for the assessment of IDD 
is urinary iodine concentration (mUIC) [4]. The advantages of mUIC as an indica-
tor of IDD are that the method directly reflects iodine supply of the individual, 
it is objective and non-invasive and urine samples can be kept for later analysis. 
However, the disadvantages of this method are that it requires laboratory space, 
special facilities and skilled technician to provide accurate determinations. In addi-
tion, this method reflects only current but not past intake of iodine [5].
Epidemiological studies stated that the population distribution of urinary iodine 
is required rather than individual levels. The frequency distribution of urinary 
iodine usually skewed towards elevated values; hence, the median value is consid-
ered instead of the mean as indicating the status of iodine nutrition [1]. The mUIC 
of 100 μg/L and above defines a population which has no IDD; i.e. at least 50% of 
the sample should be >100 ug/L. In addition, not more than 20% of sample should 
be below 50 μg/L. Iodine nutrition status is based on six categories of urinary excre-
tion classification (Table 1) [3].









Epidemiological criteria for assessing IDD in a population based on median urinary iodine concentration.
Figure 1. 
Degrees of iodine intake (iodine nutrition status) and their suitable types of human sample collection to 
determine the median urinary iodine concentration (mUIC).
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1.2 Iodine role in thyroid hormone synthesis and its contribution to human body
1.2.1 Thyroid hormone synthesis
Iodine is grouped under micronutrients, and it is needed in small amount, 
but it is very important for the development of optimum human growth. Iodine 
is needed in the synthesis of thyroid hormones [6]. Through iodination, one, 
two, three or four iodine atoms are bound to tyrosine to form monoiodothy-
ronine (MIT), diiodothyronine (DIT), triiodothyronine (T3) or thyroxine 
(T4), respectively, through the action of iodinase enzyme. Iodine is absorbed 
from the gastrointestinal system, will enter the blood circulation and will be 
transported into the thyroid follicle cells through the sodium/iodine (Na/I) 
symporter. In iodide form, it will then be transported to the thyroid follicle 
colloid through pendrin. Concurrently, thyroglobulin (TG) is being synthesised 
in the endoplasmic reticulum (ER) and being secreted into the follicle colloid 
through exocytosis. TG is the transporter protein of the thyroid hormones in 
the thyroid follicle colloid. It consists of branches of tyrosine molecules which 
will then be bound to iodine through the iodination process, forming the MIT 
and the DIT. When one MIT and one DIT bind, T3 will be formed, while upon 
binding of two DITs, T4 will then be formed. These TG-bound thyroid hormones 
will enter the thyroid follicular cell through endocytosis. TG will then undergo 
proteolysis, and T3 and T4 will be transported into the blood circulation through 
the MCT symporter [7] (Figure 2).
1.2.2 Iodine’s contribution to human body
Iodine is a micronutrient which is present in the body in minute amount. The 
quantity of iodine required by an individual is about 150–200 μg/day [8]. Its 
main role is in the synthesis of thyroid hormone which is essential for the brain 
Figure 2. 
Thyroid hormone synthesis in the thyroid gland (image reproduced with permission from the rights holder, 
Journal of Thyroid Research) [13].
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and physical development [9]. The regulation of thyroid hormones is under the 
control of the pituitary gland through thyroid-stimulating hormone (TSH). TSH 
secretion is regulated by a ‘feedback’ mechanism related to the level of thyroid 
hormones thyroxine [3,5,3′,5′-tetraiodothyronine (T4)] in the blood. Iodine is 
needed in the human body, and as the blood T4 falls, the pituitary TSH secretion 
is increased. In severe iodine deficiency disorders (IDD), the level of T4 remains 
lowered, and the level of TSH remains elevated. Both these measurements are 
used for diagnosis of hypothyroidism due to IDD at various stages in life particu-
larly in neonates [10].
2. Iodine deficiency disorders (IDD) and symptoms
2.1 Causes of IDD
Most of the iodine exists in the ocean and seafood, including saltwater fish, 
shellfish, kelp, seaweed and seaweed products which can provide a considerable 
amount of iodine [11]. Iodine exists in the sea and the soil as iodide. Iodide ions 
are oxidised by sunlight to elemental iodine which is volatile. The iodine cycle 
in nature is complete if the concentration of iodide in the seawater is about 
50–60 μg/L, approximately 0.7 μg/m3 in the air, and the iodine in the atmo-
sphere is returned to the soil through rain, with concentrations in the range of 
1.8–8.5 μg/L. Iodine deficiency occurs in the soil when the return of the iodine 
to the soil is slow and in small amount compared to the original loss of iodine. 
Hence, all crops grown in this soil will be iodine deficient [12]. Low levels of 
iodine in the diet for people who do not get enough iodine from their food may 
lead to health problems collectively referred to as iodine deficiency disorders 
(IDD) [14].
2.2 The problem of IDD to human population
IDD is a major public health problem for population throughout the world 
which affects human from early foetal life through to adulthood [15]. Although 
IDD can affect any person of any age, pregnant women and children are the 
most vulnerable high-risk group for IDD [16]. Iodine requirement is high dur-
ing pregnancy; it may increase by 50% because of increased maternal thyroxine 
production [14].
IDD in the foetus is the result of IDD in the mother, and this condition is 
associated with greater incidence of stillbirths, abortions, congenital abnormalities, 
neurological cretinism and psychomotor defects (Figure 3). In neonate, apart from 
mortality, the continuing severe IDD may affect the brain and physical develop-
ment. Low birth weight is normally associated with a higher rate of congenital 
anomalies, and there were also evidences on substantial fall in infant mortality with 
improved birth weight following the iodized oil injection. IDD in the child and ado-
lescent is associated with juvenile hypothyroidism, impaired mental function and 
retarded physical development. Studies on schoolchildren living in iodine-deficient 
areas indicated impaired school performance and IQs [17], while IDD in the adult 
had effects on their individual capacity, initiative and decision-making (Figure 3). 
These results indicate that IDD can be a major obstacle to human and social devel-
opment of population living in an iodine-deficient environment. Therefore,  
correction of iodine deficiency is considered as a major contribution to population 
development [18].
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3. Iodine needs in pregnant women and their foetuses
Pregnant woman is one of the most susceptible groups for iodine deficiency. 
An adequate intake of iodine in the diet of pregnant woman is important to ensure 
normal growth and development of the foetus. During pregnancy, iodine requirement 
increases substantially to ensure adequate supply to the foetus particularly for healthy 
brain development. Iodine deficiency during pregnancy can cause maternal and foetal 
hypothyroidism and impairs neurological development of the foetus since it is second-
ary to transplacental passage of iodide. The consequences depend upon the timing and 
severity of hypothyroidism; the most severe manifestation is cretinism [14].
Since most foods have relatively low iodine content, Universal Salt Iodization 
(USI) programmes are executed. However, in countries or setting where USI is not 
possible, other mode of iodine supplementation needs to be implemented. It is difficult 
to accurately quantify iodine intakes using traditional methods of dietary assessment 
in terms of the contribution of iodized salt use from table and cooking to total iodine 
intake. In view of the limitations of dietary assessment for adequate iodine, a mUIC 
Figure 3. 
Effect of iodine deficiency and the spectrum of IDD across the life span (clinical presentation) in various age groups, 
i.e. foetus, neonate, infant, child, adolescent and adult.
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of 150–249 μg/L has been established to determine the adequate iodine status among 
pregnant women. However, the large intra-individual variation in UIC  
from either spot or 24-hour urine samples means that UIC cannot be used to assess 
iodine status in an individual pregnant woman. Therefore, the association between iodine 
status in pregnancy and the developmental outcome of the individual child is rather 
difficult to be assessed.
4.  IDD elimination programme worldwide and Universal Salt Iodization 
(USI) programme
Universal Salt Iodization (USI) is currently the most widely used strategy 
towards sustainable control and elimination of IDD. There was a significant prog-
ress since the adoption of USI as a primary strategy to address IDD in 1993. Iodizing 
table salt is one of the best and least expensive methods of preventing IDD. Salt 
is used as a key vehicle as it is widely available and consumed in a regular amount 
throughout the year apart from a very low cost of salt iodization with US$ 0.05 per 
person per year [1]. This strategy has been implemented in most countries where 
iodine deficiency is a public health problem.
Various concerted global efforts have also been undertaken to eliminate IDD. This 
includes extensive advocacy from the international partners/alliances such as 
the WHO, UNICEF and ICCIDD (International Council for Control of Iodine 
Deficiency Disorders). These alliances have been in the forefront in helping coun-
tries to set up national salt iodization programmes. As reported by WHO/UNCEF/
ICCIDD, there are currently 65 countries worldwide implementing USI as an effec-
tive strategy to eliminate IDD [3]. However, an effective USI in correcting iodine 
deficiency adequately through iodized salt must reach the whole affected population 
including pregnant women and children. Therefore, close and regular monitoring of 
iodized salt at various levels from the production, importation, retailer and house-
hold is crucial. Such monitoring requires close collaboration between the govern-
ments, salt industries and importers. In countries or areas within countries where 
USI is not possible, iodine supplementation needs to be implemented and especially 
targeted to pregnant women and children until USI is scaled up.
5. Urinary iodine results and their implications
Upon consumption, the needed amount of iodine is retained in the body, while 
excess iodine is excreted. Thus, high urinary iodine concentration does not reflect 
a disease state yet, but if persists on repeated urine sample, further blood tests is 
recommended. Urinary iodine reflects the food consumption taken overnight, and 
it is just an immediate biomarker (short-term reflection) for iodine intake. Thus, the 
long-term reflection of iodine intake will be more representative by measuring blood 
thyroglobulin (TG) as it is synthesised parallel to the amount of iodine present in the 
thyroid follicular cells. The very low or high individual urinary iodine readings will 
usually be repeated for testing to ensure that it is replicating the first reading.
6.  Other blood biomarker measurement to support iodine-deficient 
status determined through urinary iodine measurement
For respondents with high mUIC, other biomarkers such as blood thyroglobulin 
(TG), thyroid-stimulating hormone (TSH), thyroid hormones (free thyroxine, fT4; 
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free triiodothyronine, fT3) and thyroid antibodies, thyroid peroxidase antibodies 
(TPO Ab) and thyroglobulin antibodies (TgAb) are thus suggested for further 
diagnosis. Brief information on these biomarkers is as stated below:
6.1 Free thyroxine (fT4) and free triiodothyronine (fT3)
T4 is a molecule of thyronine bond to four atoms of iodine, while T3 has three 
iodine atoms. T4 is more abundant than T3, but through deiodinase activity, the more 
potent T3 is synthesised. Low level of T4 usually indicates hypothyroidism. For clini-
cal biochemistry free T4 (fT4) and free T3 (fT3) are usually measured as these are the 
biologically active forms. Reference intervals for fT4 and fT3 are as stated in Table 2.
6.2 Thyroid-stimulating hormone (TSH)
TSH is released upon the induction by thyrotropin-releasing hormone (TRH), 
secreted from the hypothalamus. TRH is secreted when serum T3 and/or T4 is low. 
TSH induces the production of thyroid hormones T3 and T4. Low level of TSH 
usually indicates hyperthyroidism (parallel to high levels of T3 and/or T4) [17]. 
Reference interval for TSH is as stated in Table 2.
6.3 Thyroglobulin (TG)
TG is the globulin where binding of iodine to tyrosine to form thyroid hormones 
takes place. It is the long-term biomarker for iodine status in a human, besides 
urinary iodine as the short-term biomarker for iodine nutrition.
The median for reference interval for dried blood spot (DBS) TG from 5- to 
14-year-old children before intervention of iodized salt is 49 g/L. After using 
iodized salt for 5 months, the DBS-TG decreased to 13 g/L and further decreases to 
8 g/L after 10 months of consumption of iodized salt [20].
6.4  Thyroid antibodies [thyroid peroxidase antibodies (TPO Ab) and 
thyroglobulin antibodies (TgAb)]
This antibody is for binding to the antigen thyroid peroxidase (TPO) enzyme 
which is responsible for thyroid hormones synthesis. Once the enzyme is bound 
to the antibody, less free unbound enzymes are available for thyroid hormone 









TSH, mIU/L 1.31 0.05–14.50 0.30–3.63 1.36 0.12–5.29 0.40–3.77b
T4, nmol/L 101.00 52.10–209.00 71.50–158.00 98.30 61.80–173.00 70.50–157.00
T3, nmol/L 1.77 0.89–4.00 1.23–2.80 1.77 0.89–3.96 1.27–2.79
FT4, pmol/L 16.20 8.24–28.60 12.70–20.80 16.20 9.30–24.70 12.80–20.40
FT3, pmol/L 5.10 2.52–9.96 3.89–6.66 5.13 2.52–9.96 4.02–6.79
aData are reported as empirical percentiles.
bThe lower limit of the TSH reference interval in the constraint group was >5% different from the comparable limit 
of the whole group.
Table 2. 
Reference intervals for thyroid hormones from subjects with normal thyroid gland assessed sonographically 
(table reproduced with permission of the rights holder, Clinical Chemistry) [19].
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of 150–249 μg/L has been established to determine the adequate iodine status among 
pregnant women. However, the large intra-individual variation in UIC  
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table salt is one of the best and least expensive methods of preventing IDD. Salt 
is used as a key vehicle as it is widely available and consumed in a regular amount 
throughout the year apart from a very low cost of salt iodization with US$ 0.05 per 
person per year [1]. This strategy has been implemented in most countries where 
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synthesis, thus causing lower thyroid hormone production. TgAb is the antibody for 
the globulin TG. With the presence of elevated amount of TgAb, the thyroglobulin 
(TG) will bind to its antibody, and lesser TG is available to bind to the thyroid hor-
mones for transportation in the blood vessels, thus causing lesser thyroid hormones 
being circulated in the human body [21]. The reference intervals are 15 kIU/L for 
TPOAb and 31 kIU/L for TgAb [22] (Figure 4).
7. Diagnosis for the iodine-induced thyroid dysfunction in respondents
Both insufficient and excessive iodine intake can result in thyroid dysfunctional 
diseases. If the thyroid diseases are due to iodine-induced phenomena, the main 
management is to avoid or reduce iodine intake, followed by the appropriate drugs 
if symptomatic or there is abnormality with the thyroid function test (TFT) results.
7.1 Iodine-induced hypothyroidism
Iodine-induced hypothyroidism can occur in normal individuals and in those 
with chronic systemic disease and underlying thyroid disorders. It has been seen in 
patients who had a history of post-partum thyroiditis and subacute thyroiditis and in 
those treated with recombinant interferon-alpha. The hypothyroidism was described 
as transient, and thyroid function returns to normal in 2–3 weeks after iodide with-
drawal. Some patients may require transient T4 replacement therapy [23].
7.1.1 Clinical presentation
The presenting clinical features of hypothyroidism depend on the duration and 
severity, the nature of its onset and the patient’s psychological characteristics [24]. 
The following are the signs and symptoms of hypothyroidism:
Figure 4. 
Subsequent biomarker testing and further action for individual and population urinary iodine estimation.
21
Urinary Iodine: Biomarker for Population Iodine Nutrition
DOI: http://dx.doi.org/10.5772/intechopen.84969
• Fatigue
• Weight gain from fluid retention
• Dry skin and cold intolerance
• Yellow skin
• Coarseness or loss of hair
• Hoarseness
• Goitre
• Reflex delay, relaxation phase
• Ataxia
• Constipation
• Memory and mental impairment
• Decreased concentration
• Depression
• Irregular or heavy menses and infertility
• Myalgias
• Hyperlipidaemia
• Bradycardia and hypothermia
• Myxoedema fluid infiltration of tissues
7.1.2 Diagnosis
When there is clinical suspicion of hypothyroidism, a thyroid function test should 
be performed. Measurement of TSH level is the primary test to confirm primary hypo-
thyroidism. Other laboratory evaluation may include free T4 and thyroid antibodies 
(anti-thyroid peroxidase and anti-thyroglobulin autoantibodies). Imaging studies to 
evaluate any structural thyroid abnormalities include a thyroid scan, ultrasonography 
or both [24]. When iodine deficiency occurs during pregnancy, it is associated with 
foetal hypothyroidism, mental impairment and increased neonatal and infant mortal-
ity [25]. In adults, iodine-induced hypothyroidism is rare. The most common manifes-
tation is goitre. Low iodine intake leads to reduced T4 and T3 production which results 
in increased TSH secretion in an attempt to restore normal T4 and T3 production. TSH 
also stimulates thyroid growth leading to goitre. The goitre is initially diffuse but pro-
gresses to nodular goitre and eventually to thyroid autonomy and possible hyperthy-
roidism [26]. Excess iodine ingestion or exposure above the limit of the recommended 
daily iodine intake induces thyroid dysfunction. Iodine-induced thyroid dysfunction 
may be subclinical or overt. Excess iodine is generally well tolerated. However, 
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individuals with underlying thyroid disease or other risk factors may be susceptible to 
iodine-induced thyroid dysfunction following acute or chronic exposure.
7.1.2.1. Predisposing risk factors in iodine-induced hypothyroidism
Individuals with underlying thyroid disease:
a. Euthyroid Graves’ disease previously treated by radioactive iodine, thyroidectomy 
or anti-thyroid drugs
b. Hashimoto’s thyroiditis
c. Euthyroid with a history of subacute thyroiditis
d. Euthyroid with a history of post-partum thyroiditis
e. Euthyroid with a history of type 2 amiodarone-induced thyrotoxicosis
f. Euthyroid posthemithyroidectomy
g. Euthyroid after interferon-alpha therapy
The spectrum of iodine deficiency disorders (IDD) is seen across the life span in 
various age groups, i.e. foetus, neonate, infants, child, adolescent and adult. They 
include endemic goitre and cretinism, endemic mental retardation, decreased fertil-
ity rate, increased perinatal death and infant mortality and varying degrees of other 
growth and developmental abnormalities (Table 3) [27, 28]. Hypothyroidism due to 
very low iodine intake is now extremely rare. Adults usually have the typical clinical 
manifestations of hypothyroidism and goitres [29].










Increased susceptibility of the thyroid gland to nuclear radiation




Increased susceptibility of the thyroid gland to nuclear radiation
Adult Goitre with its complications
Hypothyroidism
Impaired mental function
Hyperthyroidism in the elderly (after iodized salt)
Source: Refs. [27, 28].
Table 3. 
The spectrum of IDD across the life span.
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7.2 Iodine-induced hyperthyroidism
Iodine-induced hyperthyroidism can occur after intake of excess iodine in 
the diet, exposure to radiographic contrast media for imaging procedures or 
medications [30]. In iodine-sufficient areas, iodine can induce hyperthyroid-
ism in euthyroid patients with previous thyroid diseases. These include patients 
who were treated with anti-thyroid drugs for Grave’s disease and post-partum 
 thyroiditis [31, 32].
7.2.1 Clinical presentation
The severity and spectrum of symptoms and signs of hyperthyroidism may be 
related to the duration of the illness, the effects of excess thyroid hormone and the 
age of the patient [24].
The symptoms and signs include the following:
• Nervousness and irritability
• Palpitations and tachycardia
• Heat intolerance or increased sweating
• Tremor
• Weight loss or gain
• Alterations in appetite
• Frequent bowel movements or diarrhoea
• Dependent lower-extremity oedema
• Sudden paralysis
• Exertional intolerance and dyspnoea
• Menstrual disturbance (decrease flow)
• Impaired fertility
• Mental disturbances
• Sleep disturbances (including insomnia)
• Changes in vision, photophobia, eye irritation, diplopia or exophthalmos
• Fatigue and muscle weakness
• Goitre (depending on cause)
• Pretibial myxoedema
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8. Novel strategies for the vulnerable group
In the Iodine Global Network newsletter published on its website,  
Prof. Dr. Zimmermann had laid out the strategies needed for the vulnerable groups, 
i.e., the newborns, infants and the children. He had suggested that these tests 
should be done on these groups respectively: blood thyroid-stimulating hormone, 
urinary iodine and blood spot thyroglobulin (http://www.ign.org/zimmermann-
calls-for-new-strategies-against-idd.htm). He also suggested using the TSH 
measurement in the newborn screening for iodine assessment. Commonly, iodine-
deficient newborns present with elevated TSH. The WHO reported that if the TSH 
level is greater than 5 mIU/L from the whole blood of 3% of the newborns measured 
after 3–4 days post-birth, this would indicate that the population is iodine deficient. 
Another suggestion made by him was to use the newborns’ urinary iodine as a 
marker of IDD in addition to the current practise of measuring the median urinary 
iodine of the schoolchildren. Using a non-invasive system, urine was collected from 
infants, and study had shown that in 1200 infants, the baseline TSH of 77 μg/L had 
increased to 100 μg/L after 4 days post-birth. In addition to that, a system for col-
lecting young children blood spot was done to measure their TG concentration, and a 
reference range of 4–40 μg/L had been determined. Noteworthy, there are challenges 
in order to establish a specific international reference range among newborns as there 
will be differences between the population from the USI areas and the non-USI areas.
9. Conclusion
Excess urinary iodine is generally well tolerated, but individuals with underlying 
thyroid disease or other risk factors may be susceptible to iodine-induced thyroid 
dysfunction following acute or chronic exposure. Increased iodine exposure includ-
ing the global public health efforts of iodine supplementation, the escalating use 
of iodinated contrast radiologic studies, amiodarone administration in vulnerable 
patients, excess seaweed consumption and various miscellaneous sources should be 
looked for.
Iodine-induced thyroid dysfunction may be subclinical or overt. Recognition 
of the association between iodine excess and iodine-induced hypothyroidism or 
hyperthyroidism is important in the differential diagnosis of patients who present 
without a known cause of thyroid dysfunction.
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Advancement in Analytical and 
Bioanalytical Techniques as a Boon 
to Medical Sciences
Khushaboo Pandey and Om Prakash Mishra
Abstract
The most important objectives frequently found in analytical and bioanalyti-
cal chemistry involve advancement of analytical techniques and its application to 
relevant medical/clinical problems. Keeping in view to these aspects, the present 
chapter is primarily focused on the development of advanced analytical techniques 
applied in the medical field. For example, N-acetyl-beta-D-glucosaminidase (NAG) 
enzyme is a specific biomarker of acute kidney injury. A biomarker is an entity that 
is purposely measured and estimated as an indicator of normal biological process, 
pathogenic process, or pharmacological responses to a therapeutic intervention. 
Hence, successive measurements of urinary NAG may enhance its clinical use as 
an indicator of ongoing tubular injury. Hence, in order to obtain information for 
selective monitoring of biomarker, the development of a practical and valid ana-
lytical method is important. Experimentation is driven by the need to know more 
about the medical effects and safety features of the biologically active analyte. It is 
therefore more important to evaluate the information that is already available for 
that particular analyte and to quantify the level of uncertainty for the proposed 
technique.
Keywords: analytical, bioanalytical, biomarker, clinical, medical, 
N-acetyl-beta-D-glucosaminidase
1. Introduction
This chapter represents a collective attempt to present a wide range of analytical 
techniques applied for the clinical development process. Analytical chemistry is 
concerned with the chemical characterization of matter and refining the qualitative 
and quantitative problem about that matter. It plays a vital role in almost all the 
aspects of scientific research and development, for example, clinical, forensic, envi-
ronmental, and pharmaceutical sciences. In medicine, analytical chemistry is the 
key for clinical laboratory tests which imparts basis of disease diagnosis and chart 
progress for recovery to the physicians [1]. Figure 1 describes the scheme through 
which physicians ruled out or analyze the disease prognosis and therapeutic drug 
monitoring in patients. In accord with this, an analytical chemist also explores the 
idea of developing advanced technique for betterment of human healthcare and in 
sorting out the problems related to the disease diagnosis. Implementation of an ana-
lytical technique mainly depends on the varying degree of selectivity, sensitivity, 
accuracy, precision, cost, and rapidity of that particular technique. The techniques 
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employed may be based either on physical property or chemical property of an 
analyte. An analyte is defined as a constituent which has to be determined in a given 
sample type. The classical analytical techniques include gravimetric, volumetric, 
and titrimetric methods; on the other hand, instrumental techniques involve 
ultraviolet-visible (UV-Vis), infrared (IR), and near-infrared (NIR) spectropho-
tometry fluorimetry, atomic spectroscopy (absorption/emission), electroanalytical 
chromatography, and radioimmunoassay. Instrumental techniques are usually more 
sensitive and selective than classical techniques but are less precise. Precision of 
techniques means the repeatability of a result and is expressed as standard devia-
tion. Selectivity of an analytical method defines the measurement of a particular 
analyte from sample solution to a certain degree, in the presence of other analytes, 
without any interference. However, sensitivity of a method describes the ability to 
recognize two different concentrations.
However, medical and clinical analyses are undergoing the greatest extension 
of instrumental methods [2]. Interest in identifying biologically active compounds 
is growing rapidly and providing new challenges for the analytical chemists. These 
challenges have been resolved by the introduction of bioanalytical technique as 
a modern approach to disease diagnosis and therapy. A bioanalytical method is a 
combination of different procedures which are (i) collection, (ii) processing,  
(iii) storage, and (iv) analysis of a biological sample (blood-cerebrospinal fluid 
(CSF), serum, plasma, or urine, tissue, and skin). This method is also useful for 
quantitative determination of drugs and metabolites in biological samples. For 
that reason, technologies used to perform bioanalytical methods vary according to 
the analyte’s nature. Hence, to find out the appropriate technologies involved in a 
bioanalytical method for the purpose of quantification of an analyte, the method 
validation is important. This procedure is termed as bioanalytical method valida-
tion (BMV). Few techniques commonly applied in bioanalytical studies include 
hyphenated (combination of two techniques) techniques like liquid chromatogra-
phy (LC), gas chromatography (GC), capillary electrophoresis (CE) coupled with 
mass spectrometry (MS), and advanced automated chromatographic techniques, 
for example, high-performance liquid chromatography (HPLC) [3].
During the past decades, the analytes that have been targeted in bioanalytical 
studies include amino acid, peptides, proteins, serum enzyme, tumor and cancer 
genes, carbohydrates, vitamins, catecholamines, cardiac risk factors, etc. [4].  
Figure 1. 
Schematic representation of four common decision making steps in which the result of an investigation is 
involved.
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With the recurrent analysis of biomolecules, numerous analytical techniques and 
instrumentation have been evolved and applied in the field of medical sciences 





• Optical techniques (microscopy)
• Radio- and immunochemical techniques
• Hyphenated techniques
• Point-of-care instrumentation
Biological samples have the potential to deliver important biomarkers in the 
clinic due to accessibility of these biological materials. In clinical development, the 
most important benefit offered by biomarkers is to limit investigational drugs to 
critical care patients who would gain the therapies to observe the effectiveness of 
those drugs [5]. The role of a biomarker is to give information about the biological 
mechanism involved within a disease or treatment of disease having the capabil-
ity to correlate with the clinical findings. One of the most tangible problems that 
research scientists are facing in recent years is finding disease biomarkers that 
are translated well from animal or computer simulation to humans. For example, 
increase in enzyme activity in computer or animal model may have a significant 
impact in theoretical computer or animal model, whereas same enzyme activity 
enhancement may have a very limited or no clinical impact.
There is no denying that “analytical and bioanalytical technique” is a broad topic, 
incorporating technologies from classical chromatography to point-of-care instru-
mentation. But unifying and doing them as quickly, accurately, and inexpensively as 
possible are drives to make chemical or biochemical measurements. Over the preced-
ing sections, we would study the technological improvements along those lines across 
the broad field of analytical methods. Every subsection of analytical techniques 
applied in medical field has experienced improvement and advancement as well.
Researchers are interested in mapping the neural connectivity of the brain 
through scanning electron microscopy (SEM). This could be now employed with 
more powerful microscopes, such as focused ion beam and multi-beam SEM, 
to collect serial images of ultrathin brain slices [6]. They can now build surface 
plasmon resonance substrates out of silver rather than the more typical gold and an 
SPR microscope to image and quantify 1296 binding events in parallel [7]. Those 
scientists who are interested in surface properties can now scan those surfaces faster 
than ever, thanks to high-speed atomic force microscopy [8].
2. Sample collection and storage
We have to keep in mind that biological samples, collected from the patients, 
must be transported to the initial assessment center as soon as possible.  
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The type of preservatives should be known to protect the samples from degrada-
tion prior to cryopreservation at a reasonable cost. Cryopreservation is a process 
to store biological samples at very low temperature for prevention of damage. The 
purpose is to find readily accessible and data-rich biological samples. The stability 
of a wide range of bioanalytes and cells as a component of whole blood should be 
estimated, taking into account different anticoagulant (inhibition of coagulation 
of blood) media, at different temperatures and under varying transport condi-
tions. Bioanalytes can be known biochemicals, such as DNA, defined proteins, and 
specific metabolites, or unknown analytes, such as the constituent plasma/serum 
proteome and metabonome [9].
Design and testing of the sample handling protocol considered as key factors that 
affect the stability of biological samples, including anticoagulants, stabilizing agents, 
and temperature, elapsed time from collection to initial processing and endogenous 
degrading properties (enzymes, cell death). We also aim for cost-efficiency by 
avoiding collecting multiple sources of material for the same analyte. The samples 
undergo minimal processing locally in the assessment centers before being shipped 
to the main laboratory for processing with the aim of cryopreservation within 24 h 
of collection. Samples are protected against degradation during shipping by being 
chilled at 4°C (only peripheral blood lymphocytes, at 18°C). Once the samples get 
processed in the laboratory, they are placed in cabinets maintained at −80°C for the 
working archive or in nitrogen vapor at −180°C or below for the backup archive.
3. Sample preparation
Biological samples involve plasma, serum, CSF, bile, urine, tissue homogenates, 
saliva, seminal fluid, and frequently whole blood. Quantitative analysis of drugs 
Sample preparation techniques Advantages
Liquid phase extraction (LLE) LLE is one of the first methods used for extraction. It depends on the 
partitioning of analytes between two immiscible liquids. The resulting 
extract may be directly analyzed or further purified and concentrated 
by subsequent LLE and evaporations.
Solid phase extraction (SPE) SPE is a method for the isolation and concentration of selected analytes 
from a fluid sample by their transfer on a solid phase. The analytes 
are recovered by elution or thermal desorption. This method has high 
recovery, uses less organic solvent than LLE.
Affinity separation: molecularly 
imprinted polymers (MIPs)/
antibodies
The affinity sorbent may consist of an immobilized antibody or a 
molecularly imprinted polymer. This technique is highly specific and 
very sensitive, but the sorbent is difficult to prepare; it suffers from 
cross-reactivity and leaking of template.
Solid phase micro extraction 
(SPME)
SPME, a solvent free extraction method, consists of a single extraction 
step, but the experimental variables must be well controlled. It reduces 
solvent and sample volume needs and sample preparation time. 
Improves detection limits i.e., parts per trillion level detection.
Ultrafiltration and microdialysis 
(MD)
Ultrafiltration consists of filtering the sample through a special 
size-excluding filter, either by applying pressure (10–100 psi) or by 
centrifugation. The method is widely used, simple, efficient, but 
suffers from ligand binding to the filter and shift of equilibrium.
Dialysis and MD can be used to separate an analyte by diffusion 
through a semi-permeable membrane.
Table 1. 
Sample preparation techniques used for biological samples [32].
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and metabolites containing huge amounts of proteins and large numbers of endog-
enous compounds within these samples is very complicated. Direct injection of 
drug containing biological sample into a chromatographic column results in the 
precipitation or absorption of proteins on the column packing material, resulting 
in an immediate loss of column performance. A number of advances have made to 
convert sample preparation techniques, used for the cleanup of drugs in biologi-
cal samples into formats that are acceptable for high-volume processing with or 
without automation. The most widely used cleanup methods for separation of 
biomolecules from biological samples are summarized in Table 1.
Because of this, sample preparation became a prominent step in the analysis of 
biological samples. In recent years, the necessity of new developed method is largely 
required. Frequently, it was earlier considered as a separate procedure prior to the 
analysis, while it nowadays has become a more or less integrated part of the analytical 
procedure. It is necessary to lay the foundation of their development on a systematic 
and scientific approach. Thus, fundamental understanding of the different processes 
involved in a sample preparation method is served as a basis for its optimization [10].
We should select the appropriate sample preparation method on the basis of 
requirements of the assay and time allowed to run sample preparation method.
4. Spectrophotometry
The spectrophotometric technique is used to study interactions between elec-
tromagnetic radiations and analyte (Figure 2). The concentration of an analyte is 
determined by using a graph which is called standard analytical curve. An example 
is determination of iron in blood serum. The iron content of blood serum is deter-
mined after deprotonation (by precipitating protein) with trichloroacetic acid 
and reduction with hydroxyl ammonium sulfate. Iron (II) ions are reacted in the 
medium buffered with ammonium acetate and with diphenyl-1,10-phenanthroline-
disulfonic acid disodium salt (bathophenanthroline disulfonate–Na), and the 
absorbance of the complex formed is measured at 535 nanometer. The concentra-
tion belonging to the absorbance data of the test solution is read from the standard 
analytical curve and multiplied by three for threefold dilution [11].
4.1 Optical spectroscopic techniques of human models
Optical spectroscopy for biomedical applications covers up the plethora of 
medical technological and fundamental research areas. This includes screening and 
early detection of diseases which remain clinically silent over long periods. It is a 
noninvasive, fast spectroscopic technique. The technique is also capable of obser-
vations from femtosecond time scale at nanometer spatial resolution, so it can be 
applied in all areas of life sciences. This technique is to make an early, noninvasive, 
and patient-specific diagnosis near the source of the disease and then to treat the 
Figure 2. 
Schematic representation of biological sample determination using spectrophotometric technique.
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size-excluding filter, either by applying pressure (10–100 psi) or by 
centrifugation. The method is widely used, simple, efficient, but 
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procedure. It is necessary to lay the foundation of their development on a systematic 
and scientific approach. Thus, fundamental understanding of the different processes 
involved in a sample preparation method is served as a basis for its optimization [10].
We should select the appropriate sample preparation method on the basis of 
requirements of the assay and time allowed to run sample preparation method.
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The spectrophotometric technique is used to study interactions between elec-
tromagnetic radiations and analyte (Figure 2). The concentration of an analyte is 
determined by using a graph which is called standard analytical curve. An example 
is determination of iron in blood serum. The iron content of blood serum is deter-
mined after deprotonation (by precipitating protein) with trichloroacetic acid 
and reduction with hydroxyl ammonium sulfate. Iron (II) ions are reacted in the 
medium buffered with ammonium acetate and with diphenyl-1,10-phenanthroline-
disulfonic acid disodium salt (bathophenanthroline disulfonate–Na), and the 
absorbance of the complex formed is measured at 535 nanometer. The concentra-
tion belonging to the absorbance data of the test solution is read from the standard 
analytical curve and multiplied by three for threefold dilution [11].
4.1 Optical spectroscopic techniques of human models
Optical spectroscopy for biomedical applications covers up the plethora of 
medical technological and fundamental research areas. This includes screening and 
early detection of diseases which remain clinically silent over long periods. It is a 
noninvasive, fast spectroscopic technique. The technique is also capable of obser-
vations from femtosecond time scale at nanometer spatial resolution, so it can be 
applied in all areas of life sciences. This technique is to make an early, noninvasive, 
and patient-specific diagnosis near the source of the disease and then to treat the 
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disease at primary stage, for example, Alzheimer’s disease and coronary disease. 
Thus, optics offers a wide variety of diagnostic methods and products of biomedical 
spectroscopy [12].
4.2 Absorptions and reflectance spectroscopy
This method involves investigations of brain dysfunction and mental health 
problems like depression, epilepsy, and Alzheimer’s disease [13]. The direct absorp-
tion like near-infrared (NIR) techniques and instrumentation are particularly 
suitable in routine neonatal care applications.
However, diffused reflectance spectroscopy, in the UV-Vis-NIR region, can be 
used for biomedical applications, like studies on skin condition (vitiligo, psoriasis, 
skin cancer) and glucose concentration measurement [14].
4.3 Photoacoustic spectroscopy (PAS)
This includes measurement of concentration of biomolecular species. Examples 
are glucose determination, characterization of tissue status (biopsy tissue), and 
imaging application. PAS can provide information on three-dimensional distribu-
tion of specific molecular species in a specimen, by appropriate choice of excitation 
wavelength [15].
4.4 Raman and infrared spectroscopy
The “fingerprint” molecular specific technique will be of great advantage in 
understanding the biochemical interactions involved in induction, progression, 
therapeutic invention, and regression. This technique is suitable for biomedical 
applications such as breath analysis, drug-cell interaction, microscopy, and imaging 
of biopsy sample (tissue, fine needle aspiration) [16–18].
4.5 Fluorescence spectroscopy
Depending on excitation wavelength, the fluorescence peak has been observed 
in blood and urine spectra. A few examples are spectra observed from epithelial 
tissues, proteins, NAH, FAD, and hemoglobin [19].
4.6 Mass spectrometry
Mass spectroscopy (MS) measures masses within the sample. In mass spec-
troscopy, chemical species get ionized and ions get sorted on the basis of their 
mass-to-charge ratio (Figure 3). Major application of MS includes confirmation of 
immunoassay-positive drug screens, identification of inborn errors of metabolism, 
and analysis of steroid hormones [20]. Conclusive identification of molecules that 
range in size from tens of daltons (small molecules) to hundreds of thousands of 
daltons (biomolecules) is based on different principles.
Discovery of highly sensitive polymerase chain reaction (PCR) was a major 
step forward in the biomedical research and diagnostics. This technique is used for 
analysis of small quantities of short sequences of DNA and RNA without cloning. 
PCR can detect the presence of pathogens earlier than the culture tests. The minia-
turization of MS systems allows a transportable device that minimizes the need of 
highly skilled operators and allows for rapid and accurate MS analysis in a point-of-
care format (near the physician’s clinic) [21].
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4.7 Imaging techniques
Advances in medical imaging present a great opportunity in drug development. 
A number of different imaging technologies are available. These include computed 
tomography (CT), magnetic resonance imaging (MRI), magnetic resonance spec-
troscopy (MRS), positron-emission tomography (PET), and single photon emission 
computed tomography (SPECT). If adequately qualified, imaging biomarkers can 
be very helpful in the early stages of clinical development [22].
5. Sensors
An electrochemical sensor consists of a diffusion barrier, a sensing electrode 
(working electrode, measuring electrode, or anode), a counter electrode (cathode), 
and an electrolyte. Their fabrication includes various types of systems such as con-
ductometry, voltammetry, potentiometry, and capacitance, and it is an important tool 
to detect various analytes in environmental, clinical, and biological fields due to their 
high sensitivity, cheapness, and miniaturization. These sensors have the potential to 
achieve sensitive, specific, and low-cost detection of biomolecules which is relevant to 
the diagnosis and monitored treatment of disease [23]. A few are listed below:
5.1 Potentiometric sensors
Techniques based on measurement of potential sensor are termed as potenti-
ometry, for example, determination of potassium in blood serum by direct poten-
tiometry with an ion-selective electrode. The determination of urea is a frequent 
task of clinical laboratories. The basis of enzyme electrode function is the selective 
recognition of urea by urease enzyme. The following reaction takes place:
  Urea + 3  H 2 O  Urease   ⎯ → 2  NH 4 + +  HCO 3 
−
 +  OH 
−
 (1)
This reaction can be followed using different potentiometric electrodes [24].
5.2 Molecularly imprinted polymer (MIP) sensors
MIP could be one of the important tailor-made systems for targeted analyte recog-
nition exclusively even their presence in complex real biological samples in parts per 
million to parts per billion levels. The general idea is to create the cavity in the presence 
of the guest. The guest organizes and promotes energy-minimized interactions with 
polymer forming around it. Thus, after washing the guest out, the polymers retain 
Figure 3. 
Schematic representation of mass spectrometry detection of sample.
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Discovery of highly sensitive polymerase chain reaction (PCR) was a major 
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analysis of small quantities of short sequences of DNA and RNA without cloning. 
PCR can detect the presence of pathogens earlier than the culture tests. The minia-
turization of MS systems allows a transportable device that minimizes the need of 
highly skilled operators and allows for rapid and accurate MS analysis in a point-of-
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a template cavity of the guest’s size and shape which subsequently display binding 
selectivity toward the guest just like induced-fit model of enzyme (Figure 4). The 
MIP-modified sensors can be used for biological and pharmaceutical analyte determi-
nation from biological samples. An example is the development of a polyscopoletin-
based MIP nanofilm for the electrochemical determination of elevated human serum 
albumin (HSA) in urine. The results suggest that MIP-based sensors may be applicable 
for quantifying high-abundance proteins in a clinical setting [25].
5.3 Biosensors
The need for rapid, simple handheld testing devices in medicine paves the 
way for introduction of biosensor. Biological sensors are optical, electrical, and 
piezoelectrical devices that have the ability to detect biological compounds, such as 
nucleic acids and proteins [26, 27]. Early diagnosis of inherited disease is important 
for effective treatment and is sometimes lifesaving. Methods, like enzyme-linked 
immunosorbent assay and PCR, can require highly skilled professionals and expen-
sive chemicals and can be time-consuming. In this area, many biosensor schemes 
had developed as an alternative to classical methods.
The latest advancements in nanotechnology result in its application for cancer 
biomarker recognition [28]. Several other biosensors include nanomaterial-based 
biosensors [29], peptide nucleic acid-based biosensors, biosensors for medical 
mycology, optical DNA biosensors, and last but not least, the biosensors for the 
diagnosis of heart disease [30].
6. Chromatographic separation techniques
In chromatographic separation technique, various constituents of the mixture 
in the given sample travel at different speeds, causing them to separate. This 
technique involves two phases: a mobile phase and a stationary phase. The separa-
tion mainly depends on the differential partitioning between these two phases. 
A bonded phase is a stationary phase that is covalently bonded to the support 
particles or to the inside wall of the column tubing. The stationary phase is the 
substance fixed in place for the chromatography procedure, and the mobile phase 
is moving in a definite direction [31]. Examples include the silica layer in thin 
Figure 4. 
Synthesis of molecularly imprinted polymer.
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layer chromatography (TLC). Archer John Porter Martin and Richard Laurence 
Millington Synge won a Nobel Prize in chemistry for chromatography invention 
[32]. Their work encouraged the rapid development of several advanced chro-
matographic methods such as paper chromatography, gas chromatography, and 
HPLC. The differences in a compound’s partition coefficient bring about dif-
ferential retention on the stationary phase and thus affect the separation process. 
Chromatography may be preparative or analytical. The preparative chromatog-
raphy separates the components of a mixture for later use and is thus a form of 
purification. Analytical chromatography is done normally with smaller amounts 
of material and is for establishing the presence or measuring the relative propor-
tions of analytes in a mixture. Figure 5 describes a chromatogram for a biological 
system where the signal is proportional to the concentration of the specific analyte 
separated.
Depending upon the shape of stationary phase, chromatography may be  
(i) planar chromatography, having one-dimensional bed support such as paper or 
TLC, or (ii) column chromatography with three-dimensional bed support. TLC is 
useful for separating mixtures of organic compounds and is often used to monitor 
the progress of organic reactions and to check the purity of products.
On the basis of physical state of mobile phase, chromatographic technique may 
be GC or LC. GC can be used to separate mixtures of volatile organic compounds. 
A GC consists of a flowing mobile phase, an injection port, a separation column 
containing the stationary phase, a detector, and a data recording system. LC is 
useful for separating mixtures of ions or molecules that are dissolved in a solvent. 
If the matrix support, or stationary phase, is polar (e.g., paper, silica, etc.), it is 
normal-phase chromatography; and if it is nonpolar (C-18), it is reversed-phase 
chromatography.
In short, chromatography is a method of separating the constituents of a solu-
tion, based on one or more of its chemical or physical properties. This could be 
charge, polarity, or a combination of these traits and pH balance. The solution is 
passed through a medium which will hinder the movement of some particles more 
than others. These principles are used to isolate and analyze enzymes, pigments, 
amino acids, constituents of DNA, and almost any other molecule you can imag-
ine. A wide variety of chromatography techniques had developed to allow mixed 
substances to be separated [33].
Figure 5. 
Chromatogram response of a biological sample. The retention time is plotted on X-axis and signal on Y-axis 
obtained from detector corresponding to the response created by the analytes exiting the system.
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raphy separates the components of a mixture for later use and is thus a form of 
purification. Analytical chromatography is done normally with smaller amounts 
of material and is for establishing the presence or measuring the relative propor-
tions of analytes in a mixture. Figure 5 describes a chromatogram for a biological 
system where the signal is proportional to the concentration of the specific analyte 
separated.
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useful for separating mixtures of ions or molecules that are dissolved in a solvent. 
If the matrix support, or stationary phase, is polar (e.g., paper, silica, etc.), it is 
normal-phase chromatography; and if it is nonpolar (C-18), it is reversed-phase 
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charge, polarity, or a combination of these traits and pH balance. The solution is 
passed through a medium which will hinder the movement of some particles more 
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7. Capillary electrophoresis (CE)
Jorgenson and Lukacs in 1981 invent capillary electrophoresis (CE) most often 
termed as capillary zone electrophoresis (CZE) [34]. It is a type of electrophoresis 
in which analytes are separated by applying an electric field across buffer solution-
filled capillary tubes. The proposed instrumental technique was later implemented 
in a number of applications such as bioanalytical [35] and forensic drug analysis 
[36]. This technique is an alternative to the gel electrophoresis or LC (Figure 6).
CZE method correlated well with an automated kinetic fluorescent assay. An 
example is analysis of NAG by CE after incubation of urine samples using synthetic 
substrate, methylumbelliferyl-β-d-glucosaminide [37].
8. Microscopy
In the simplest microscopic methods, a specimen is illuminated by visible 
light and observed either against a bright background (bright-field microscopy) 
or a dark background (dark-field microscopy). The presence of cells that are not 
expected in the healthy person may be an indicator of disease. For example, a simple 
microscopic analysis of blood sample identifies the sickle cell anemia, and analysis 
of urine quantifies the presence of pus cells, which is an indicator of infection.
Light microscopy uses light as the illumination radiation. This is used to identify 
the microorganisms based on their morphology. An application of microscopy is to 
count the number of different cells per unit volume of blood or any other sample 
using a hemocytometer. Fluorescence microscopy has emerged as a very powerful 
tool for studying molecular processes owing largely to the advancement in optics 
and discovery of the green fluorescent protein and development of its analogs with 
different spectral properties [38]. Several advancements in the field of fluorescence 
microscopy have been achieved that includes the following techniques:
• Confocal laser scanning microscopy (CLSM)
CLSM is a type of fluorescence microscopy that allows imaging of the samples at 
different focal planes that light emitting from below or above the desired focal plane 
is eliminated. This results in very high lateral resolution and allows determining the 
spatial localization of the molecules [39].
• Total internal reflection fluorescence (TIRF) microscopy
TIFR is another type of fluorescence microscopy wherein the optics allows 
imaging of the molecules that are almost like microscopic slide. The resolution of 
light microscopes depends on the wavelength of the light used. The smaller the 
Figure 6. 
Capillary electrophoresis separation method.
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wavelength of the light used, the better the resolution obtained. Wavelength of 
the visible light imposes a resolution limit of ~0.2 μm on the light microscopes. 
Hemocytometer (Neubauer chamber) is a glass slide which has a counting chamber 
at the center. A glass cover is placed on the hemocytometer, and the sample is gently 
introduced into the chamber. The sample chamber has a grid which allows counting 
of cells in a defined region using a microscope [40].
9. Gene therapy protocol
Gene therapies are considerable improvements over the existing therapy because 
of the advantage in dosing schedule, patient compliance, toxicity, immunogenicity, 
and cost. Owing to this, gene therapy provides novel approaches for the treatment 
of inherited and acquired diseases. The development of a nonviral gene delivery 
vehicle capable of efficient, cell-specific delivery will be a valuable addition to the 
clinical armamentarium [41]. For example, the liver places a central role in the 
metabolism and production of serum proteins; it is an important target organ for 
gene therapy. Hepatic metabolic diseases as well as acquired diseases may also serve 
as targets for hepatic gene therapy [42]. Most recent gene therapy protocols describe 
delivery of foreign genes by means of injecting lentiviral particles [43].
10. Immunological and radioisotope techniques
Immunoassays are the quantitation of bioanalyte that depends on the reaction 
of an antigen (analyte) and an antibody. These methods are based on a competitive 
binding reaction between a fixed amount of labeled form of an analyte and a variable 
amount of unlabeled sample analyte for a limited amount of binding sites on a highly 
specific anti-analyte antibody. When immunoanalytical reagents (analyte or antibody) 
are mixed and incubated, the analyte is bound to the antibody forming an immune 
complex. This complex is separated from the unbound reagent fraction by physical or 
chemical separation technique. Analysis is achieved by measuring the label activity 
(e.g., radiation, fluorescence, or enzyme) in either of the bound or free fraction [44].
Immunoassay methods have been widely used in many important areas such as 
diagnosis of diseases, therapeutic drug monitoring, clinical pharmacokinetic and 
bioequivalence studies in drug discovery, and pharmaceutical industries. A few 
immunoassays based on different labels are as follows:
• Radioimmunoassay (RIA) methods have been used successfully for the deter-
mination of a limitless number of pharmaceutically important compounds in 
biological fluids. RIA is used to analyze thyroid hormone testing in patients 
after iodine-131 therapy.
• Enzyme immunoassay (EIA) is analogous to RIA except that the label is an 
enzyme rather than a radioisotope.
• Fluoroimmunoassay (FIA) is analogous to RIA except that the label is a fluoro-
phore rather than a radioisotope.
• Chemiluminescence immunoassay (CLIA) involves a chemiluminescent 
substance as a label.
• Liposome immunoassay (LIA) is the assay involving a liposome-encapsulating 
marker.
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7. Capillary electrophoresis (CE)
Jorgenson and Lukacs in 1981 invent capillary electrophoresis (CE) most often 
termed as capillary zone electrophoresis (CZE) [34]. It is a type of electrophoresis 
in which analytes are separated by applying an electric field across buffer solution-
filled capillary tubes. The proposed instrumental technique was later implemented 
in a number of applications such as bioanalytical [35] and forensic drug analysis 
[36]. This technique is an alternative to the gel electrophoresis or LC (Figure 6).
CZE method correlated well with an automated kinetic fluorescent assay. An 
example is analysis of NAG by CE after incubation of urine samples using synthetic 
substrate, methylumbelliferyl-β-d-glucosaminide [37].
8. Microscopy
In the simplest microscopic methods, a specimen is illuminated by visible 
light and observed either against a bright background (bright-field microscopy) 
or a dark background (dark-field microscopy). The presence of cells that are not 
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count the number of different cells per unit volume of blood or any other sample 
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and discovery of the green fluorescent protein and development of its analogs with 
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spatial localization of the molecules [39].
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TIFR is another type of fluorescence microscopy wherein the optics allows 
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light microscopes depends on the wavelength of the light used. The smaller the 
Figure 6. 
Capillary electrophoresis separation method.
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wavelength of the light used, the better the resolution obtained. Wavelength of 
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of cells in a defined region using a microscope [40].
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• Enzyme immunoassay (EIA) is analogous to RIA except that the label is an 
enzyme rather than a radioisotope.
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substance as a label.
• Liposome immunoassay (LIA) is the assay involving a liposome-encapsulating 
marker.
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• Cloned enzyme donor immunoassay (CEDIA) methodology is a novel 
approach which uses the DNA technology to produce homogenous enzyme 
immunoassays for drugs.
• Flow injection immunoassay (FIIA) methods were recently introduced to 
enhance the efficiency of immunochemical reaction, as well as to increase the 
performance of the analysis.
• Capillary electrophoresis immunoassay (CEIA) has been recently introduced 
as a sensitive analytical technique, particularly when combined with a sensitive 
detection method.
11.  Hyphenated separation techniques and its application in clinical 
chemistry
The hyphenated techniques improved detection limits, sample identification 
capability, and miniaturization potential; hence, about 60% of the application of 
electrochemical detection (ED) has been found in the field of bioanalysis. The prin-
ciple of ED used in biomedical analysis is a transfer of charge between substances 
in a column effluent and a working electrode; mainly, two types of ED either 
coulometric detection or amperometric detection are frequently used. The main 
advantages of using ED are the selectivity and sensitivity over UV-Vis detection. In 
HPLC, most of the application has been carried out by using UV-Vis detector, and 
ED is only used in small portion. The development of HPLC with ED facilitated 
highly sensitive and selective determination of homovanillic acid (HVA) and vanil-
lylmandelic acid (VMA) in urine for the differential diagnosis of neuroblastoma 
pheochromocytoma and related tumors [45]. HPLC, coupled with UV-Vis using 
photodiode array as a detector, is widely used for determination of different drugs 
in serum. Other applications include determination of vitamins, antioxidants, and 
other components in biological samples.
CE coupled with MS provides an advantage of the sensitivity (parts per 
million range) and selectivity of these detection systems [46]. A detector that 
is becoming more frequently attached to CE is inductively coupled plasma 
mass spectrometry (ICP-MS). To date, CE-ICP-MS has been performed using a 
quadrupole detector within the MS allowing a small number of elements to be 
analyzed at any one time [47].
12. Lab on a chip (LoC)
Lab on a chip is defined as a microform of analytical devices that assimilate 
numerous laboratory operations such as PCR and DNA sequencing into a single chip 
on a very small scale. Miniaturized version of LoC provides cost-efficiency, use of 
low-volume reagents, high parallelization, high diagnostic speed, high sensitivity, 
and high expandability [48].
On the other hand, chronic disease (CD) healthcare is experiencing few limi-
tations owing to lengthy and costly diagnosis procedures. Rapid, reliable, and 
low-cost diagnostic tools at point-of-care (PoC) instrumentation are therefore on 
high demand. LoC technology has a high potential to enable improved biomedical 
applications [49, 50]. In this regard, research toward developing new LoC-based 
PoC systems for CD diagnosis is fast growing into a nascent area such as chronic 
respiratory diseases (CRD), diabetes, and chronic kidney diseases (CKD) [51].
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13. Conclusions
This chapter summarizes various non-separation and separation methods 
used for biomedical analysis. Although routine clinical methods indicate normal/
abnormal levels of bioanalytes in urine/blood, still they often lack specificity due 
to severe complex biological sample interferences. In this regard, sample cleanup 
and highly sensitive techniques have proven to be helpful for early-stage disease 
diagnosis [52, 53] and detecting medical abnormalities [54]. To date, an array of 
hyphenated techniques plays an important role in the determination of bioanalytes, 
with improved selectivity and sensitivity.
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13. Conclusions
This chapter summarizes various non-separation and separation methods 
used for biomedical analysis. Although routine clinical methods indicate normal/
abnormal levels of bioanalytes in urine/blood, still they often lack specificity due 
to severe complex biological sample interferences. In this regard, sample cleanup 
and highly sensitive techniques have proven to be helpful for early-stage disease 
diagnosis [52, 53] and detecting medical abnormalities [54]. To date, an array of 
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Appendices
The analyte is the substance to be separated and to be found during chromatog-
raphy from the mixture.
A chromatograph is an equipment that enables a sophisticated separation, for 
example, gas chromatographic or liquid chromatographic separation.
The output of the chromatograph is termed as chromatogram. In the case of an 
ideal separation, different peaks on the chromatogram correspond to different 
components of the separated mixture.
The effluent is the mobile phase leaving the column.
The eluent is the solvent that carries the analyte.
The retention time is the characteristic time it takes for a particular analyte to pass 
through the system (from the column inlet to the detector) under a set of conditions.
The solute is termed as the sample component in partition chromatography.
The solvent means any substance capable of solubilizing another substance, such 
as liquid mobile phase in LC.
The detector refers to an instrument used for quantitative and qualitative detec-
tion of analytes.
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Pre-analytical steps contribute to an overall quality of the results of laboratory
trials. The volume of blood drawn into the blood-collection tube and the anticoag-
ulant amount introduced into the tube during its production should ensure the
anticoagulant level in the recommended range; otherwise, the results can be altered.
In evacuated blood-collection tubes, the internal under-pressure at the instant of
the blood specimen collection affects the draw volume. During the shelf life, the
internal under-pressure deteriorates. With no testing procedures in place, inappro-
priate anticoagulant levels can pass unnoticed. The chapter details testing proce-
dures ensuring that the tubes are used only if, and only until, they are of the
adequate quality. The reasoning behind the methodology is fully explained, and the
case studies of the quality evaluations are discussed.
Keywords: evacuated blood-collection tubes, K3EDTA, K2EDTA, citrate, quality
evaluation, draw-volume measurement, anticoagulant concentration
1. Introduction
Evacuated blood-collection tubes are evacuated containers intended for a venous
blood specimen collection. They consist of a tube and a closure, which has to be
tight to restrain low pressure—vacuum inside the tubes during their shelf life—but,
on the other hand, it also has to be soft enough to let a sharp end of a blood-
collection device to penetrate into a tube. The collection device has a disposable
needle attached to the other side for phlebotomy.
Evacuated blood-collection tubes improved patients’ and medical personnel’s
safety and mostly replaced classical tubes, which required a syringe and a needle for
a specimen collection. In a continuation, wherever a tube is mentioned, the evacu-
ated blood-collection tube is meant.
To prevent blood coagulation, tubes contain anticoagulants, either as dry sub-
stances attached to the internal walls or as solutions. Widely known and used are
sodium citrate and salts of ethylenediaminetetraacetic acid (EDTA), usually present
either as dipotassium or tripotassium salts, K2EDTA or K3EDTA.
Other substances, additives might be introduced as well to ensure the adequate
properties or behavior of the tubes’ internal walls or closures; nevertheless, they are
expected not to interfere with a determination and affect analytical results. A
noncompliant constituent detected in citrate tubes was magnesium which leached
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from a stopper and was consequently influencing the prothrombin time (PT) results
[1]. A comprehensive study evaluating different tubes comprising also recently
introduced low-magnesium version confirmed that the PT and INR differences
between the tubes are correlated with the magnesium concentration differences [2].
Manufacturers are obliged to specify on the label of a tube: a type of anticoagu-
lant, a nominal draw volume, a lot number, and expiration date; within this text, we
use a term expiry date as well.
Anticoagulant concentration in a blood sample after specimen collection should
be within an appropriate range; otherwise, analytical results might be altered. To
reach this objective, an accurate amount of anticoagulant should be introduced into
a tube during production, and a draw at the moment of a specimen collection
should be adequate to ensure a volume of blood entering a tube is within an
acceptable range. A label on a tube provides guidance for inspection if the volume is
within the suggested limits; however, this is only true if the label is precisely and
accurately positioned.
The latest version of the GP39-A6 standard of the CLSI standardization body
(Clinical and Laboratory Standards Institute) [3] requires of the tubes’ manufac-
turers to ensure that until expiration date, the anticoagulant concentration remains
within the 5% range of the value stated on a label. A draw volume is considered
acceptable if it does not differ from the stated nominal volume for more than10%.
The standard GP34-A recognizes the importance of appropriate blood-to-EDTA
ratio for obtaining optimal examination results but avoids stating the exact limits.
The EDTA can, if in a concentration which is too high hypertonically shrink red
cells, affect red cell size and cause morphological changes. On the other hand, it can
too extensively chelate calcium and other cations such as magnesium and zinc and
affect the activity of alkaline phosphatase enzyme label used in chemiluminescent
assays or reduce the efficiency of the recognition of proteins by antibodies due to
the proteins’ conformation changes [4].
The predecessor of CLSI, the National Committee for Clinical Laboratory Stan-
dards (NCLLS), was in the H1-A5 standard more explicit in terms of some antico-
agulants’ concentrations [5]. It explains that only a little bit less than a half
(1.15 mmol/L) out of the total calcium concentration (2.5 mmol/L) corresponds to
unbound calcium that needs to be chelated stoichiometrically with EDTA to prevent
coagulation. For that reason, it suggests that EDTA concentration in blood should be
between 3.7 and 5.4 mmol/L, since excessive concentration causes morphological
changes in the blood.
Not consistent with this requirement was DIN ISO 6710: 1996-12 standard
requiring the EDTA concentration within the 4.11–6.843 mmol/L range [6].
A potential user can during time come across the tubes which were
produced by not having the same set of requirements on the mind. As we already
previously demonstrated, the tubes if evaluated as such not yet in contact with a
blood sample are not all the same, and change in their own characteristics
during their shelf life and the testing procedure which we suggested are easy to
perform [7].
A concise review reflects on the behavior of EDTA as an anticoagulant in hema-
tology and furthermore discusses its usage in proteomics, general clinical chemistry,
and its applicability for measuring cytokines, protein, peptides, and cardiac markers
[8]. Elsewhere, influences of a form of EDTA and its concentration on the results of
hematological tests were profoundly discussed in relation to spurious counts and
results regarding platelets [9], white blood cells, red blood cells, hemoglobin, red
cell indices, and reticulocytes [10]; under-filled or over-filled evacuated tubes
changing the anticoagulant level in a sample are exposed as an influential pre-
analytical source of errors.
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For citrate tubes the DIN ISO 6710: 1996-12 standard recommends trisodium
citrate solutions with concentrations between 100 and 136 mmol/L; however, the
H1-A5 standard specifies the concentrations 105, 109, and 129 mmol/L.
Due to all these differences, the GP39-A6 standard omitted all the anticoagulant
concentrations’ details, leaving it entirely to a producer to bear the responsibility for
securing appropriate concentration, fulfilling all the requirements, and demon-
strating that they are actually met, or in other words verifying that the tubes are
actually fit for purpose.
The GP34-A standard provides guidance for validation and verification of tubes
for venous and capillary blood specimen collection [4]. Both a manufacturer and a
clinical laboratory are required to perform a comparability study on blood samples
for two or more sets of tubes comprising a set which was already evaluated and
approved previously. A manufacturer performs such a test after a new product was
developed or where any correction actions are necessary for the production process.
The laboratory needs to do it when switching from one product to another or when
changing a vendor.
A within-tube precision study requires a minimum of 20 subjects, and each
sample needs to be analyzed in replicates; an appropriate number of samples,
evenly distributed through the analytical measurement, are essential for trueness
evaluation [4]. Several studies with sometimes dissimilar outcomes can be found in
the literature.
Two blood-collection devices either with an aligned [Becton Dickinson (BD)] or
at an angle needle holder (Greiner Labortechnik GmbH) were evaluated either
enabling a direct linear (BD) or interrupted nonlinear blood flow. A mechanical
strain on blood cells was recognized as a factor potentially causing the efflux of
intracellular constituents into the serum in an interrupted nonlinear flow. The
magnesium, plasma hemoglobin, and prothrombin time within-subject variations
were confirmed in 55 healthy individuals using a Student paired t-test. A difference
in a tube material either glass or polymer was also recognized as a likely contribut-
ing factor [11].
Nevertheless, contrasting outcomes were obtained for prothrombin time deter-
minations in the glass and PVC tubes with two distinct citrate concentrations where
neither material caused the significantly different results [12]. Yet another study,
establishing a protocol for comparing the citrate evacuation blood-collection tubes
with glass tubes employing eight measuring systems, confirmed a statistically sig-
nificant but clinically not relevant difference in prothrombin time results, which
were more pronounced with the tubes of the lowest 2.7 mL draw volume [13].
Differences in some parameters were confirmed if BD plastic citrate tubes were
used instead of glass tubes, but they were considered unlikely to be clinically
significant [14], though a comprehensiveness of a study was challenged arguing
that only healthy volunteers were involved and by these means it was not yet
proven that glass tubes are interchangeable with the plastic tubes [15]. But a study
performed on Greiner glass citrate and plastic tubes confirmed that the tubes are
substitutable as far as either untreated or patients on a traditional oral anticoagulant
therapy are concerned and that this applies for the whole shelf life of the tubes [16].
Nevertheless, the plastic tubes of different brands evaluated on patients and
healthy volunteers were confirmed to be statistically but not clinically significantly
different [17]. For patients on oral anticoagulant therapy with vitamin K antago-
nists, ANOVA test confirmed statistically significant differences in prothrombin
time for the tubes of four different types [18]. The study supports the claim that
validation is always necessary when there is a change in a tube type.
A research performed on a group of individuals evaluating the effect of under-
filled EDTA tubes on hematological parameters by employing a particular type of
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analyzer [19] leads to contrasting outcomes not necessarily aligned with other
studies [20] and general principles and recommendations.
Validations and verifications as required by the standard GP34-A are complex to
perform, time demanding, and require resourceful personnel [4].
The standard exposes a blood collection as a pre-analytical (preexamination)
source causing varying degrees of errors. It brings to light a lack of a mechanism
that would enable systematic evaluations of the influences of pre-analytical
(preexamination) variables on laboratory test (examination) results [4].
The characteristics of the tubes entering the pre-analytical phase are such vari-
ables, and this is where this chapter tends to contribute.
Differences between tubes of different brands examined 5 years apart in time
are going to be enlightened, and the testing procedures which are fast, cheap, and
easy to implement into laboratory practice are explained in full details. Robustness
of personal profiles of athletes and validation studies performed on blood samples
can profit from knowing the attributes of the tubes that were actually used or
evaluated.
2. Quality of evacuated blood-collection tubes for hematological tests
reevaluated in 5 years’ time
In this section, we compare the results of a quality evaluation of the blood-
collection tubes, on which we previously reported [7], with the results obtained in
5 years’ time. The same producers were considered, namely, Becton Dickinson,
Greiner Bio-One, and Laboratorijska tehnika Burnik d. o. o.
Figures 1–4 are dedicated to the tubes of four different brands. The abscise axis
stands for a draw volume. Ordinate on the right indicates an anticoagulant concen-
tration expected for a blood sample after a specimen collection. We are going to
explain the meaning of the left ordinate axis, which relates to a testing procedure,
later. A frame in green indicates the limits set by the H1-A5 standard [5]. The
horizontal lines confine the range of the acceptable anticoagulant concentration; the
left vertical line represents a limit under which a draw volume is expected not to fall
to prevent the anticoagulant concentration to rising too high.
We kept the assigned marks A, B, and C from the previous study for the
K3EDTA tubes, and D for the K2EDTA tubes, not disclosing the producers’ identity.
We additionally included the tubes F, not previously evaluated. The more recent
Figure 1.
Anticoagulant concentrations and draw volumes of the A brand tubes obtained 5 years apart in time (orange/
blue) and of the tubes F not previously included (the numbers in the labels indicate time until the expiration).
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Figure 2.
Anticoagulant concentrations and draw volumes of the B brand tubes obtained 5 years apart in time (orange/
blue); the numbers in the labels indicate the time until the expiration.
Figure 3.
Anticoagulant concentrations and draw volumes of the C brand tubes obtained 5 years apart in time (orange/
blue); the numbers in the labels indicate the time until the expiration.
Figure 4.
Anticoagulant concentrations and draw volumes of the D brand tubes obtained 5 years apart in time (orange/
blue); the numbers in the labels indicate the time until the expiration.
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explain the meaning of the left ordinate axis, which relates to a testing procedure,
later. A frame in green indicates the limits set by the H1-A5 standard [5]. The
horizontal lines confine the range of the acceptable anticoagulant concentration; the
left vertical line represents a limit under which a draw volume is expected not to fall
to prevent the anticoagulant concentration to rising too high.
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Figure 2.
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results are marked with an asterisk; a number indicates the number of days until the
expiration.
Ellipses in Figures 1–4 provide an insight into a spread of results obtained for
the tubes within a series of measurements. Ellipses in blue correspond to the more
recent results; those in orange originate from a previous study. A length of a
horizontal axis of an ellipse equals a standard deviation of the draw-volume mea-
surements; a vertical axis indicates a standard deviation of the anticoagulant con-
centration as expected for blood samples. A crossing of the two axes of an ellipse is
defined by the mean values of the two parameters. The smaller the ellipse, the
higher the quality of the produced tubes in terms of their precision or, in other
words, a repeatability of a product.
2.1 K3EDTA tubes
From this point of view, the A brand tubes were and remain of a high quality. In
spite of having a very long expiration date, unless very close to the expiration
(A*18), the draw volumes generally remain adequate; however, the anticoagulant
concentration is too high and not in the accordance with the higher limit set by the
H1-A5 standard [5]. All the ellipses of the A brand tubes are above the green
rectangle in Figure 1. The same is true for the tubes F, which are of the same
manufacturer. This example demonstrates that an adequate draw volume does not
yet ensure the adequate anticoagulant concentration as far as the H1-A5 is
concerned. The tubes were obviously produced following an older DIN ISO 6710:
1996-12 standard, for which the anticoagulant concentration 6.843 mmol/L was still
acceptable. With this limit in mind, only the A*18A anticoagulant concentration
would be excessive. The characteristics of these tubes clearly contrast those of the
tubes B and C, as the figures in the continuation demonstrate.
In the B brand tubes (Figure 2), an improvement in the overall quality of the
results is evident in 5 years’ time. Previously the ellipses were much larger, and they
exceeded the upper anticoagulant concentration limit even with the draw volumes
very close to the nominal 3 mL mark. The ellipses in blue are small and remain
within the green rectangle during the whole shelf life; nevertheless it has to be
mentioned the shelf life was at the time of purchase much shorter than in the A
brand tubes.
The C brand tubes exhibit a good repeatability of the product; however, the
anticoagulant concentration starts exceeding slightly the higher-anticoagulant con-
centration limit already with the draw volumes approaching 2.8 mL, proving that
the draw volume within the acceptable range does not yet guarantee the correct
anticoagulant concentration.
2.2 K2EDTA tubes
The product repeatability of the D brand tubes is good, but the anticoagulant
concentration starts exceeding the upper limit already approximately 200 days
before the expiration date and with the draw volumes falling below 2.9 mL what is
far above the acceptable lower limit.
This study confirmed that a control of a draw volume is not the main quality
issue and does not ensure that the anticoagulant concentration is adequate. Only in
four cases, the draw volumes below the 2.7 mL limit were observed, and this only
happened when the tubes were tested closer than 20 days before their expiration
date. On the other hand, in more than 20 cases, the anticoagulant concentration
limit as set by the H1-A5 standard was exceeded at the draw volumes in the
recommended range.
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It also needs to be mentioned that if the draw-volume inspection relays on the
label mark a judgment can be false. During our first study, we found out that only
one brand of the tubes had a label positioned precisely; in all others the indicators
on the tube were misleading.
Easy-to-perform testing procedures as we used here which do not require blood
samples can as a precautious measure ensure that the tubes are used only if they are
of the adequate quality and their quality does not fluctuate too much during the
time. It can alert a laboratory when it would be advisable to perform a much more
complex and time-demanding verification study on blood samples. Archived data
on the tubes’ characteristics and quality during a longer period of time can provide a
piece of evidence for other studies and rule the tubes out as a potential cause for
variations.
2.3 Tubes’ drawing capability reduces during the time
In this section, we explain the changes in a behavior of the tubes during their
shelf life.
The tubes’ drawing capability depends on a difference between the external (pst)
and internal (pint_20°C) pressure. The lower the internal pressure, and the higher the
difference to the external pressure, the higher a drawing capability. A tube’s internal
volume (Vtube) also contributes to higher capacity to draw a liquid.
The tubes of different brands differ in their drawing capability and, in a way,
how it reduces during the time, as Figure 5 demonstrates. No container is entirely
tight and leaks to some extent. The conditions to which the tubes were exposed or
under which they were stored contribute. The tubes of the same lot would behave
differently in different circumstances.
Even though tubes are of a high quality, are purchased at the same time, and
are of the same lot, they are not all the same if used during their shelf life.
Figure 5.
Drawing capability of the tubes reduces continuously during their shelf life.
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acceptable. With this limit in mind, only the A*18A anticoagulant concentration
would be excessive. The characteristics of these tubes clearly contrast those of the
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In the B brand tubes (Figure 2), an improvement in the overall quality of the
results is evident in 5 years’ time. Previously the ellipses were much larger, and they
exceeded the upper anticoagulant concentration limit even with the draw volumes
very close to the nominal 3 mL mark. The ellipses in blue are small and remain
within the green rectangle during the whole shelf life; nevertheless it has to be
mentioned the shelf life was at the time of purchase much shorter than in the A
brand tubes.
The C brand tubes exhibit a good repeatability of the product; however, the
anticoagulant concentration starts exceeding slightly the higher-anticoagulant con-
centration limit already with the draw volumes approaching 2.8 mL, proving that
the draw volume within the acceptable range does not yet guarantee the correct
anticoagulant concentration.
2.2 K2EDTA tubes
The product repeatability of the D brand tubes is good, but the anticoagulant
concentration starts exceeding the upper limit already approximately 200 days
before the expiration date and with the draw volumes falling below 2.9 mL what is
far above the acceptable lower limit.
This study confirmed that a control of a draw volume is not the main quality
issue and does not ensure that the anticoagulant concentration is adequate. Only in
four cases, the draw volumes below the 2.7 mL limit were observed, and this only
happened when the tubes were tested closer than 20 days before their expiration
date. On the other hand, in more than 20 cases, the anticoagulant concentration
limit as set by the H1-A5 standard was exceeded at the draw volumes in the
recommended range.
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It also needs to be mentioned that if the draw-volume inspection relays on the
label mark a judgment can be false. During our first study, we found out that only
one brand of the tubes had a label positioned precisely; in all others the indicators
on the tube were misleading.
Easy-to-perform testing procedures as we used here which do not require blood
samples can as a precautious measure ensure that the tubes are used only if they are
of the adequate quality and their quality does not fluctuate too much during the
time. It can alert a laboratory when it would be advisable to perform a much more
complex and time-demanding verification study on blood samples. Archived data
on the tubes’ characteristics and quality during a longer period of time can provide a
piece of evidence for other studies and rule the tubes out as a potential cause for
variations.
2.3 Tubes’ drawing capability reduces during the time
In this section, we explain the changes in a behavior of the tubes during their
shelf life.
The tubes’ drawing capability depends on a difference between the external (pst)
and internal (pint_20°C) pressure. The lower the internal pressure, and the higher the
difference to the external pressure, the higher a drawing capability. A tube’s internal
volume (Vtube) also contributes to higher capacity to draw a liquid.
The tubes of different brands differ in their drawing capability and, in a way,
how it reduces during the time, as Figure 5 demonstrates. No container is entirely
tight and leaks to some extent. The conditions to which the tubes were exposed or
under which they were stored contribute. The tubes of the same lot would behave
differently in different circumstances.
Even though tubes are of a high quality, are purchased at the same time, and
are of the same lot, they are not all the same if used during their shelf life.
Figure 5.
Drawing capability of the tubes reduces continuously during their shelf life.
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A reduction in a drawing capacity results in a diminished draw volume and
enhanced anticoagulant concentration.
The tubes’ validations and verifications with blood samples are essential;
however complex and with no insight into characteristics of the tubes as such, it
is not clear what was actually tested and how representative it is. The outcomes
might vary and can be influenced by a choice of a group of individuals, its
representativeness, a normality of a distribution of the investigated parameter,
and the sources of uncertainty originating from the whole procedure, compris-
ing pre-analytical, analytical, and post-analytical phases. All these factors can
influence the conclusions of a paired t-test or ANOVA, a difference between
two brands, or lots of the tubes might turn out insignificant. Insight into tubes’
characteristics can give the verification and validation studies some basic orien-
tation on what was the status of the tubes that were investigated. If the evalu-
ation is repeated later, one can know how comparable are the examined tubes
entering the process.
If a difference between the results obtained for the tubes of different brands is
confirmed to be statistically significant by the tests performed on blood samples,
they are frequently considered not clinically important. However, variations, which
are not important on the level of a group of individuals, might reflect differently
when a single person is concerned. Personal variations in blood parameters are
narrower than variations on the level of a population. A personal medicine and
athlete’s biological passport require higher sensitivity and attention paid to all
sources of uncertainty.
It is not possible to perform validation study with blood samples for each indi-
vidual, but it is easily possible to perform a quality control of the tubes which are
used for personal profiles.
The athlete’s biological passport (ABP) requires accurate and reliable results of
hematological tests, which are stable enough for evaluations of the probabilities of
abnormalities in a personal profile. Hence, some parameters, e.g., hemoglobin and
erythrocytes, were identified as highly stable; the others such as reticulocytes, mean
red blood cell volume, and hematocrit did not turn out as such. Sample storage
conditions and treatment and the choice of an analyzer are considered the contrib-
uting factors [21].
It was proven that during a training season hemoglobin and hematocrit reduce in
their value, and reticulocytes do as well but independently. The pattern is general
but the size of a change is sport’s discipline dependent. It was recognized that
reliable reference ranges in sportsmen could not be defined without the best labo-
ratory practices [22].
Not univocal and entirely clear outcomes of different studies on the
stability of the blood variables raise concerns and request for more clearly
defined characteristics, procedures, threshold limits, personal reference ranges,
and criteria for recognizing abnormalities to prevent false convictions in
athletes [23].
In order to raise awareness to which extent different pre-analytical phases could
affect the outcomes of hematological and biochemical tests on which sports medi-
cine depends in following athletes, different pre-analytical aspects and the choice of
anticoagulant, instabilities of some molecules were addressed to prevent misinter-
pretation of data and improve the usefulness of results [24]. Specimen homogeni-
zation as a pre-analytical phase received special attention [25].
The variations in tubes’ characteristics did not receive attention in relation to
ABP in spite of the fact that easy-to-perform testing procedures are available [7].
They are thoroughly explained in the continuation.
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3. A methodology for K3EDTA or K2EDTA evacuated blood-collection
tubes’ quality evaluation
A methodology for a quality evaluation of evacuated blood-collection tubes for
hematological tests consists of two successive measurements, a measurement of a
draw volume and electrolytic conductivity, from which one can predict the antico-
agulant concentration in a blood sample. No patient- or person-related samples are
required. A medium for the tests is purified water.
Only low-cost equipment, a Bang burette and a field conductivity meter, is used.
One also needs to know an ambient temperature and a non-reduced pressure for a
period during which measurements were performed. The latter can be obtained
from a local meteorological institution on request, and temperature is easy to mea-
sure. We explain the testing procedures in full details in the following section.
We previously published the nomograms for K2EDTA and K3EDTA tubes with
nominal 3 mL draw volume, which enable a prediction on how is an anticoagulant
concentration going to rise with a diminishing draw volume that happens during
the time because of the aging of the tubes [7].
In Figure 6 we present a nomogram for the K3EDTA tubes with a 2 mL nominal
draw volume relating the electrolytic conductivity, κ, with a predicted anticoagu-
lant concentration, c, and a draw volume, V. The points are the results of the quality
evaluation of the tubes of two different brands, E and G, at the particular moment
in time. If the tubes in a lot are of a homogenous quality and they are going to be
tested later during their shelf life, the anticoagulant concentration as expected for
blood samples is going to rise as the curves indicate. In such a case, a draw-volume
measurement can already give an insight into the quality of the examined tubes.
If we take the G tubes as an example, for the great majority of the tested tubes,
with a draw volume close to 2.1 mL, the anticoagulant concentration anticipated
initially was 4.45 mmol/L. If we assume that later in time we find out that the
draw volume has fallen to 1.9 mL, the anticoagulant concentration for blood
samples is going to be close to 4.95 mmol/L. A green rectangle indicates the limits
set by H1-A5 standard [5], demonstrating that the tubes would still have been of
adequate quality.
Skills needed to perform the tests are not difficult to master, and a laboratory or
medical staff can easily develop them. The quality of the tubes does not deteriorate
very rapidly. It is important to test tubes when they are put into use, and later only
Figure 6.
A nomogram for a prediction on how is the anticoagulant concentration in 2 mL K3EDTA tubes of two different
brands (E, G) going to change with a declining draw volume; green rectangle outlines the characteristics
considered acceptable by H1-A5 standard [5].
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A reduction in a drawing capacity results in a diminished draw volume and
enhanced anticoagulant concentration.
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however complex and with no insight into characteristics of the tubes as such, it
is not clear what was actually tested and how representative it is. The outcomes
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entering the process.
If a difference between the results obtained for the tubes of different brands is
confirmed to be statistically significant by the tests performed on blood samples,
they are frequently considered not clinically important. However, variations, which
are not important on the level of a group of individuals, might reflect differently
when a single person is concerned. Personal variations in blood parameters are
narrower than variations on the level of a population. A personal medicine and
athlete’s biological passport require higher sensitivity and attention paid to all
sources of uncertainty.
It is not possible to perform validation study with blood samples for each indi-
vidual, but it is easily possible to perform a quality control of the tubes which are
used for personal profiles.
The athlete’s biological passport (ABP) requires accurate and reliable results of
hematological tests, which are stable enough for evaluations of the probabilities of
abnormalities in a personal profile. Hence, some parameters, e.g., hemoglobin and
erythrocytes, were identified as highly stable; the others such as reticulocytes, mean
red blood cell volume, and hematocrit did not turn out as such. Sample storage
conditions and treatment and the choice of an analyzer are considered the contrib-
uting factors [21].
It was proven that during a training season hemoglobin and hematocrit reduce in
their value, and reticulocytes do as well but independently. The pattern is general
but the size of a change is sport’s discipline dependent. It was recognized that
reliable reference ranges in sportsmen could not be defined without the best labo-
ratory practices [22].
Not univocal and entirely clear outcomes of different studies on the
stability of the blood variables raise concerns and request for more clearly
defined characteristics, procedures, threshold limits, personal reference ranges,
and criteria for recognizing abnormalities to prevent false convictions in
athletes [23].
In order to raise awareness to which extent different pre-analytical phases could
affect the outcomes of hematological and biochemical tests on which sports medi-
cine depends in following athletes, different pre-analytical aspects and the choice of
anticoagulant, instabilities of some molecules were addressed to prevent misinter-
pretation of data and improve the usefulness of results [24]. Specimen homogeni-
zation as a pre-analytical phase received special attention [25].
The variations in tubes’ characteristics did not receive attention in relation to
ABP in spite of the fact that easy-to-perform testing procedures are available [7].
They are thoroughly explained in the continuation.
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3. A methodology for K3EDTA or K2EDTA evacuated blood-collection
tubes’ quality evaluation
A methodology for a quality evaluation of evacuated blood-collection tubes for
hematological tests consists of two successive measurements, a measurement of a
draw volume and electrolytic conductivity, from which one can predict the antico-
agulant concentration in a blood sample. No patient- or person-related samples are
required. A medium for the tests is purified water.
Only low-cost equipment, a Bang burette and a field conductivity meter, is used.
One also needs to know an ambient temperature and a non-reduced pressure for a
period during which measurements were performed. The latter can be obtained
from a local meteorological institution on request, and temperature is easy to mea-
sure. We explain the testing procedures in full details in the following section.
We previously published the nomograms for K2EDTA and K3EDTA tubes with
nominal 3 mL draw volume, which enable a prediction on how is an anticoagulant
concentration going to rise with a diminishing draw volume that happens during
the time because of the aging of the tubes [7].
In Figure 6 we present a nomogram for the K3EDTA tubes with a 2 mL nominal
draw volume relating the electrolytic conductivity, κ, with a predicted anticoagu-
lant concentration, c, and a draw volume, V. The points are the results of the quality
evaluation of the tubes of two different brands, E and G, at the particular moment
in time. If the tubes in a lot are of a homogenous quality and they are going to be
tested later during their shelf life, the anticoagulant concentration as expected for
blood samples is going to rise as the curves indicate. In such a case, a draw-volume
measurement can already give an insight into the quality of the examined tubes.
If we take the G tubes as an example, for the great majority of the tested tubes,
with a draw volume close to 2.1 mL, the anticoagulant concentration anticipated
initially was 4.45 mmol/L. If we assume that later in time we find out that the
draw volume has fallen to 1.9 mL, the anticoagulant concentration for blood
samples is going to be close to 4.95 mmol/L. A green rectangle indicates the limits
set by H1-A5 standard [5], demonstrating that the tubes would still have been of
adequate quality.
Skills needed to perform the tests are not difficult to master, and a laboratory or
medical staff can easily develop them. The quality of the tubes does not deteriorate
very rapidly. It is important to test tubes when they are put into use, and later only
Figure 6.
A nomogram for a prediction on how is the anticoagulant concentration in 2 mL K3EDTA tubes of two different
brands (E, G) going to change with a declining draw volume; green rectangle outlines the characteristics
considered acceptable by H1-A5 standard [5].
55
Pre-Analytical Within-Laboratory Evacuated Blood-Collection Tube Quality Evaluation
DOI: http://dx.doi.org/10.5772/intechopen.80685
occasionally, but at regular intervals. Since the tests are not time-consuming and not
performed in high numbers, this additional workload does not represent an impor-
tant additional burden for personnel; however, the benefits for an institution are
obvious and important.
An institution implementing a quality evaluation scheme always has an adequate
insight into the characteristics and quality of the tubes it is using. It can ensure that
the tubes are used only if and only until they are of adequate quality or it can use the
data in medical and clinical studies to test possible correlations or covariations.
4. Testing procedures
Testing procedures consist of a draw volume and an electrolytic conductivity
measurement (Figure 7 left/right), both later corrected to correspond to a temper-
ature 20°C and an external pressure 101 kPa as required by the standards [5, 6].
4.1 Draw volume
In the schematic (Figure 7), far left, an evacuated tube, characterized by an
internal pressure (pint) and an internal tube volume (Vtube), defining a conserved
energy of withdrawal for a blood specimen collection is depicted.
In the middle, a draw-volume measurement is schematically represented. A
starting point is a Bang burette filled with purified water to the 0 mL mark. A tip of
the burette is attached to a flexible tubing, which is at the other end connected to a
blood-collection device. This part too is entirely filled with purified water. When we
attach an evacuated tube to the venipuncture device, the tube starts filling with
water, and consequently the water level in the Bang burette starts falling. The rising
water level in the tube acts as a moving piston, reducing the void volume and
causing the internal pressure to rise until it equals the external pressure (pext). At
this moment, the withdrawing ends, and we can read the draw volume from a
burette.
Hence, the external pressure and temperature (T) affect a draw-volume test.
The external pressure depends on the altitude and current weather conditions and
can be obtained from the local meteorological institution. The ambient temperature
is also important and has to be taken into account. It affects the internal pressure in
Figure 7.
A setup for a draw-volume measurement (left) and a conductivity cell for the anticoagulant concentration
estimation (right).
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a tube at the instant of the draw-volume measurement. At a higher temperature, the
air in the tube expands, the internal pressure rises, or, in other words, the internal
under-pressure deteriorates, and a tube’s withdrawing ability falls.
For these two reasons, a draw volume (Vdraw) should be corrected to obtain an
estimation of a draw volume, as it would have been, if measured at 1013 hPa and
20°C (Vdraw_st) (1); the symbol K and hPa stand for the units Kelvin and
hectopascal, respectively:
Vdraw_st ¼ Vtube �
pext � 293:16� K
T � 1013� hPa Vtube � Vdrawð Þ (1)
The standards [5, 6] admit that if the draw volume under these conditions does
not differ from the nominal volume for more than 10%, the tubes are expected to be
of the adequate quality for a blood specimen collection. For the 3 mL tubes, this
means that the draw volumes between 2.7 and 3.3 mL are acceptable.
Even though the standards [3, 4] expose as the main quality issue in a noncon-
formity of a draw volume with the requirements, our results in Section 2 prove that
a draw volume within the acceptable range does not necessarily ensure the correct
anticoagulant level. An additional insight into this aspect of quality is necessary. For
the K2EDTA and K3EDTA tubes, respectively, a conductance measurement can
provide such an insight.
4.2 Ionic conductivity
K2EDTA and K3EDTA are salts, and salt in water dissociates in ions. Solutions
containing ions conduct electric current, to which extent depends on the ions’
characteristics and their concentration. In other words, conductance (G) of a solu-
tion reflects an overall ionic composition, but, if a solution contains only a single
salt, as it is a case for K2EDTA and K3EDTA tubes, it can provide an insight into a
salt concentration.
A conductance depends on the geometry of a conductivity cell. A cell we used is
depicted in Figure 7 (far right). It was an immersive four-electrode cell, not directly
applicable to our needs. We closed the bottom of the cave with a parafilm and the
hole at the right with a stopper made of a pipette tip to transform it into a conduc-
tivity cell applicable for conductance measurements in solutions of a small volume.
The conductance measurement is affected by a size of electrodes and a distance
between them; a cell geometry is reflected in a cell constant K. If the results of
measurements are expressed as ionic conductivity (κ), they are universally useful
and comparable between different measuring systems (2):
κ ¼ G� K (2)
Another concern is a temperature during a measurement; it also affects the
conductance value. At higher temperatures, a conductance is higher. This is taken
into account by reporting an ionic conductivity at a selected reference temperature,
e.g., 20°C. Measurements obtained at an ambient temperature are transformed into
the values as would have been at the reference temperature by taking a temperature
compensation into account. A linear compensation is frequently used; a compensa-
tion factor is usually approximately 2%/°C. In our case, the values confirmed
experimentally were 1.99 or 2.01% for K3EDTA or K2EDTA, respectively.
Conductivity measurements are in fact easy to perform. A conductivity cell has a
temperature sensor incorporated. We select the reference temperature, define a
temperature compensation factor and a cell constant, and perform measurements.
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occasionally, but at regular intervals. Since the tests are not time-consuming and not
performed in high numbers, this additional workload does not represent an impor-
tant additional burden for personnel; however, the benefits for an institution are
obvious and important.
An institution implementing a quality evaluation scheme always has an adequate
insight into the characteristics and quality of the tubes it is using. It can ensure that
the tubes are used only if and only until they are of adequate quality or it can use the
data in medical and clinical studies to test possible correlations or covariations.
4. Testing procedures
Testing procedures consist of a draw volume and an electrolytic conductivity
measurement (Figure 7 left/right), both later corrected to correspond to a temper-
ature 20°C and an external pressure 101 kPa as required by the standards [5, 6].
4.1 Draw volume
In the schematic (Figure 7), far left, an evacuated tube, characterized by an
internal pressure (pint) and an internal tube volume (Vtube), defining a conserved
energy of withdrawal for a blood specimen collection is depicted.
In the middle, a draw-volume measurement is schematically represented. A
starting point is a Bang burette filled with purified water to the 0 mL mark. A tip of
the burette is attached to a flexible tubing, which is at the other end connected to a
blood-collection device. This part too is entirely filled with purified water. When we
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water, and consequently the water level in the Bang burette starts falling. The rising
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causing the internal pressure to rise until it equals the external pressure (pext). At
this moment, the withdrawing ends, and we can read the draw volume from a
burette.
Hence, the external pressure and temperature (T) affect a draw-volume test.
The external pressure depends on the altitude and current weather conditions and
can be obtained from the local meteorological institution. The ambient temperature
is also important and has to be taken into account. It affects the internal pressure in
Figure 7.
A setup for a draw-volume measurement (left) and a conductivity cell for the anticoagulant concentration
estimation (right).
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a tube at the instant of the draw-volume measurement. At a higher temperature, the
air in the tube expands, the internal pressure rises, or, in other words, the internal
under-pressure deteriorates, and a tube’s withdrawing ability falls.
For these two reasons, a draw volume (Vdraw) should be corrected to obtain an
estimation of a draw volume, as it would have been, if measured at 1013 hPa and
20°C (Vdraw_st) (1); the symbol K and hPa stand for the units Kelvin and
hectopascal, respectively:
Vdraw_st ¼ Vtube �
pext � 293:16� K
T � 1013� hPa Vtube � Vdrawð Þ (1)
The standards [5, 6] admit that if the draw volume under these conditions does
not differ from the nominal volume for more than 10%, the tubes are expected to be
of the adequate quality for a blood specimen collection. For the 3 mL tubes, this
means that the draw volumes between 2.7 and 3.3 mL are acceptable.
Even though the standards [3, 4] expose as the main quality issue in a noncon-
formity of a draw volume with the requirements, our results in Section 2 prove that
a draw volume within the acceptable range does not necessarily ensure the correct
anticoagulant level. An additional insight into this aspect of quality is necessary. For
the K2EDTA and K3EDTA tubes, respectively, a conductance measurement can
provide such an insight.
4.2 Ionic conductivity
K2EDTA and K3EDTA are salts, and salt in water dissociates in ions. Solutions
containing ions conduct electric current, to which extent depends on the ions’
characteristics and their concentration. In other words, conductance (G) of a solu-
tion reflects an overall ionic composition, but, if a solution contains only a single
salt, as it is a case for K2EDTA and K3EDTA tubes, it can provide an insight into a
salt concentration.
A conductance depends on the geometry of a conductivity cell. A cell we used is
depicted in Figure 7 (far right). It was an immersive four-electrode cell, not directly
applicable to our needs. We closed the bottom of the cave with a parafilm and the
hole at the right with a stopper made of a pipette tip to transform it into a conduc-
tivity cell applicable for conductance measurements in solutions of a small volume.
The conductance measurement is affected by a size of electrodes and a distance
between them; a cell geometry is reflected in a cell constant K. If the results of
measurements are expressed as ionic conductivity (κ), they are universally useful
and comparable between different measuring systems (2):
κ ¼ G� K (2)
Another concern is a temperature during a measurement; it also affects the
conductance value. At higher temperatures, a conductance is higher. This is taken
into account by reporting an ionic conductivity at a selected reference temperature,
e.g., 20°C. Measurements obtained at an ambient temperature are transformed into
the values as would have been at the reference temperature by taking a temperature
compensation into account. A linear compensation is frequently used; a compensa-
tion factor is usually approximately 2%/°C. In our case, the values confirmed
experimentally were 1.99 or 2.01% for K3EDTA or K2EDTA, respectively.
Conductivity measurements are in fact easy to perform. A conductivity cell has a
temperature sensor incorporated. We select the reference temperature, define a
temperature compensation factor and a cell constant, and perform measurements.
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4.3 Anticoagulant concentration
For a solution of a single salt, electrolytic conductivity values are easy to trans-
form into a salt amount concentration, c. If one prepares a set of the solutions with
the known salt concentrations and determines their electrolytic conductivity at the
reference temperature, one can relate the two parameters by depicting a graph,
with the first parameter on the abscise axis, and the second on the ordinate, defin-
ing a trend line (3):
κ ¼ aþ b� c (3)
The symbols, a and b, are the parameter of the linear equation; a stands for the
intercept and b for the slope.
After these two parameters are known, one can measure the electrolytic con-
ductivity of the anticoagulant solution obtained after a draw-volume test to obtain
κV_draw and use the equation in a rearranged form to calculate a concentration of the
anticoagulant, cV_draw (4):
cV_draw ¼ κV_draw � ab (4)
This concentration is valid at the draw volume, but one wants to know the
anticoagulant concentration as expected in blood after a specimen collection,
cV_draw_st. As already explained, the draw volume had to be corrected to obtain an
estimation of a blood sample volume; a concentration is volume dependent, and
therefore it has to be corrected too, to correctly represent the anticoagulant con-
centration as expected after a blood specimen collection (5):
cV_draw_st ¼ cV_draw VdrawVdraw_st (5)
Draw volume and anticoagulant concentration determination can be
implemented into laboratory quality control routines. If followed during the time in
a form of control charts, they can ensure that the tubes are used only if and only
until they are of adequate quality.
5. Citrate tubes a distinct case
The same testing procedure for a draw-volume measurement is applicable also
to citrate tubes. However, in terms of a determination of the anticoagulant concen-
tration, this is a distinct case. The reason is that citrate in the tubes can be either
buffered or unbuffered. As a result, a solution after a draw-volume test can have
quite a different pH and contains different citrate equilibrium forms in different
proportions. For this reason measurement of electrolytic conductivity cannot be
used here, and an adequate low-cost and easy-to-perform testing procedure yet has
to be developed.
We evaluated the citrate tubes of two different brands, A and B. Both were (1:9)
type tubes but differed in nominal draw volumes, which were 4.5 and 3.6 mL for
tubes A and B, respectively. Measured draw volumes that we obtained were 4.55
and 3.47 mL; it has to be pointed out that these are uncorrected values.
Getting insight into the composition of the anticoagulant solution after a draw-
volume test is possible, but the approach is complex and time-consuming. We used
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two ion chromatographic techniques, ion-exclusion chromatography for determi-
nation of citrate and ion-exchange chromatography for determination of cations.
Figure 8 depicts chromatograms obtained for determinations of cations after a
draw-volume test. Four chromatographic peaks emerge. The first peak appearing
between 4 and 6 minutes pertains to the major cation, sodium, originating from the
anticoagulant, trisodium citrate. This peak is presented twice with two different y-
axis scales, in the main chromatogram with its top is out of scale and in the inserted
frame where it is fully visible.
The peak for the A brand tubes is smaller, indicating that in this case citrate is
buffered, while in addition to sodium ions there are hydronium ions (H+, or H3O
+)
to neutralize a negative charge of citrate equilibrium forms. In other words, in the
case of the A brand tubes, the anticoagulant solution was prepared not only from a
trisodium citrate but also with an addition of citric acid. Consequently, the pH of a
solution is lower than with the B brand tubes; the pH results we obtained were 6.1
and 7.9, correspondingly.
As Figure 8 demonstrates, we also confirmed the presence of potassium, a peak
between 6 and 8 minutes; magnesium, a peak at around 10 minutes; and calcium, a
peak at around 12 minutes.
Presence of magnesium came with no surprise; authors using a different analyt-
ical method previously reported on it and explained that it leaks from a closure and
originates from an additive [1]. Though we confirmed a difference between A and B
brand tubes, the latter contained magnesium in much lower concentration.
The concentration of calcium is low in both cases and might be considered an
impurity originating from other chemicals. But what makes a real difference
between the tubes of the two brands and was not expected is potassium. While it is
nearly inexistent in tube B, it is obviously present in tube A. We used infrared
spectroscopy to explain where it originates from; it appears that the source might be
a tripotassium salt of EDTA; if this is the case, its concentration is approximately
200 times lower than the citrate concentration.
6. Conclusions
This research proved differences in characteristics of tubes of different brands
and different lots, and their attributes are also changing during a shelf life. We
suggested fast, easy-to-perform testing procedures, which already by using purified
Figure 8.
Chromatograms for determination of sodium, potassium, magnesium, and calcium in the tubes of two different
brands, A and B, after a draw-volume test.
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two ion chromatographic techniques, ion-exclusion chromatography for determi-
nation of citrate and ion-exchange chromatography for determination of cations.
Figure 8 depicts chromatograms obtained for determinations of cations after a
draw-volume test. Four chromatographic peaks emerge. The first peak appearing
between 4 and 6 minutes pertains to the major cation, sodium, originating from the
anticoagulant, trisodium citrate. This peak is presented twice with two different y-
axis scales, in the main chromatogram with its top is out of scale and in the inserted
frame where it is fully visible.
The peak for the A brand tubes is smaller, indicating that in this case citrate is
buffered, while in addition to sodium ions there are hydronium ions (H+, or H3O
+)
to neutralize a negative charge of citrate equilibrium forms. In other words, in the
case of the A brand tubes, the anticoagulant solution was prepared not only from a
trisodium citrate but also with an addition of citric acid. Consequently, the pH of a
solution is lower than with the B brand tubes; the pH results we obtained were 6.1
and 7.9, correspondingly.
As Figure 8 demonstrates, we also confirmed the presence of potassium, a peak
between 6 and 8 minutes; magnesium, a peak at around 10 minutes; and calcium, a
peak at around 12 minutes.
Presence of magnesium came with no surprise; authors using a different analyt-
ical method previously reported on it and explained that it leaks from a closure and
originates from an additive [1]. Though we confirmed a difference between A and B
brand tubes, the latter contained magnesium in much lower concentration.
The concentration of calcium is low in both cases and might be considered an
impurity originating from other chemicals. But what makes a real difference
between the tubes of the two brands and was not expected is potassium. While it is
nearly inexistent in tube B, it is obviously present in tube A. We used infrared
spectroscopy to explain where it originates from; it appears that the source might be
a tripotassium salt of EDTA; if this is the case, its concentration is approximately
200 times lower than the citrate concentration.
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This research proved differences in characteristics of tubes of different brands
and different lots, and their attributes are also changing during a shelf life. We
suggested fast, easy-to-perform testing procedures, which already by using purified
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Chromatograms for determination of sodium, potassium, magnesium, and calcium in the tubes of two different
brands, A and B, after a draw-volume test.
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water and low-cost equipment only give an insight into draw volume and anticoag-
ulant concentration as can be expected for a blood specimen collection.
No doubt, a laboratory has to prove on blood samples that a particular type of
tubes it is using or intends to use is fit for purpose. But already with a minimum
required number of samples of 20 individuals, a study becomes complex, profes-
sionally demanding, and time-consuming. However, not knowing the characteris-
tics of the tubes entering the investigation lacks generality.
Testing procedures as suggested are not to replace but to support such investi-
gations and to make them more economical. A quality control of the tubes as such is
easy to introduce into a laboratory practice and does not importantly contribute to a
workload. The tubes do not change very rapidly over the time and do not need to be
tested very frequently if of the same lot. However, insight into their characteristics
provides guidance when a study on blood samples needs to step in to cover impor-
tant distinctive conditions a laboratory is likely to face during its everyday routine.
A draw-volume test we described is generally applicable. Procedures for deter-
mining K2EDTA and K3EDTA concentrations in the tubes before a specimen col-
lection are well established; nevertheless comparably easy-to-perform testing
procedures for citrate tubes yet need to be developed.
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workload. The tubes do not change very rapidly over the time and do not need to be
tested very frequently if of the same lot. However, insight into their characteristics
provides guidance when a study on blood samples needs to step in to cover impor-
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Chapter 5
In Silico Proteomics EVOO
Therapy for Lipid Lowering in
the Patients of Diabetes Mellitus
Muhamamd Suhail and Samreen Riaz
Abstract
Diabetes mellitus is a chronic disease caused by inherited and/or acquired
deficiency in the production of insulin by the pancreas, or by ineffectiveness of the
insulin produced. Diabetes is a life-long disease marked by elevated levels of sugar
in the blood. It is considered as the second progressing cause of color blindness and
kidney defects throughout the world. There are four times higher chances of getting
heart disease and strokes suffering with diabetes than other ailments. Type-2
diabetes has approximately 90% cases in Pakistan and need to be checked out for its
therapy. Olive oil could be helpful in diabetes via many of ways, as prolonged
inflammation plays a role as an enhancer of diabetes and other diabetes problems.
This study reports identification of some of the cheapest ways to lower the choles-
terol in the diabetes mellitus in the local population by using advanced technologies.
In this work, the main focus of the research was to use olive oil as a therapy, and as a
lipid lowering agent, to improve and reduce the chance of blood pressure, lipids,
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1. In silico proteomics
Bioinformatics is a science of intellectual biology with respect to molecule
recognition as it uses informatics principles to sort out the information of molecules
on large scale. Applied math, statistics and computer laid down its foundation.
In simple words, bioinformatics work as a platform for management of data in
molecular biology field. It has many other applications too in molecular biology [1].
Bioinformatics has many applications in different fields of biology like geno-
mics, biotechnology, molecular biology, and many areas of biomedical sciences.
For instance, it is used in DNA fingerprinting, agriculture and drug designing
approaches [1]. Drug designing is done in silico by the comparative association of
ligand protein interactions; leads obtained this way provide innovative medicines.
This type of association is the base of synthetic drug designing. The 3-D structure of
proteins is studied via pyMOL or VMD softwares. These softwares clearly demon-
strate the receptor ligand relationship in drug designing process. The drug devel-
oped by this way requires less budget with greater efficiency and less or no harmful
side effects. Drug development is done utilizing informatics principles (Lagunin
et al., 2014).
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In Silico Proteomics EVOO
Therapy for Lipid Lowering in
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Diabetes mellitus is a chronic disease caused by inherited and/or acquired
deficiency in the production of insulin by the pancreas, or by ineffectiveness of the
insulin produced. Diabetes is a life-long disease marked by elevated levels of sugar
in the blood. It is considered as the second progressing cause of color blindness and
kidney defects throughout the world. There are four times higher chances of getting
heart disease and strokes suffering with diabetes than other ailments. Type-2
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Now a days criminal are captured by using bioinformatics tools like phylogenetic
analysis provide a proof against the criminal in court of law. In forensic analysis
Bayesian statistics are utilized to detect DNA of culprit [2]. Bioinformatics has
made of healthcare system modernize with the introduction of personalized
drugs etc. [3].
Now it has become possible with the advancement in the knowledge of bioin-
formatics that genetic defects are pin pointed on time and are tried to be eliminated
before their expression. In this way better treatment has become possible in this era
(Takeichi et al., 2015). Bioinformatics has revolutionized the agriculture system
with the introduction of new and better crops varieties with increased production
potential and resistant against crop damaging agents (Katam et al., 2015).
Bioinformatics is not only limited to Allied health fields but it is also play





• Climate change analysis
• Comparative studies
• Crop betterment













• Waste cleanup process
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1.1 In silico drug designing
Discovery of new drug is lengthy and expensive process and require lots of
mass efforts too. Many of the times the year’s hard work in drug discovery is wasted
away due to certain factors like toxic effects, poor drug metabolism etc. (Grinter
and Zou, 2014).
So with the advancement in the field of informatics, the drug discovery process
has been completely changed as drugs are developed in silico with the help of latest
Bioinformatics tools and applications. Today many fields use in silico drug design-
ing (Figure 1) method like biochemistry, nanotechnology and molecular biology.
This method has major advantage on others is its cost effectiveness and quickness
(Grinter and Zou, 2014).
Many outstanding tools and softwares are used for drug development by in silico
method, those includes;
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• Patch dock &
• AutoDock Vina
This in silico based approach is used in every stage of drug discovery starting
from preclinical phase to terminal phase of drug development process [4].
1.2 Phytochemicals
Olea europaea (extra virgin olive oil EVOO) was selected as an anti-diabetic
agent as it has many beneficial effects like improvement of hyperglycaemia and
lowering of lipid profile of diabetic patients. That is why it was selected and its
docking was augmented against certain proteins genetically linked to diabetes.
1.3 Proteins involved in diabetes
There are following proteins which are genetically linked to diabetes, these
proteins with their characteristics and available commercial drugs against these
protein markers have been shown in Table 1.






protein kinase type 1D
42,914 Da 385 No drug found Quaternary
structure
A disintegrin and metalloproteinase
with thrombospondin motifs 9
216,491 Da 1935 No drug found Quaternary
structure
Calpain-10 74,952 Da 672 No drug found Quaternary
structure
Cell division cycle protein 123
homolog








30,022 Da 270 No drug found Quaternary
structure
Insulin-degrading enzyme 117,968 Da 1019 6bK inhibitor Quaternary
structure
Homodimer
Insulin-like growth factor 2
mRNA-binding protein 2
66,121 Da 599 No drug found Quaternary
structure
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1.4 Significance of in silico, drug designing
In silico medical practitioner to select best suitable drug for the treatment of
disease. The drug designed by this way prove to be less toxic, fewer or no side effect
and more capable than any other drug available. In silico drug designing has appli-
cation in all the phases of new drug development process. All these in silico analysis
are done with the help of different tools and application softwares of bioinformatics
(Schmidt et al., 2014; Tian et al., 2015).
1.5 Aims of study
In silico bioinformatics analysis were used to screen and check the therapeutic
potential of Olea europaea to treat type two diabetes mellitus. For this purpose
certain proteins responsible for diabetes were selected and in silico analysis were
done to check the reversion effect of Olea europaea against these diseases causing
proteins expression. The purpose of the study was to screen and isolate potential
therapeutic agent present in the Olea europaea which could be the best treatment
option of diabetes.
1.6 Future prospective
The in silico drug development could be meaningful in the certain aspects:





Juxtaposed with another zinc finger
protein 1




43,541 Da 390 Sulfonylurea Quaternary
structure
Potassium voltage-gated channel
subfamily KQT member 1




G-protein coupled receptor 5
99,998 Da 907 No drug found Quaternary
structure

















219,607 Da 1953 No drug found Quaternary
structure
Tetraspanin-8 26,044 Da 237 No drug found Quaternary
structure
Wolframin 100,292 Da 890 Incretin Quaternary
structure
Table 1.
Proteins involved in diabetes along with their properties, structure and available drugs has been demonstrated.
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• Reduction of drug invention time and cost
• Harmless, effective and target specific drug development
• To improvement in result analysis






Diabetes is a persistent ailment which happens because of the raised blood
glucose due to the lack of the body’ ability to produce insulin secretion or sufficient
insulin secretions. Insulin secretion is obtained from the pancreas gland in the body
and is prerequisite for the transport of glucose from bloodstream to the living cells
where it is utilized to obtain energy for the body. Deficit of insulin or impotence of
cells to response to insulin results in high level of blood glycaemia or
hyperglycaemia which is distinctive feature of diabetes. Hyperglycaemia, if
remained uncontrolled over long period, can cause severe damage to different body
parts leading to development of disabling or many life-threatening health issues like
cardiovascular disorders, neuropathy, nephropathy and eye diseases leading to
retinopathy and blindness. Proper management of diabetes helps prevent or delay
those complications (Atlas 2017 intro 1).
The term diabetes was initiated from Greek word “syphon” or “mellitus” means
Honeyed proposed by Rollo in late eighteenth century [5]. Matthew Dobson for the
first time reported the hyperglycemic nature of diabetes in his article during 1776;
he observed elevated glucose level in urine and plasma of patients. Holt et al. [6]
reported the raised level of ketone bodies in diabetes.
Million people die of diabetes each year, mostly from cardiovascular disease
exacerbated by lipid disorders and other complications. Identification of new treat-
ment strategies using olive oil for lipid lowering in diabetes through proteomic
analysis was needed. With the increase in the world population the proportion of
diabetes is also increasing with great speed so, the more health care budget is
needed to cope with this problem. As without proper primary strategies and care it
will take the face of epidemic which will kill millions of lives in the world. With this
speed it is possible that diabetes would become the number one killer of the world
within next coming 25 years. Abrupt actions are required to root out the diabetes
from the world.
Olive oil supplementation with daily food intake might play a protective role to
reduce lipid profile in diabetes due to the beneficial effect of olive oil exerted by its
antioxidant constituents.
In most of the cases when the disease is detected it is already too late to be cured.
The percentage of fatalities in patients is therefore very high. Not only there is a vast
number of precious lives are lost but the treatment and maintenance of such
patients is a heavy financial burden on the individual families and the national
68
Biochemical Testing - Clinical Correlation and Diagnosis
resources. It is therefore necessary that cheap and quick methods are made available
which can be used to screen population so that the diseases can be detected at a very
early stage. Research and development work based on the samples from our popu-
lation groups is essential because findings have been reported to be dependent on
race variations, and socio-economic and other factors. Thus the studies reported on
the basis of population groups in other parts of the world may not be valid at least in
some cases.
This study reports identification of some of the cheapest way to lower the
cholesterol profile in the diabetes mellitus in the local population by using
advance technologies. In this work, the prime focus was to the use of olive oil as
therapy for cholesterol lowering agent to improve and reducing the chance of
blood pressure, lipids and hence diabetes and cardiovascular disease will be
discussed. The findings from present research work would prove better
treatment options for diabetic patients by introduction and characterization of
new therapy methods.
DM is one out of many lethal melodies. It is ranked fourth deadliest malady, and
the rate of prevalence is increasing sharply. Olive oil a liquid fat captured from
olives tree crop cultivating in the Mediterranean Basin. Complete olives are pressed
to gain olive oil.
Results generated from this research will help devise for the novel diagnostic
procedures for early and control of diabetes complications in our population. These
findings will provide a base in planning better treatment strategies for diabetic
patients by suggested dose of olive oil nutritional supplement. The research work
proposed to be undertaken under this project shall elucidate the roles of olive oil in
diabetes mellitus in our population. Therapy for the diabetes to be investigated
should lead to not only saving lot of precious lives but also ensure saving of huge
numbers of man-hours and colossal amount financial resources spent on treatment
and patient maintenance. The other financial gains accruing from this project is the
application of the project results in developing therapy methods locally for routine
use in our clinical laboratories.
2.1 Classification
Diabetes has been grouped into two types since 600 BC but the clear classifica-
tion into two types was done in nineteenth century. Diabetes of young before
ketoacidosis and diabetes of obese people, later these two types were named as
MODY by WHO. By the discovery of human leukocyte antigen (HLA) and anti-
bodies in 1970, it was become clear that all the patients on insulin treatment were
suffering with autoimmune disorder [6]. WHO revised the classification into two
types of diabetes in 1980 and 1985 based on the clinical findings, which were
insulin-dependent diabetes mellitus (IDDM) and the noninsulin-dependent diabe-
tes mellitus (NIDDM). Classification of 1999 was accepted and revised with small
changes and diabetes was grouped into (T1DM), (T2DM), gestational diabetes
mellitus, and some other types [7].
For the diagnosis of diabetes, the diagnostic criterion has been adopted and
revised over and again by world health organization (WHO). The current criteria
states that diabetes is diagnosed by the elevated level of glucose in the bloodstream
of diabetic patients (Table 2).
2.2 Type 1 diabetes mellitus
T1DM is an autoimmune ailment caused when the body’s immune system attack
on the Beta-cells in the islets of pancreas gland. As a conclusion body produce very
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little or none insulin with a relative or absolute deficiency of insulin in the body.
The reason of this deadliest process are not completely understood but it is thought
that genetic susceptibility and environmental factors like viral infection, toxins and
some dietary factors could be the cause of the problem (Chapt1 type1 10). Type 1
diabetes occurs mostly in children and adolescents. It is managed with proper daily
injections of insulin otherwise the survival of the patient would be impossible.
Type 1 is diagnosed by raised level of glucose and with the specific symptoms
(Figure 2). Type 1 diabetes incidence rate in Karachi, the largest city of Pakistan is
1.02/100,000 in comparison to type 2 diabetes mellitus [8].
2.3 Type 2 diabetes mellitus
Type 2 diabetes is commonest type of diabetes throughout the world accounting
around 90% of all the diabetic patients. It is occurred due to insufficient production
of insulin or insulin resistance. During insulin resistance insulin become ineffective




The symptoms of type 1 diabetes.
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glucose but as the time passes productive ability of insulin producing cell is lost
ultimately a state of inadequate insulin production is developed. Usually type 2
diabetes occurs in older adults but it is increasingly seen in children, adolescent and
young adults due to physical inactivity, poor diet increasing level of obesity (13–15).
Type 2 diabetes alarming incidence in Pakistan is associated with poor diet etc. [9].
The estimated prevalence of Pakistan ranges from 7.6 to 11% in 2011 [10]. The
symptoms of T2DM are like T1DM (Figures 3 and 4).
2.4 Gestational diabetes mellitus (GDM)
GDM is a non-pathophysiological condition and one out of seven new born has
gestational diabetes according to [11]. GDM caused by glucose intolerance which
was first diagnosed in pregnancy period and may remain after pregnancy (Gavin III
et al., 1997). The development of undiagnosed asymptomatic T2DM and T1DM
during pregnancy is referred as GDM [12]. The occurrence of GDM is reported
during the last 6 months of the pregnancy while the development of diabetes in
women during first trimester is termed as T2DM [13].
2.5 Type 1.5 diabetes
Latent Autoimmune Diabetes in Adults (LADA) non-officially called as Type 1.5
diabetes. The term 1.5 indicates that disease is a type 1 diabetes mellitus but it shares
Figure 3.
The symptoms of typ. 2 diabetes.
Figure 4.
Different risk factors of typ. 2 diabetes mellitus (T2DM).
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during the last 6 months of the pregnancy while the development of diabetes in
women during first trimester is termed as T2DM [13].
2.5 Type 1.5 diabetes
Latent Autoimmune Diabetes in Adults (LADA) non-officially called as Type 1.5
diabetes. The term 1.5 indicates that disease is a type 1 diabetes mellitus but it shares
Figure 3.
The symptoms of typ. 2 diabetes.
Figure 4.
Different risk factors of typ. 2 diabetes mellitus (T2DM).
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some feature with type 2 diabetes mellitus that is the reason it is called as Type 1.5
diabetes means in between T1DM and T2DM. It is also known as Type 3 diabetes.
Type 1.5 diabetes is diagnosed during adulthood and has slow onset similar to T2DM
however, it is type 1 diabetes mellitus and will need insulin therapy in future.
Around 15–20% patients with type 2 diabetes are actually suffering with type 1
diabetes. They are treated with oral medication initially but will need insulin ther-
apy after some period of oral treatment. Type 1.5 diabetic patients do not have
standard symptoms of type 2 diabetes and have reduced risk of heart problem if
their blood sugar is kept in control (Diabetes, UK).
2.6 Other specific types of diabetes
Some other types of diabetes occur due to the genetic malfunctions, impaired
secretory activity of pancreas and over production of certain hormones. For
instance MODY situation affects certain genes which are responsible for beta-cells
development, functioning and regulation of glucose. Likewise excessive production
certain growth hormones, cortisol, epinephrine and glucagon enhance the glucose
production in liver cells and increase insulin resistance in muscle cells resulting in
the progression of diabetes mellitus [14]. Cystic fibrosis–related diabetes (CFRD)
occurred in cystic fibrosis patients due to insulin resistance and genetic dysfunction
of beta-cell linked with inflammation and infection [15].
2.7 Epidemiology
With every passing decade individual with diabetic ailment are increasing tre-
mendously, currently there are 425 million people suffering with diabetes and 352
million people have falsified glucose tolerance (IGT). IGT is also named as impaired
fasting glucose (IFG) or “Pre-Diabetes”. The individual with IFG has been at peak
Figure 5.
Worldwide distribution of diabetes. Adapted from: IDF diabetes (IDF 2017).
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risk of diabetes in near future. According to IDF, 1 in 11 people has diabetes till now
and it is projected to be 1 in 10 till 2040 (IDF 2017).
Pakistan is among the top 10 most affected diabetic countries of the world and is
projected to be at 8th position until 2045 (20–79 years of age. Other major countries
on the top of the list are China, India, United States, Brazil, Mexico, Indonesia,
Russian federation, Egypt, Germany and Pakistan respectively. According to latest
estimates Pakistan has 7.2 million population of diabetes and projected to be 16.1
million by 2045 (Atlas 2017). Previous studies reported 5.2 million diabetic popula-
tion of Pakistan in 2000 and projected to be 13.9 million till 2030 [16]. The world-
wide prevalence of diabetes is shown in Figure 5. In urban areas the ratio of
diabetes is 22.04% and in rural areas it is 17.15%. In Punjab, diabetes in female is
19.3% and in male it is 16.6%. In KPK it is 11.1% in both male and female in
Balochistan it is 10.8% in both [17, 18]. But in Sindh female proportion is 11.7% and
in male is 16.2% (Hussain and Ali, 2017) Figure 6 demonstrate the distribution of
diabetes in all the provinces of Pakistan (Figure 7) [19–39].
Figure 6.
Distribution of diabetes in different provinces of Pakistan [40].
Figure 7.
List of top 10 countries having diabetes (IDF Atlas 2017).
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2.8 Prevention of diabetes
As diabetes is multifactorial gene disorder, as genetic information and environ-
mental effects both play a role in this disease. Type 1 diabetes is comparatively less
affected with environmental factors but type 2 does. So, it is difficult to stop the
onset of type 1 diabetes, but for type 2 diabetes there are many known preventive
measures. These preventive measures include maintaining normal body weight, use
of healthful diet and regular physical exercise. Changing in eating habits are known
to reduce the risk of diabetes, such as taking whole grain diet, using diet with good
fats (nut, fish) and reducing use of saturated fats (red meat). But above all, limit use
of sweet edibles is the most important and effective preventive measure as well as
in controlling the complication of diabetes. In addition, if an individual quits smoking,
the risk of onset of diabetes reduces many folds (Figure 7) [41].
3. Extra virgin olive oil (EVOO)
EVOO is one of the most important components of Mediterranean diet having
many health benefits. At first, excess of (MUFA) especially oleic acid, was thought
Figure 8.
Representing health benefits of extra virgin olive oil.
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as the major beneficial constituent of virgin olive oil. Most important health benefit
of EVOO (Figure 8) is improved cardiovascular heal, reduction of inflammation
and oxidative stress. It is used in Mediterranean diet since many decades. Studies
suggested that Mediterranean food specimen along with EVOO lowers the risk of
heart disorders as compared to controls. Other studies reported that EVOO improve
hyperglycemia and lipid level in patients with dysfunctional fasting glucose
(Roberto et al., 2016). Almost 200 ‘minor particles’ in the un-saponifiable portion of
olive oil comprise about 2% of the total weight of EVOO [42–63].
3.1 Nutritional effects of EVOO
One tablespoon of EVOO contains 14 g of total fat, 2 g of saturated fats and has
no fiber, sugar, cholesterol etc. Vitamins E, K are also present in it also has phytos-
terols, a which is structurally similar to cholesterol because it hinders cholesterol
absorption from food and lower LDL values associated with heart disease. Major
EVOO polyphenols include secoiridoids, phenols, and lignans. The chemical struc-
tural formula of EVOO is shown in Figure 9 and metabolism of EVOO is shown in
Figure 10.
3.2 Effects on cholesterol level
There is no cholesterol in the EVOO while other animal obtained fats contain
different amount of cholesterol. Recently, the European Food Safety Authority
(EFSA) has reported beneficial effect of EVOO on LDL oxidation process due to its
phenolic (Figure 10).
4. Justification
Diabetes mellitus is one of the most lethal melodies of the world and ranked
fourth in deadliest diseases. It is metabolic defect that results in hyperglycaemia.
The distribution of diabetes is spreading with great speed. The diabetic mass of
Pakistan is among the top 10 diabetic populations of the world and is projected to be
at 8th position among most prevailing diabetic countries by 2045 (IDF 2017). With
this rate 1 out of 4 persons in Pakistan is diabetic. It is not a single etiological
condition but it is a multifactorial ailment that is affecting Pakistan population
severely. Diabetes has no cure at the moment only preventive and supportive
therapy is given to improve the living of people by means of oral medication and
insulin injections [63–72].
Million people die of diabetes each year, mostly from cardiovascular disease
exacerbated by lipid disorders and other complications.
Olive oil use has may a protective role to reduce the lipid profile in diabetes due
to the beneficial effect of its antioxidant level. Since oral medications and insulin are
the best possible treatment option but still these have some side effects like drugs
toxicity, renal failure and inflammation and infection at the point of injection of
insulin to minimize the effect and to obtain a better alternative treatment option
which should be natural, harmless, cheap and could prove a permanent cure of
diabetes we chose EVOO as a therapy of the type 2 diabetes.
Since there are some recent studies available which support the use of EVOO
as a lipid and glucose lowering agent in type 2 diabetes mellitus. EVOO improves
the post prandial glycaemia by incretin like mechanism in which up-regulation
of incretin took place in this way lipid and glucose levels are reduce by EVOO.
EVOO also reduce oxidative stress, inflammation lower lipid level which is the
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hallmark of the diabetes that is why EVOO is compound of choice for the therapy
of diabetes. The phenols in the EVOO are the major components responsible for
these beneficial effects. Due of the fact that the EVOO therapy for the treatment of
diabetes has never been studied before in the diabetic population of Pakistan we
step forward and to use this natural compound as a therapy for treatment of type 2
diabetes [72–80].
There is no study available in Pakistan that support the therapeutic effect of
EVOO in type 2 diabetes so got the idea to prove the therapeutic value of EVOO in
the Diabetic population of Pakistan, for this we selected the Lahore region that is
one of the populated city of Pakistan.
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Chapter 6
ZIKV Diagnostics: Current 
Scenario and Future Directions
Zilton Vasconcelos, Renata Campos Azevedo, Andrea Zin, 
Luiza Neves and Daniela Prado Cunha
Abstract
Since the discovery of the Zika virus in Uganda in 1947, diagnostic challenges 
remain, especially when we take into account the epidemiological context of the 
surveyed population. Genetic similarities with other flavivirus are responsible 
for cross-reac tivity during serological evaluation that would often be the only 
resources to confirm the infection in asymptomatic cases or samples collected 
after the short window of viral RNA detection. The importance of Zika virus 
infection diagnosis is undoubtedly useful for pregnant women. This statement 
became evident after 2015 Brazil’s Zika outbreak when a significant increase in 
cases of newborn with microcephaly was observed. Reverse transcriptase real-
time PCR is the most reliable tool for Zika virus infection diagnosis. It detects 
viral RNA in both biological fluids and tissues and contributes to clinical case 
classification for initial description of developmental changes observed in neo-
nates exposed congenitally to Zika virus. In conclusion, advances in serological 
diagnostic are urgent. The safest pathway for these studies requires laborious, 
subjective, and low throughput PRNT evaluations. Consequently, critical public 
health questions remain unanswered: how serum prevalent is the general popula-
tion and pregnant women; can we define risk for congenital Zika syndrome (CZS) 
and Guillain-Barré syndrome; and how to assess vaccine efficacy and long-term 
protection.
Keywords: congenital Zika syndrome, real-time RT-PCR, PRNT, serum prevalence
1. Introduction
The Zika virus (ZIKV) belongs to the family Flaviviridae, genus Flavivirus, 
phylogenetically related to the dengue, yellow fever, and West Nile virus [1]. The 
main vector is the Aedes aegypti, hematophagous arthropod well adapted to urban 
living conditions, and for this reason, they are considered as emergent arboviruses, 
transmitted mainly by mosquitoes of the genus Aedes.
Clinically, the infection produces a self-limited febrile disease, whose symptoms 
of the acute phase are fever, headache, myalgia, and cutaneous rash. The virus 
incubation period in humans can range from 3 to 12 days, very similar to other 
arboviruses such as dengue and chikungunya virus. Thus, in regions where there is 
co-infection of these viruses, ZIKV can be sub-notified [2].
The ZIKV is transmitted to humans by the bite of infected female mosquitoes. 
However, other mechanisms of transmission have been described such as sexual 
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1. Introduction
The Zika virus (ZIKV) belongs to the family Flaviviridae, genus Flavivirus, 
phylogenetically related to the dengue, yellow fever, and West Nile virus [1]. The 
main vector is the Aedes aegypti, hematophagous arthropod well adapted to urban 
living conditions, and for this reason, they are considered as emergent arboviruses, 
transmitted mainly by mosquitoes of the genus Aedes.
Clinically, the infection produces a self-limited febrile disease, whose symptoms 
of the acute phase are fever, headache, myalgia, and cutaneous rash. The virus 
incubation period in humans can range from 3 to 12 days, very similar to other 
arboviruses such as dengue and chikungunya virus. Thus, in regions where there is 
co-infection of these viruses, ZIKV can be sub-notified [2].
The ZIKV is transmitted to humans by the bite of infected female mosquitoes. 
However, other mechanisms of transmission have been described such as sexual 
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transmission, blood transfusion, and through breastfeeding [3–6]. In addition, the 
presence of ZIKV RNA has been identified already in body fluids such as endocer-
vical or nasopharyngeal swab, saliva, and urine, which highlights other possible 
routes of transmission [7–11]. For example, ZIKV RNA detection in amniotic fluid 
was essential to define fetal infection during vertical transmission [12].
During 1947, ZIKV was originally isolated from the serum of a febrile rhesus mon-
key female, which was used as a sentinel to detect wild yellow fever virus in the Zika 
forest, localized at Uganda [13]. At the same site, the ZIKV was also isolated from a 
mosquito genus Aedes Africanus sample. More than one decade later, the first case of 
ZIKV infection in humans was reported in Uganda, with a detailed clinical descrip-
tion performed by a doctor who described his own infection. He described symptoms 
such as a mild headache, diffuse maculopapular rash, fever, and malaise [14].
Despite this report, ZIKA infections remained relatively unknown until 2007, 
when it occurred as a major outbreak in Micronesia, representing the first evidence 
of virus circulation outside the African continent [15].
The disease spread rapidly across the islands of the Pacific Ocean, and in 
October 2013, initial cases were diagnosed in French Polynesia that culminates with 
a major epidemic [16]. In February 2014, for the first time, ZIKV was detected in 
the Americas, and those cases were reported on Easter Island (Chilean territory 
in the Pacific Ocean), probably related to the outbreak in Micronesia and French 
Polynesia [17].
In Brazil, the first autochthonous transmission was observed in April 2015 in 
patients from Rio Grande do Norte, where the sequence of a fragment of viral enve-
lope protein revealed high identity with ZIKV sequences of the Asian lineage [2]. The 
Ministry of Health of Brazil confirmed the circulation of ZIKV in the country, after 
identifying the viral RNA in 16 serum samples (8 cases from Bahia and the others 
from Rio Grande do Norte). The main symptoms described were arthralgia, edema 
of the extremities, low fever, headache, and retro-orbital pain, conjunctival hyper-
emia, and maculopapular rashes, besides pruritus, dizziness, myalgia, and digestive 
disorder [18]. Approximately 80% of ZIKV infections are asymptomatic or display 
mild-to-moderate symptoms that are self-limited and last between 5 and 7 days [19].
However, before ZIKV outbreak detection, the number of infants born with 
microcephaly in the second half of 2015 increased tremendously, when compared 
with historical reports. This observation was done in the Northeast region of the 
country, and Recife and Salvador and their surroundings were the most severely 
affected cities [18]. Retrospectively, the anamnesis of most parturients revealed 
episodes of febrile illness and exanthematous skin lesions during pregnancy [20]. 
Considering the epidemiological situation, in November 2015, the World Health 
Organization confirmed the relationship between ZIKV infection and congenital 
malformations in neonates, with most cases developing microcephaly and/or 
ventriculomegaly [21, 22].
In addition to CNS malformations due to congenital infections, ZIKV outbreak 
was also associated with increased number of cases of Guillain-Barré Syndrome 
(GBS) in French Polynesia, indicating another CNS-related complication resulting 
from ZIKV infection [23, 24]. In Brazil, severe manifestations associated with ZIKV 
infections were also described such as GBS, transverse myelitis, and meningitis in 
adults [23, 25].
2. Structural properties, genetic context, and evolution
ZIKV particle is composed of a positive-sense, single-stranded RNA about 
10,794 bp in length involved by a protein capsid and surrounding a lipid 
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membrane. The RNA genome presents 5′ and 3′ untranslated regions (UTR), 
flanking a single long open reading frame (ORF) that translates one polyprotein 
(5’-C-prM-E-NS1-NS2A-NS2BNS3-NS4A-NS4B-NS5–3′). After cleavage, the 
polyprotein originates three structural proteins: capsid (C), membrane (M), 
and envelope (E), which are virus particle components, and seven nonstructural 
proteins: NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5, which are involved in 
genome replication, polyprotein cleavage, and evasion of immunologic response 
(Figure 1) [26, 27]. The genome region, encoding flavivirus structural proteins, 
is more susceptible to genome variation when compared to nonstructural coding 
regions. Envelope protein (E), the major virion surface protein, is responsible for 
virus-cell interaction and membrane fusion, therefore being the major target for 
neutralizing antibodies [28]. Three domains were identified in E protein EDI, EDII, 
and EDIII. Karin Stettler and colleagues demonstrated that monoclonal antibod-
ies (mAbs) directed to EDIII domain presented a potent and specific neutralizing 
activity to ZIKV, whereas mAbs directed to EDI/EDII domains partially neutralized 
ZIKV. Additionally, EDI/EDII-specific mAbs displayed higher cross-reactivity with 
dengue virus and enhanced in vitro viral infection, the phenomena described as 
antibody-dependent enhancement (ADE) [29]. This information should be con-
sidered in the development of ZIKV-specific diagnostic tool using antibody-based 
detection.
Figure 1. 
Flavivirus particle diagram. Flavivirus are small spherical enveloped particles. Envelope protein (E), 
responsible for virus-cell interaction and membrane fusion, is the main target for neutralizing antibodies. The 
membrane-associated protein (M) results from the cleavage of the precursor to membrane protein (PrM) 
during virus maturation. Capsid proteins (C) assemble into an icosahedral structure (capsid) and involve the 
virus genomic material (ssRNA+). The genomic RNA coding region is flanked by two untranslated regions 
(5’ UTR and 3’ UTR) and produces a polyprotein that after proteolytic cleavage generates all functional virus 
proteins. Adapted from de Vasconcelos et al. [32].
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transmission, blood transfusion, and through breastfeeding [3–6]. In addition, the 
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However, before ZIKV outbreak detection, the number of infants born with 
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from ZIKV infection [23, 24]. In Brazil, severe manifestations associated with ZIKV 
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adults [23, 25].
2. Structural properties, genetic context, and evolution
ZIKV particle is composed of a positive-sense, single-stranded RNA about 
10,794 bp in length involved by a protein capsid and surrounding a lipid 
85
ZIKV Diagnostics: Current Scenario and Future Directions
DOI: http://dx.doi.org/10.5772/intechopen.82373
membrane. The RNA genome presents 5′ and 3′ untranslated regions (UTR), 
flanking a single long open reading frame (ORF) that translates one polyprotein 
(5’-C-prM-E-NS1-NS2A-NS2BNS3-NS4A-NS4B-NS5–3′). After cleavage, the 
polyprotein originates three structural proteins: capsid (C), membrane (M), 
and envelope (E), which are virus particle components, and seven nonstructural 
proteins: NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5, which are involved in 
genome replication, polyprotein cleavage, and evasion of immunologic response 
(Figure 1) [26, 27]. The genome region, encoding flavivirus structural proteins, 
is more susceptible to genome variation when compared to nonstructural coding 
regions. Envelope protein (E), the major virion surface protein, is responsible for 
virus-cell interaction and membrane fusion, therefore being the major target for 
neutralizing antibodies [28]. Three domains were identified in E protein EDI, EDII, 
and EDIII. Karin Stettler and colleagues demonstrated that monoclonal antibod-
ies (mAbs) directed to EDIII domain presented a potent and specific neutralizing 
activity to ZIKV, whereas mAbs directed to EDI/EDII domains partially neutralized 
ZIKV. Additionally, EDI/EDII-specific mAbs displayed higher cross-reactivity with 
dengue virus and enhanced in vitro viral infection, the phenomena described as 
antibody-dependent enhancement (ADE) [29]. This information should be con-
sidered in the development of ZIKV-specific diagnostic tool using antibody-based 
detection.
Figure 1. 
Flavivirus particle diagram. Flavivirus are small spherical enveloped particles. Envelope protein (E), 
responsible for virus-cell interaction and membrane fusion, is the main target for neutralizing antibodies. The 
membrane-associated protein (M) results from the cleavage of the precursor to membrane protein (PrM) 
during virus maturation. Capsid proteins (C) assemble into an icosahedral structure (capsid) and involve the 
virus genomic material (ssRNA+). The genomic RNA coding region is flanked by two untranslated regions 
(5’ UTR and 3’ UTR) and produces a polyprotein that after proteolytic cleavage generates all functional virus 
proteins. Adapted from de Vasconcelos et al. [32].
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Regarding the nonstructural proteins, NS1 glycoprotein is a multifunctional 
virulence factor that intracellularly co-localizes with the virus replication com-
plex. In addition, an infected cell secretes NS1 as a hexameric lipoprotein, and 
several immunomodulatory functions are proposed for this particular protein 
[27]. The secretion of NS1 during acute dengue infection culminates in high 
serum levels of this protein. It occurs mainly during viremic period and encour-
ages the development of NS1-based serologic diagnostic tests during previous 
dengue outbreaks [30]. Recently, one serologic test for ZIKV based on NS1 
reinforces the use of this protein as an acute phase biomarker for flavivirus infec-
tion [31]. The NS5 protein is the largest viral protein whose C-terminal portion 
has RNA-dependent RNA polymerase (RdRP) activity. The polymerase region of 
the protein is generally conserved and can be used for the design of a broad range 
of primers.
Genetic studies using nucleotide sequences derived from the NS5 gene indicated 
three ZIKV lineages: East African, West African, and Asian [1]. However, after 
genome-based phylogenetic analysis, Asian and African strains remained as the 
only two genetic lineages for ZIKV [1]. ZIKV was associated with sporadic human 
infections in Africa and Southeast Asia by the end of the last century and was 
described as a zoonotic pathogen [33]. Due to the first isolation in monkeys and 
mosquitoes, the maintenance of the enzootic ZIKV was first attributed to those two 
groups of animals. However, antibodies have been detected in other animal species 
[26]. The ZIKV ability to switch species can play a special role in virus evolution. 
Especially in virus presenting RNA genome, nucleotide polymorphisms have long 
been noted as an evolutionary mechanism and indicate viral adaptation to the host 
[34, 35]. The mutation rate of ZIKV was demonstrated to be between 12 and 25 
bases per year and corresponds to 0.2% of total ZIKV genome [36]. On top of the 
mutation rate, recombination events also play an important role in virus evolution. 
Fay et al. studying the molecular evolution of ZIKV reported a possible event of 
recombination in E and NS5 genes affecting African samples [28]. Han et al. pro-
pose a recombinant event within Brazilian strain (ZikaSPH2015), French Polynesia 
strain (H/PF/2013), and strain Z1106033 from Suriname [37]. Noteworthy, the 
recombination within Asian strains was not supported by Jun and colleagues when 
196 ZIKV genomes were analyzed [38]. Therefore, further investigation is needed 
in order to accurately correlate genome changes and virulence.
3. Molecular tests (virus detection)
3.1 Quantitative polymerase chain reaction (qPCR)
Quantitative polymerase chain reaction amplification (qPCR) assays have been 
used for laboratory diagnosis of viral infectious diseases, since the sensitivity, 
specificity, and speed of the method allow the rapid detection of viruses in the 
host, human clinical samples, biopsies, and autopsy tissue. Since ZIKV is an RNA 
virus, running an initial reverse transcriptase step followed by a qPCR (RT-qPCR) 
is recommended. This method has been proved to be the most reliable one to 
confirm ZIKV infection during acute phase. Then, the first step for molecular ZIKV 
detection is the RNA isolation from different patient biological samples. When one 
is dealing with tissue samples, it is necessary to mechanically dissociate the freshly 
isolated tissue fragment to further conduct the nucleic acid extraction process. 
Other body fluid samples could be directly processed by an RNA isolation kit before 
viral genome reverse transcriptase reaction followed by amplification using ZIKV-
specific primers and probes.
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One of the limitations of the PCR technique is related to the presence of 
inhibitory substances, such as IgG, hemoglobin, lactoferrin in blood samples, and 
anticoagulants as heparin, that have already been described as PCR inhibitors 
[39]. In urine samples, the most critical component described as PCR inhibitors is 
urea, which can lead to degradation of the polymerase. However, its direct effect 
is dependent on urea concentration in the sample [40]. One way to monitor an 
inhibitory effect performed by PCR inhibitors is to carry out PCR positive control 
reactions. Spike-in experiments where an exogenous microorganism is added to 
your patient sample, to be co-extracted and amplified by another pair of primers 
and probe, could demonstrate inhibitors’ presence when no amplification  
occurs [41].
Other limitations of the technique are related to both the time of infection 
(acute phase) and the type of sample chosen. This relationship is directly associ-
ated with the success of the laboratory confirmation. It is known that the presence 
of the virus in the plasma, saliva, breast milk, and nasopharyngeal swab is short, 
which allows the detection of viral RNA for a limited time, and during the acute 
phase of the disease, it is calculated on average 3–7 days after the occurrence of 
the symptoms. On the other hand, urine and saliva biological samples are opti-
mal in the context of infant and newborn diagnosis due to low invasiveness and 
easy sample access [7, 10, 42–44]. In term of RNA detection, urine samples are 
described to present positivity from the fourth day until 29 days after the onset of 
symptoms [45], another time this sample opens the possibility of virus detection 
in longer times, even after the period of viremia. In adults, the biological sample 
that displays an increased period of viral persistence was semen, with cases where 
RNA detection occurred months after ZIKV infection. This raises the possibility 
that viral persistence could exist in both female and male genital tract (Figure 2) 
[8, 42, 46–48].
Apart of a positive RT-qPCR result for ZIKV, quantitative PCR offers the opportu-
nity to deliver viral copies relative to tissue milligrams or fluid milliliters. To calculate 
viral load is imperative to construct a standard curve, from a serial dilution from a 
Figure 2. 
Literature evidence on the average period of virus RNA positivity in different body fluids and serum 
immunoglobulins levels after symptoms onset. Bars following the timeline indicate sample and proper molecular 
test that should be used to investigate infection after viral exposition, and dashes represent virus load decrease. 
*Immunoglobulins development expected for a primary flavivirus infected patient. A secondary exposition 
should promote earlier and higher IgG serum titles with short and reduced IgM levels. **ZIKV detection in 
genital fluids without viremia suggests viral tropism and persistence in those organs.
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several immunomodulatory functions are proposed for this particular protein 
[27]. The secretion of NS1 during acute dengue infection culminates in high 
serum levels of this protein. It occurs mainly during viremic period and encour-
ages the development of NS1-based serologic diagnostic tests during previous 
dengue outbreaks [30]. Recently, one serologic test for ZIKV based on NS1 
reinforces the use of this protein as an acute phase biomarker for flavivirus infec-
tion [31]. The NS5 protein is the largest viral protein whose C-terminal portion 
has RNA-dependent RNA polymerase (RdRP) activity. The polymerase region of 
the protein is generally conserved and can be used for the design of a broad range 
of primers.
Genetic studies using nucleotide sequences derived from the NS5 gene indicated 
three ZIKV lineages: East African, West African, and Asian [1]. However, after 
genome-based phylogenetic analysis, Asian and African strains remained as the 
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recombination within Asian strains was not supported by Jun and colleagues when 
196 ZIKV genomes were analyzed [38]. Therefore, further investigation is needed 
in order to accurately correlate genome changes and virulence.
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3.1 Quantitative polymerase chain reaction (qPCR)
Quantitative polymerase chain reaction amplification (qPCR) assays have been 
used for laboratory diagnosis of viral infectious diseases, since the sensitivity, 
specificity, and speed of the method allow the rapid detection of viruses in the 
host, human clinical samples, biopsies, and autopsy tissue. Since ZIKV is an RNA 
virus, running an initial reverse transcriptase step followed by a qPCR (RT-qPCR) 
is recommended. This method has been proved to be the most reliable one to 
confirm ZIKV infection during acute phase. Then, the first step for molecular ZIKV 
detection is the RNA isolation from different patient biological samples. When one 
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isolated tissue fragment to further conduct the nucleic acid extraction process. 
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One of the limitations of the PCR technique is related to the presence of 
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anticoagulants as heparin, that have already been described as PCR inhibitors 
[39]. In urine samples, the most critical component described as PCR inhibitors is 
urea, which can lead to degradation of the polymerase. However, its direct effect 
is dependent on urea concentration in the sample [40]. One way to monitor an 
inhibitory effect performed by PCR inhibitors is to carry out PCR positive control 
reactions. Spike-in experiments where an exogenous microorganism is added to 
your patient sample, to be co-extracted and amplified by another pair of primers 
and probe, could demonstrate inhibitors’ presence when no amplification  
occurs [41].
Other limitations of the technique are related to both the time of infection 
(acute phase) and the type of sample chosen. This relationship is directly associ-
ated with the success of the laboratory confirmation. It is known that the presence 
of the virus in the plasma, saliva, breast milk, and nasopharyngeal swab is short, 
which allows the detection of viral RNA for a limited time, and during the acute 
phase of the disease, it is calculated on average 3–7 days after the occurrence of 
the symptoms. On the other hand, urine and saliva biological samples are opti-
mal in the context of infant and newborn diagnosis due to low invasiveness and 
easy sample access [7, 10, 42–44]. In term of RNA detection, urine samples are 
described to present positivity from the fourth day until 29 days after the onset of 
symptoms [45], another time this sample opens the possibility of virus detection 
in longer times, even after the period of viremia. In adults, the biological sample 
that displays an increased period of viral persistence was semen, with cases where 
RNA detection occurred months after ZIKV infection. This raises the possibility 
that viral persistence could exist in both female and male genital tract (Figure 2) 
[8, 42, 46–48].
Apart of a positive RT-qPCR result for ZIKV, quantitative PCR offers the opportu-
nity to deliver viral copies relative to tissue milligrams or fluid milliliters. To calculate 
viral load is imperative to construct a standard curve, from a serial dilution from a 
Figure 2. 
Literature evidence on the average period of virus RNA positivity in different body fluids and serum 
immunoglobulins levels after symptoms onset. Bars following the timeline indicate sample and proper molecular 
test that should be used to investigate infection after viral exposition, and dashes represent virus load decrease. 
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reference sample that was previously determined RNA copies or plaque forming units 
(PFU). Then, the sample result will be possible to extrapolate from a relative mea-
surement to an absolute quantification applied to a patient sample. This quantitative 
molecular diagnosis, in some pathologies (e.g., Hepatitis B and C, HIV, and herpes), 
has been already described as important indicators of health status and guide treat-
ment choices. In the case of ZIKV infection, viral load does not appear to be related 
with clinical adverse events in congenital infections [49] or general population [50], 
but it was important to demonstrate viral load in different biological samples. As 
shown in Figure 3, the amniotic fluid has the highest viral load when compared with 
other biological fluids (urine or blood). However, in the context of an epidemiological 
outbreak, blood and urine are the more accessible samples with a significantly higher 
amount of virus and prolonged RNA detection (Figure 2) in urine than blood. The 
placenta did not present a significant difference when compared to blood and urine.
However, as discussed before, potential ZIKV RNA viral mutation turns RT-qPCR 
methods not infallible. Viral genetic evolution raises the possibility that polymor-
phisms inside primer annealing site may generate false negative amplification 
reactions of the ZIKV genome targeted region. During 2015 ZIKV outbreak, there 
was six widely used in-house RT-qPCR methods for diagnostic [1, 51–53], and their 
suitability for detection of ZIKV Asian strain was reported by Corman et al. with 
clear differences in sensitivity between them [54]. Poor PCR sensitivity and low RNA 
viral load observed in patient samples can be one of the explanations for the reduced 
number of laboratory-confirmed cases during the last epidemics. Few RT-qPCR kits 
for ZIKV detection were commercially available, and high costs also limited their use 
and could be the other reason for lower confirmed cases, especially in most of the 
endemic countries [55]. Besides the small amount of proficient clinical laboratories, 
performance control of in-house methodologies continues to be a challenging task; 
therefore, constant interlaboratory control should be stimulated, and standardized 
reagents, suitable probes, and primers should be used whenever possible.
3.2 Immunoenzymatic assays for virus detection
3.2.1 NS1 tests
Another flavivirus laboratory test that has gained prominence is the detection of 
NS1 viral protein in the serum, which in turn reflects a viral infection during the acute 
Figure 3. 
ZIKV RNA viral load in different biological samples. Noninvasive biological samples urine presents a higher 
viral load than blood samples (**p-value < 0.001). AF viral load is the highest when compared with other 
maternal samples (***p-value < 0.0001). AF, amniotic fluid. CSF, cerebrospinal fluid. Data generated from 13 
placentas, 12 CSF, 6 fetal tissues, 4 AF, 24 urine, and 49 blood samples.
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phase [56]. Largely used during DENV outbreaks, it is based on NS1 protein secre-
tion by infected cells that reach high serum concentrations during periods of viral 
replication during flaviviruses and is considered an important acute phase biomarker 
for dengue fever. The assay format is suitable for use in routine laboratories around 
the world, allowing high-throughput testing in epidemic regions [31, 56]. Serological 
identification of ZIKV infections could also be maximized by parallel testing for IgM/
IgG and NS1. The limitation of this assay is related to cross-reactivity between Zika 
and other flaviviruses, once they display a high degree of homology around their viral 
proteins, especially with dengue [1]. However, serological tests are constantly improv-
ing in order to increase the specificity through the use NS1-based anti-ZIKV, and it 
has been recently shown to be more sensitive and highly specific for the serodiagnosis 
of ZIKV infections but has not yet been commercially available [31].
3.2.2 Immunohistochemistry
Immunohistochemistry is an important tool to evaluate vertical transmission 
(placenta infection). Through this, viral particles of ZIKV have already been detected 
in placental defense cells, known as Hofbauer cells. These cells are of fetal origin and 
have the ability to migrate, in areas that have contact with trophoblastic epithelium 
and vessels of the fetus. It is believed that ZIKV has an immune system evasion 
mechanism and Hofbauer cells are responsible for viral dissemination, facilitating 
their access to the fetal compartment besides being a viral reservoir [57]. Due to access 
to the fetal compartment, ZIKV gains open access to fetal layer where no more immu-
nological barrier could arrest their access to fetal central nervous system (CNS) [58].
ZIKV neuronal tropism was observed and described in affected fetus through 
necropsy studies. It was clearly demonstrated ZIKV antigens being expressed in 
large amounts in the brain with sporadic amounts of ZIKV antigens found in other 
fetal tissues, like liver, kidney, heart, and lung [59]. The opportunity to demonstrate 
CNS prolonged viral persistence was showed in a necropsy study conducted in a 
5-month infant deceased after ZIKV congenital infection, which occurred in the 
first trimester of pregnancy. In this case report, ZIKV was still present in the brain 
tissue with no evidence of inflammation or brain damage evolution [60].
3.3 Virus isolation
Virus isolation using cell culture or animals remains as an option for virus 
detection. Vertebrate or invertebrate cells (e.g., Aedes albopictus clone C6/36) can 
be used for ZIKV propagation from the biological sample. This methodology allows 
the identification of infectious particles and was used to evaluate the body fluid 
potential to transmit the virus, such as saliva, breast milk, and urine. Additionally, 
cellular propagation increases the sensitivity in low viral load samples; however, the 
condition of sample transport and storage can impact the test result. This seems to 
be even more important for ZIKV, which demonstrates reduced stability in fluids 
and tissues [61]. Due to the time required for virus propagation and the cell culture 
structure need, viral isolation is not used in the diagnostic routine.
4. Serology tests
4.1 ELISA tests
The considerable cross-reactivity between flavivirus antibodies is the major 
challenge for serological test development. In endemic areas, where dengue and 
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ing in order to increase the specificity through the use NS1-based anti-ZIKV, and it 
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their access to the fetal compartment besides being a viral reservoir [57]. Due to access 
to the fetal compartment, ZIKV gains open access to fetal layer where no more immu-
nological barrier could arrest their access to fetal central nervous system (CNS) [58].
ZIKV neuronal tropism was observed and described in affected fetus through 
necropsy studies. It was clearly demonstrated ZIKV antigens being expressed in 
large amounts in the brain with sporadic amounts of ZIKV antigens found in other 
fetal tissues, like liver, kidney, heart, and lung [59]. The opportunity to demonstrate 
CNS prolonged viral persistence was showed in a necropsy study conducted in a 
5-month infant deceased after ZIKV congenital infection, which occurred in the 
first trimester of pregnancy. In this case report, ZIKV was still present in the brain 
tissue with no evidence of inflammation or brain damage evolution [60].
3.3 Virus isolation
Virus isolation using cell culture or animals remains as an option for virus 
detection. Vertebrate or invertebrate cells (e.g., Aedes albopictus clone C6/36) can 
be used for ZIKV propagation from the biological sample. This methodology allows 
the identification of infectious particles and was used to evaluate the body fluid 
potential to transmit the virus, such as saliva, breast milk, and urine. Additionally, 
cellular propagation increases the sensitivity in low viral load samples; however, the 
condition of sample transport and storage can impact the test result. This seems to 
be even more important for ZIKV, which demonstrates reduced stability in fluids 
and tissues [61]. Due to the time required for virus propagation and the cell culture 
structure need, viral isolation is not used in the diagnostic routine.
4. Serology tests
4.1 ELISA tests
The considerable cross-reactivity between flavivirus antibodies is the major 
challenge for serological test development. In endemic areas, where dengue and 
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Zika viruses cocirculate besides several proposed ELISA tests, individuals previ-
ously exposed to other flaviviruses are not prevented to be misclassified. Another 
complication for patients experiencing a second flavivirus infection is a shorten IgM 
antibody response that could misdiagnose the time for acute infection [1].
This presents a diagnostic dilemma for patients living in regions in which flavivi-
ruses are endemic, and reliable diagnostic tools that are able to discriminate between 
primary and secondary ZIKV or DENV infections are urgently needed [1, 62, 63].
Although the precise period of onset and duration IgM class antibodies in 
response to ZIKV is not well defined, data known by other flaviviruses suggest that 
IgM for ZIKV should start to be detectable 7 days following infection, in the major-
ity of symptomatic patients (Figure 2). However, it has been recently reported in 
the literature that seroconversion may occur earlier for one-third of patients [1, 42]. 
While anti-ZIKV antibody titers decrease, IgM to ZIKV has a window of detection 
more than 12 weeks following infection for over 80% of individuals [42]. According 
to the modeling studies with other flaviviruses, including West Nile virus (WNV) 
and dengue (DENV), this serum persistence is consistent with the antibody 
responses following infection, suggesting that the mean time to IgM seronegativity 
ranges from 5 to 6 months [64, 65].
Apart from initial antibody response, IgG neutralizing antibodies (NA) nor-
mally develop after IgM response and should persist for years to decades following 
primary infection. It is believed that NA to ZIKV directed to a key epitope after 
infection should be highly specific in patients without prior exposure to flavivi-
ruses; however, NA specificity, in the setting of past exposure to a closely related 
flavivirus, such as DENV, once shares diverse antigenic determinants, decrease 
specificity to ZIKV epitopes [1].
Another tool that is being proposed in the context of outbreaks is rapid point of 
care (POC) tests which are based on the IgM/IgG immunochromatography assay. 
They should be used carefully and are normally interpreted as qualitative screening 
tests, and further serological investigations are needed. When they present a posi-
tive result, the patient samples should be sent for plaque reduction neutralization 
test (PRNT), or in the case of pregnant women, RT-qPCR is recommended [66, 67].
Special attention should be given to the risk group composed of newborns, 
where the immunoenzymatic serological test is extremely important to define con-
genital infection. ZIKV IgG antibody detection in a newborn may reflect maternal 
infection due to the passive transfer of this class of immunoglobulins. Based on 
other congenital infections, uninfected newborns display IgG levels that decline 
gradually in the first months of life, and this corresponds to the time of elimination 
of the antibody transmitted by the mother [68]. For this reason, tests to detect IgM 
are commonly used to confirm infection in the child, and in the context of flavivirus 
infection, only ZIKV was demonstrated to cross the placental and fetal immuno-
logical barriers [69, 70]. ZIKV IgM positivity in CSF, after congenital infection, was 
described as a reliable tool to discriminate fetal infection, and it characterized high 
risk for neuroinvasive disease [71].
4.2 Plaque reduction neutralization test (PRNT)
Until now, the unique reference standard for NA detection related to flaviviruses 
remains the plaque reduction neutralization test (PRNT). Although technically 
cumbersome, with several challenges: (1) long turnaround time of days to weeks; 
(2) requirement for live viral cultures; (3) technical-experience dependence; and 
(4) high degree of subjectivity, it offers the highest achievable level of specificity. 
This test initiates with a serial dilution of patient serum that is preincubated with 
live ZIKV or other closely related viruses (e.g., DENV), followed by deposition 
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onto a virus-susceptible cell monolayer. After proper incubation time, any resulting 
plaques suggest nonneutralized live virus and absence of specific antibodies. Those 
plaques are quantified and compared to plaques number obtained in culture wells 
containing virus-only in order to establish which serum dilution promotes 90% 
reduction in plaques occurrence in this patient sample (PRNT90). ZIKV and DENV 
PRNT90 titers are subsequently compared to define the specificity of the NAs [72]. 
Although the PRNT assay has a higher sensitivity than other tests such as hemag-
glutination and enzyme immunoassay and is more specific than other serological 
methods for the diagnosis, the limitation of this test is not discriminate between 
antibody classes and, especially in secondary flavivirus infections, cross-reactive 
neutralizing antibodies may contribute to virus neutralization [73]. In addition, 
PRNTs are time-consuming and laborious and are to be restricted to reference 
laboratories and research centers because they require the technical capacity to 
carry them out, as well as a complex laboratory structure [46].
5. Clinical context
Zika virus (ZIKV) infection is usually an asymptomatic or a mild symptomatic 
disease in adults, with maculopapular and pruritic rash, fever, conjunctivitis, joint 
pain, headache, and muscle pain [74]. However, infection during pregnancy may be 
transmitted to the fetus and causes severe systemic fetuses’ malformations, com-
prising the congenital Zika syndrome (CZS).
The clinical features of CZS have been described since 2015 Zika’s outbreak in 
Brazil. They can be divided into structural and functional components [75]. The 
structural components are cranial morphology, brain, and ocular anomalies, as 
well as congenital contractures [75]. The functional component is related to neuro-
logic sequelae [75]. Therefore, CZS may consist of (A) cranial morphology: severe 
microcephaly, overlapping cranial sutures, prominent occipital bone, redundant 
scalp skin, and neurologic impairment; (B) brain anomalies: thin cerebral cortices, 
abnormal gyral patterns, increased fluid spaces, subcortical calcifications, corpus 
callosum abnormalities, decreased white matter, and cerebellar hypoplasia; (C) 
ocular anomalies: macular scarring (Figure 4A), focal pigmentary retinal mottling 
(Figure 4B), and optic nerve hypoplasia or atrophy (Figure 4A); (D) congenital 
contractures: arthrogryposis and club feet; and (E) neurologic sequelae: marked 
early hypertonia, symptoms of extrapyramidal involvement, epilepsy, and irritabil-
ity [75–77]. Early recognition and referral to multidisciplinary care may result in a 
better outcome for each one of the abnormalities described.
Figure 4. 
(A) Right eye retinography showing macular (black arrowhead) and peripheral (black arrow) scarring and 
optic nerve hypoplasia (white arrow); (B) left eye retinography showing focal pigmentary retinal mottling 
(black arrow).
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ranges from 5 to 6 months [64, 65].
Apart from initial antibody response, IgG neutralizing antibodies (NA) nor-
mally develop after IgM response and should persist for years to decades following 
primary infection. It is believed that NA to ZIKV directed to a key epitope after 
infection should be highly specific in patients without prior exposure to flavivi-
ruses; however, NA specificity, in the setting of past exposure to a closely related 
flavivirus, such as DENV, once shares diverse antigenic determinants, decrease 
specificity to ZIKV epitopes [1].
Another tool that is being proposed in the context of outbreaks is rapid point of 
care (POC) tests which are based on the IgM/IgG immunochromatography assay. 
They should be used carefully and are normally interpreted as qualitative screening 
tests, and further serological investigations are needed. When they present a posi-
tive result, the patient samples should be sent for plaque reduction neutralization 
test (PRNT), or in the case of pregnant women, RT-qPCR is recommended [66, 67].
Special attention should be given to the risk group composed of newborns, 
where the immunoenzymatic serological test is extremely important to define con-
genital infection. ZIKV IgG antibody detection in a newborn may reflect maternal 
infection due to the passive transfer of this class of immunoglobulins. Based on 
other congenital infections, uninfected newborns display IgG levels that decline 
gradually in the first months of life, and this corresponds to the time of elimination 
of the antibody transmitted by the mother [68]. For this reason, tests to detect IgM 
are commonly used to confirm infection in the child, and in the context of flavivirus 
infection, only ZIKV was demonstrated to cross the placental and fetal immuno-
logical barriers [69, 70]. ZIKV IgM positivity in CSF, after congenital infection, was 
described as a reliable tool to discriminate fetal infection, and it characterized high 
risk for neuroinvasive disease [71].
4.2 Plaque reduction neutralization test (PRNT)
Until now, the unique reference standard for NA detection related to flaviviruses 
remains the plaque reduction neutralization test (PRNT). Although technically 
cumbersome, with several challenges: (1) long turnaround time of days to weeks; 
(2) requirement for live viral cultures; (3) technical-experience dependence; and 
(4) high degree of subjectivity, it offers the highest achievable level of specificity. 
This test initiates with a serial dilution of patient serum that is preincubated with 
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Although the PRNT assay has a higher sensitivity than other tests such as hemag-
glutination and enzyme immunoassay and is more specific than other serological 
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antibody classes and, especially in secondary flavivirus infections, cross-reactive 
neutralizing antibodies may contribute to virus neutralization [73]. In addition, 
PRNTs are time-consuming and laborious and are to be restricted to reference 
laboratories and research centers because they require the technical capacity to 
carry them out, as well as a complex laboratory structure [46].
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disease in adults, with maculopapular and pruritic rash, fever, conjunctivitis, joint 
pain, headache, and muscle pain [74]. However, infection during pregnancy may be 
transmitted to the fetus and causes severe systemic fetuses’ malformations, com-
prising the congenital Zika syndrome (CZS).
The clinical features of CZS have been described since 2015 Zika’s outbreak in 
Brazil. They can be divided into structural and functional components [75]. The 
structural components are cranial morphology, brain, and ocular anomalies, as 
well as congenital contractures [75]. The functional component is related to neuro-
logic sequelae [75]. Therefore, CZS may consist of (A) cranial morphology: severe 
microcephaly, overlapping cranial sutures, prominent occipital bone, redundant 
scalp skin, and neurologic impairment; (B) brain anomalies: thin cerebral cortices, 
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Figure 4. 
(A) Right eye retinography showing macular (black arrowhead) and peripheral (black arrow) scarring and 
optic nerve hypoplasia (white arrow); (B) left eye retinography showing focal pigmentary retinal mottling 
(black arrow).
Biochemical Testing - Clinical correlation and Diagnosis
92
Figure 5. 
Flowchart showing initially two clinical scenarios (symptomatic and asymptomatic pregnant women) 
and the different primary and secondary tests and results for Zika virus diagnosis during pregnancy. NAT: 
RT-qPCR nucleic acid test. IgM: Immunoglobulin M. US: Intrauterine ultrasound. PRNT: Plaques reduction 
neutralization test.
The diagnostic approach during prenatal care should be different in an endemic 
area and in a nonendemic area. Endemic area means residence in or travels to the 
affected area. In addition, in each of these two scenarios, the diagnosis is divided 
into symptomatic and asymptomatic pregnant women.
5.1 Endemic area (residence or travel)
5.1.1 Symptomatic pregnant women
The ZIKV infection is divided into acute and convalescent phases. The acute 
phase is within the first 7 days of the symptoms, and the convalescent phase is 
2–12 weeks after [78]. As shown in Figure 5, during the acute phase, the possible 
primary tests are the ZIKV RT-qPCR and the Immunoglobulin (Ig) M. The first one 
can be obtained from serum, saliva, urine, or amniotic fluid. When it is detected in 
the serum or saliva, it is confined to 5–7 days after onset of symptoms, and when 
it is detected in urine, it lasts up to 3 weeks after onset of illness. The evidence is 
lacking on the diagnostic accuracy of RT-qPCR of amniotic fluid and on the optimal 
time to perform amniocentesis [74]. The IgM is detectable ≥4 days after onset of 
illness [78]. In the convalescent phase, the primary test is IgM and the second test is 
plaque reduction neutralization test (PRNT). However, the Zika virus RT-qPCR can 
also be performed during this phase.
If the primary results are negative ZIKV RT-qPCR and negative ZIKV IgM 
(red flowchart in Figure 5), there is no evidence of virus detection, but an intra-
uterine ultrasound scan (US) should be done. If there are any fetal development 
abnormalities, serological tests for others congenital infections could be done and 
the pregnant woman should be referred to a specialized care. The possible congenital 
infections are toxoplasmosis, rubella, cytomegalovirus (CMV), herpes virus, parvo-
virus B19, varicella, and syphilis, known by the acronym TORCH’s syndrome (Sd). 
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The possible fetal abnormalities are microcephaly, intracranial calcifications, ocular 
lesions and calcifications, ventriculomegaly, abnormal sulcation and gyration, 
abnormal cortical development (lissencephaly), cerebral atrophy, callosal dysgen-
esis, cerebellar atrophy, brainstem hypoplasia, microphthalmia and arthrogryposis, 
intrauterine growth restriction, and evidence of placental insufficiency [74]. If there 
is absence of fetal abnormalities, the pregnant can follow routine antenatal care and 
it should be considered to repeat the US at 28–30 weeks [74].
If the primary results are negative ZIKV RT-qPCR and non-negative ZIKV IgM, 
the secondary test PRNT should be performed. It can be done for any other flavivirus 
that might be found in that geographic area [74]. If ZIKV PRNT ≤10 (white flowchart 
in Figure 5), there is no evidence of Zika virus infection. If ZIKV PRNT ≥10 and 
dengue virus PRNT ≥10 (blue flowchart in Figure 5), there is evidence of a flavivirus 
infection but no confirmation of a specific virus. Finally, if ZIKV PRNT ≥10 and den-
gue virus PRNT <10 (green flowchart in Figure 5), there is evidence of ZIKV infec-
tion. In any of the last two scenarios, the timing of infection cannot be determined.
If the primary result is positive ZIKV RT-qPCR (green flowchart in Figure 5), 
acute ZIKV infection is confirmed and US should be done. If there is any fetal abnor-
mality, the pregnant woman should be referred to a specialized care, and if there 
is no abnormality, routine antenatal care should be done, as well as a US follow-up 
every 4 weeks until birth [74, 79].
5.1.2 Asymptomatic pregnant women
In endemic area of residence or traveling, the pregnant woman with possible 
ZIKV exposure should be first tested at initiation of prenatal care and three times 
during pregnancy [67]. The primary tests should be ZIKV RT-qPCR and ZIKV IgM 
serology. If available, US should be considered for fetal morphology assessment. 
The possible results of the laboratory tests and US are described above.
5.2 Nonendemic area
The asymptomatic woman should follow the routine antenatal care. The symp-
tomatic woman should do the primary tests ZIKV RT-qPCR and ZIKV IgM serology. 
If available, US for fetal morphology assessment should be considered.
Additionally, the differential diagnosis is also crucial for the correct assessment 
and management of the disease. Signs of maternal disease, as well as intrauterine 
and neonatal findings, are similar in most of the TORCH’s congenital infections 
[75, 80]. Moreover, some genetic syndromes (Sd), such as Aicardi-Goutières Sd, 
pseudo-TORCH Sd, and mutations in the JAM3, NDE1, and ANKLE2 genes can also 
be in the differential diagnosis [75].
The main clinical findings in maternal TORCH infections include nonspecific 
signs, like fever, fatigue, malaise, headache, myalgia, arthralgia, lymphadenopathy, 
conjunctivitis, and making the ability to recognize the specific etiological agent dif-
ficult. Moreover, there are typical findings in some of these infections that can lead 
to the diagnosis. In herpes simplex virus infection, there is also painful genital ulcer, 
pruritus, and dysuria [80]. In primary syphilis infection, there is a firm, round, and 
painless chancre on external genitals and vagina, lasting 3–6 weeks [81]. In rubella, 
parvovirus B19, varicella, and ZIKV, cutaneous rash is an additional important sign 
[80, 82, 83]. The rash in rubella is maculopapular and usually progresses from the 
face to the body, fading within 2–4 days [80, 82, 83]. In parvovirus B19, the rash is 
also maculopapular, persisting until the 6th day and disappearing on the 7–9th day 
after the first appearance [80, 82, 83]. First, it occurs on the face, sparing nasal, 
and periorbital zones and second, on the trunk and extremities [83]. In varicella, it 
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affected area. In addition, in each of these two scenarios, the diagnosis is divided 
into symptomatic and asymptomatic pregnant women.
5.1 Endemic area (residence or travel)
5.1.1 Symptomatic pregnant women
The ZIKV infection is divided into acute and convalescent phases. The acute 
phase is within the first 7 days of the symptoms, and the convalescent phase is 
2–12 weeks after [78]. As shown in Figure 5, during the acute phase, the possible 
primary tests are the ZIKV RT-qPCR and the Immunoglobulin (Ig) M. The first one 
can be obtained from serum, saliva, urine, or amniotic fluid. When it is detected in 
the serum or saliva, it is confined to 5–7 days after onset of symptoms, and when 
it is detected in urine, it lasts up to 3 weeks after onset of illness. The evidence is 
lacking on the diagnostic accuracy of RT-qPCR of amniotic fluid and on the optimal 
time to perform amniocentesis [74]. The IgM is detectable ≥4 days after onset of 
illness [78]. In the convalescent phase, the primary test is IgM and the second test is 
plaque reduction neutralization test (PRNT). However, the Zika virus RT-qPCR can 
also be performed during this phase.
If the primary results are negative ZIKV RT-qPCR and negative ZIKV IgM 
(red flowchart in Figure 5), there is no evidence of virus detection, but an intra-
uterine ultrasound scan (US) should be done. If there are any fetal development 
abnormalities, serological tests for others congenital infections could be done and 
the pregnant woman should be referred to a specialized care. The possible congenital 
infections are toxoplasmosis, rubella, cytomegalovirus (CMV), herpes virus, parvo-
virus B19, varicella, and syphilis, known by the acronym TORCH’s syndrome (Sd). 
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lesions and calcifications, ventriculomegaly, abnormal sulcation and gyration, 
abnormal cortical development (lissencephaly), cerebral atrophy, callosal dysgen-
esis, cerebellar atrophy, brainstem hypoplasia, microphthalmia and arthrogryposis, 
intrauterine growth restriction, and evidence of placental insufficiency [74]. If there 
is absence of fetal abnormalities, the pregnant can follow routine antenatal care and 
it should be considered to repeat the US at 28–30 weeks [74].
If the primary results are negative ZIKV RT-qPCR and non-negative ZIKV IgM, 
the secondary test PRNT should be performed. It can be done for any other flavivirus 
that might be found in that geographic area [74]. If ZIKV PRNT ≤10 (white flowchart 
in Figure 5), there is no evidence of Zika virus infection. If ZIKV PRNT ≥10 and 
dengue virus PRNT ≥10 (blue flowchart in Figure 5), there is evidence of a flavivirus 
infection but no confirmation of a specific virus. Finally, if ZIKV PRNT ≥10 and den-
gue virus PRNT <10 (green flowchart in Figure 5), there is evidence of ZIKV infec-
tion. In any of the last two scenarios, the timing of infection cannot be determined.
If the primary result is positive ZIKV RT-qPCR (green flowchart in Figure 5), 
acute ZIKV infection is confirmed and US should be done. If there is any fetal abnor-
mality, the pregnant woman should be referred to a specialized care, and if there 
is no abnormality, routine antenatal care should be done, as well as a US follow-up 
every 4 weeks until birth [74, 79].
5.1.2 Asymptomatic pregnant women
In endemic area of residence or traveling, the pregnant woman with possible 
ZIKV exposure should be first tested at initiation of prenatal care and three times 
during pregnancy [67]. The primary tests should be ZIKV RT-qPCR and ZIKV IgM 
serology. If available, US should be considered for fetal morphology assessment. 
The possible results of the laboratory tests and US are described above.
5.2 Nonendemic area
The asymptomatic woman should follow the routine antenatal care. The symp-
tomatic woman should do the primary tests ZIKV RT-qPCR and ZIKV IgM serology. 
If available, US for fetal morphology assessment should be considered.
Additionally, the differential diagnosis is also crucial for the correct assessment 
and management of the disease. Signs of maternal disease, as well as intrauterine 
and neonatal findings, are similar in most of the TORCH’s congenital infections 
[75, 80]. Moreover, some genetic syndromes (Sd), such as Aicardi-Goutières Sd, 
pseudo-TORCH Sd, and mutations in the JAM3, NDE1, and ANKLE2 genes can also 
be in the differential diagnosis [75].
The main clinical findings in maternal TORCH infections include nonspecific 
signs, like fever, fatigue, malaise, headache, myalgia, arthralgia, lymphadenopathy, 
conjunctivitis, and making the ability to recognize the specific etiological agent dif-
ficult. Moreover, there are typical findings in some of these infections that can lead 
to the diagnosis. In herpes simplex virus infection, there is also painful genital ulcer, 
pruritus, and dysuria [80]. In primary syphilis infection, there is a firm, round, and 
painless chancre on external genitals and vagina, lasting 3–6 weeks [81]. In rubella, 
parvovirus B19, varicella, and ZIKV, cutaneous rash is an additional important sign 
[80, 82, 83]. The rash in rubella is maculopapular and usually progresses from the 
face to the body, fading within 2–4 days [80, 82, 83]. In parvovirus B19, the rash is 
also maculopapular, persisting until the 6th day and disappearing on the 7–9th day 
after the first appearance [80, 82, 83]. First, it occurs on the face, sparing nasal, 
and periorbital zones and second, on the trunk and extremities [83]. In varicella, it 
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is initially pruritic and maculopapular, following a vesicular phase until crushing 
occurs, usually about 5 days later [84]. Finally, the rash in ZIKV infection is pru-
ritic, descending, and maculopapular, beginning proximally and spreading to the 
extremities with resolution occurring within 1–4 days of onset [14, 74].
Nonspecific intrauterine US findings in TORCH infections are intrauterine 
growth restriction, abnormal fluid imbalance (ascites, hydrops, pericardial effu-
sion, pleural effusion, and oligo-polyhydramnios), hepatosplenomegaly and 
hepatic calcifications, echogenic bowel, echogenic kidneys, and limb deformities 
[80, 85]. Cerebral brain calcification, although relatively common in most of these 
infections, can be an important distinguishing factor due to its location [80, 85]. In 
congenital toxoplasmosis, the calcifications are diffuse and widely distributed, and 
in rubella, they are at basal ganglia [80, 85]. In CMV congenital infection, the cal-
cifications are usually punctate and periventricular or cortical [80, 85]. Conversely, 
in ZIKV, the calcifications are larger and denser, usually appearing at the gray and 
white matter junction [80, 86].
As well as seen with maternal clinical signs and intrauterine US findings, 
TORCH congenital infection can also produce a similar neonatal clinical presenta-
tion, although the features rarely occur simultaneously [87, 88]. The common 
clinical features include growth retardation, prematurity, jaundice, anemia, 
hepatosplenomegaly, microcephaly, cerebral calcifications, chorioretinitis, cata-
racts, microphthalmia, and others [87, 88]. However, clinical findings are more 
associated, although not exclusively, with a determined etiological agent. Cardiac 
lesions and deafness have been described in CMV and rubella congenital infections. 
Cicatricial skin lesions and limb hypoplasia are seen in varicella virus congenital 
infection [87]. Petechial or purpuric form exanthema (blueberry muffin spot) is 
typical of CMV infection [80, 82]. Chorioretinitis, hydrocephalus, and cerebral 
calcifications comprise the characteristic triad of congenital toxoplasmosis [89].
Finally, clinical signs of CZS can also be found in other TORCH infections. 
Cranial ZIKV morphology and brain anomalies can occur in congenital CMV infec-
tion [75]. Congenital contractures can appear in congenital rubella, varicella, and 
Coxsackie B infections [75]. Neurologic sequelae are seen in most TORCH infections 
[75]. Ocular anomalies, such as pigmentary mottling and chorioretinal scars, can 
manifest differently in each of these congenital infections. In rubella, the pigment 
mottling is usually diffused compared with the focal pigment mottling seen in Zika 
virus infection (Figure 4B) [77]. Chorioretinal lesions in toxoplasmosis can present 
with active exudative retinitis or regressed macular or peripapillary retinal scar [77]. 
In ZIKV congenital infection, chorioretinal lesions are atrophic and colobomatous-
like and are found in the macula or retinal periphery (Figure 4A) [77]. Optic nerve 
hypoplasia, commonly seen in ZIKV congenital infection, is seldom seen in rubella, 
toxoplasmosis, herpes, and CMV congenital infections [77].
6. Conclusions
Human clinical diagnosis of ZIKV infection in regions where other arboviruses 
circulate, mainly DENV and CHIKV, has become a daunting task; therefore, labora-
tory confirmation is crucial for conclusive diagnosis. Detection of virus genome 
by RT-qPCR is helpful and demonstrated to be a reliable tool; however, the limited 
window for virus detection, low viral load, and stability restricted the use of these 
methodologies. Antibody screening is also hampered by cross-reactivity among 
other flaviviruses.
Due to impact of ZIKV infection, especially for pregnant women, a confident 
ZIKV serology test is urgently needed, and this will promote a better prenatal 
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follow-up, especially in endemic areas. Nonetheless, as mentioned above, there are 
typical findings to aid the correct diagnosis and, thus, the appropriate management 
and counseling of the disease.
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Abstract
Since the introduction of the most expensive drug in the world (Eculizumab) 
in the therapeutic arsenal of many diseases involving the alternative complement 
pathway (ACP) in their pathophysiology, the unmet need to perform simple 
ACP assays affordable for all countries has become one of the major challenges 
of the contemporary medicine. The assay currently used is AH50, despite it still 
challenging for several laboratories. This educational chapter consists on a detail 
protocol of standardized hemolytic assay AP100 and aims to help clinical labo-
ratories over the world and especially those of the developing and low incomes 
countries to perform it. The procedure is essentially the same as for the timed 
lysis assay and dilution methods (AP50) except the concentration of ACP buf-
fer and the chicken erythrocyte density used to make the gels. In clinical field, 
AP100 has at least nine applications in disease diagnosis and follow-up. AP100 has 
many advantages over the AH50 as it is more reliable for the Eculizumab monitor-
ing and more practical with a purpose to be stored and transported for several 
weeks. AP100 is a portable and easy to use device both at the bedside and in the 
companion medical care.
Keywords: alternative complement pathway, AP100, medicine, simple assay,  
low income countries
1. Introduction
Complement system is the pillar of the immune system by its dual role in 
homeostasis and disease. It is the first line of the innate immunity and augments 
adaptive immunity. Indeed, complement acts as a rapid and efficient immune 
surveillance system that has distinct effects on healthy and altered host cells and 
foreign intruders through a complex cascade of proteases [1]. Activation of the 
pathway occurs through three primary pathways: classical, lectin, and alternative 
pathways. Instead to the other pathways and in addition to properdin as the initiat-
ing molecule, the alternative complement pathway (ACP) is activated via a low 
level of constitutive spontaneous hydrolysis of C3 in a process known as tick-over. 
Importantly, thanks to its amplification loop, ACP plays a major role for the final 
effect of initial specific activation of the classical and lectin complement pathways 
and contributed to 80–90% of any C5 activation regardless the initiating pathway 
[2]. Interestingly, ACP has been shown to play a particularly important role in 
preclinical disease models [3].
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foreign intruders through a complex cascade of proteases [1]. Activation of the 
pathway occurs through three primary pathways: classical, lectin, and alternative 
pathways. Instead to the other pathways and in addition to properdin as the initiat-
ing molecule, the alternative complement pathway (ACP) is activated via a low 
level of constitutive spontaneous hydrolysis of C3 in a process known as tick-over. 
Importantly, thanks to its amplification loop, ACP plays a major role for the final 
effect of initial specific activation of the classical and lectin complement pathways 
and contributed to 80–90% of any C5 activation regardless the initiating pathway 
[2]. Interestingly, ACP has been shown to play a particularly important role in 
preclinical disease models [3].
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The ACP functional assessment constitutes an unmet need in medicine and 
applied research fields as the health valorization of bio-molecules extracted from 
nature. In clinical field it has at least nine applications in disease diagnosis and 
follow-up. For instance in therapy monitoring, it allows to screen patients respond-
ers to the complement blockers like Eculizumab, a patient with abolished activity 
means that he has no C5 mutation and is considered as eligible to this therapy. 
Furthermore, ACP activity makes possible to assess drug effectiveness at the 
plasmatic level [4]. Moreover, by evaluating ACP function we can predict and avoid 
immune-complex diseases flares and end organs damages as in systemic lupus 
erythematosus (SLE).
For the disease diagnosis, several international consensuses include functional 
hypocomplementemia and ACP abnormalities as a diagnostic criterion:
1. Kidney diseases resulting from abnormal control of ACP especially atypical 
hemolytic uremic syndrome (aHUS), C3 glomerulonephritis (C3GN), and dense-
deposit disease (DDD), as well as atypical postinfectious glomerulonephritis [5].
2. Hypocomplementemia by a hemolytic assay constitutes one point in the 
diagnosis score of EULAR/ACR Lupus Classification Criteria 2017 and useful 
marker for evaluating SLE renal disease activity and outcomes [6].
3. The clinical hallmark of paroxysmal nocturnal hemoglobinuria (PNH) is the 
chronic intravascular hemolysis that is a consequence of unregulated activa-
tion of ACP [7].
4. Individuals deficient in components of the alternative and terminal comple-
ment pathways are highly predisposed to invasive, often recurrent menin-
gococcal infections [8]. The most frequent bacterial meningitides related to 
complement proteins deficiencies are dues to factor B, factor D and membrane 
complex attack proteins deficiency.
Disease presentation ACP proteins involved
Immune complex (IC) diseases, SLE with and 
without glomerulonephritis (GN).
Most of ACP proteins trigger tissue injury because 
ACP constitutes the amplification loop of the 
classical pathway
Severe and often repeated pyogenic infections. Deficiency of C3 either primary, or secondary to 
fH or fI deficiency, or the presence of C3 nephritic 
factors. Can also occur with classical component 
deficiency.
Mesangiocapillary glomerulonephritis (MCGN) 
or membranoproliferative glomerulonephritis 
(MPGN)
C3 deficiency classically caused by C3 nephritic 
factors, also fH deficiency
Neisserial infections, usually recurrent 
meningococcal infections.
Occasionally disseminated N. gonorrhea infections.
Terminal component (C5–8) deficiencies; the 
association is less strong in patients with C9 
deficiency. Patients are usually otherwise healthy.
Severe, occasionally repeated, N. meningitidis 
infections in males
Properdin deficiency or Factor D deficiency (very 
rare, not sex linked)
Paroxysmal nocturnal hemoglobinuria Rare acquired clonal disorder of hemopoietic cells 
which lack glycosylphosphatidylinositol (GPI) 
membrane anchored Complement control proteins 
[(DAF) And CD59].
Table 1. 
Clinical presentations of ACP proteins acquired or genetic abnormalities.
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5. Hypocomplementemic hypersensitivity reactions to synthetic hemodialysis 
membrane at the origin of cardiovascular complication, the most frequent and 
life-threatening complication in hemodialysis [9].
6. Several clinical presentations linked to ACP abnormalities as resumed in 
Table 1 [2].
7. ACP is particularly considered in sepsis, due to its uncontrolled amplification 
in sepsis conditions [10].
2. Protocol
The procedure is essentially the same as for the ACP by kinetic fluid phase assay 
except the concentration of AP buffer and the chicken erythrocyte density used to 
make the gels [11]. A value of 100% of plasma ACP function should be defined by 
the pooled normal human plasmas (NHP standard), prepared from a total of 100 
healthy individuals separate for each sex.
2.1 Samples
Patient serum samples for the functional hemolytic assays need to be fresh, 
that is serum should be separated on the day of venepuncture and used the same 
day, or stored at −80°C. This is probably the single most difficult, yet important, 
step because if the cold chain is broken, the results become impossible to interpret 
correctly [12]. Whole blood, with ethylenediaminetetraacetic acid (EDTA) as the 
anticoagulant can also be used.
Chicken red blood cells (CRBC) was collected in tubes containing Alsever or 
20% (v/v) acid citrate dextrose (ACD) and stored at 4°C.
2.2 Buffers and other reagents
1. Phosphate-buffered saline (PBS) contains: 137 mM NaCl, 2.7 mM KCl, 1.5 mM 
KH2PO4, 8.1 mM Na2HPO. Sodium azide can be added if required.
2. Alternative complement pathway buffer (ACP buffer) is PBS containing 
100 mM ethylene glycol-bis(β-aminoethyl ether)N,N′,N′-tetraacetic acid 
(EGTA) and 7 mM MgCl2; resulting in chelation of Ca2+, but not Mg2+, and 
providing additional Mg2+ [13]. This prevents complement activation via the 
classical pathway and facilitates complement activation via the ACP in aga-
rose gels. ACP buffer/gelatin contains 1 g/L gelatin and is used when protein 
concentrations are low.
3. Agarose: use an agarose that has a low melting point as plates are easier to pour.
2.3 Procedure
1. Before starting, in a sterile tube put 9.8 mL of 1×ACP buffer at 56°C. Also let 
warming some Petri dish (or rectangular plate) in the 56°C incubator.
2. Preparation of chicken erythrocytes (CE) for ACP assay
Biochemical Testing - Clinical correlation and Diagnosis
104
The ACP functional assessment constitutes an unmet need in medicine and 
applied research fields as the health valorization of bio-molecules extracted from 
nature. In clinical field it has at least nine applications in disease diagnosis and 
follow-up. For instance in therapy monitoring, it allows to screen patients respond-
ers to the complement blockers like Eculizumab, a patient with abolished activity 
means that he has no C5 mutation and is considered as eligible to this therapy. 
Furthermore, ACP activity makes possible to assess drug effectiveness at the 
plasmatic level [4]. Moreover, by evaluating ACP function we can predict and avoid 
immune-complex diseases flares and end organs damages as in systemic lupus 
erythematosus (SLE).
For the disease diagnosis, several international consensuses include functional 
hypocomplementemia and ACP abnormalities as a diagnostic criterion:
1. Kidney diseases resulting from abnormal control of ACP especially atypical 
hemolytic uremic syndrome (aHUS), C3 glomerulonephritis (C3GN), and dense-
deposit disease (DDD), as well as atypical postinfectious glomerulonephritis [5].
2. Hypocomplementemia by a hemolytic assay constitutes one point in the 
diagnosis score of EULAR/ACR Lupus Classification Criteria 2017 and useful 
marker for evaluating SLE renal disease activity and outcomes [6].
3. The clinical hallmark of paroxysmal nocturnal hemoglobinuria (PNH) is the 
chronic intravascular hemolysis that is a consequence of unregulated activa-
tion of ACP [7].
4. Individuals deficient in components of the alternative and terminal comple-
ment pathways are highly predisposed to invasive, often recurrent menin-
gococcal infections [8]. The most frequent bacterial meningitides related to 
complement proteins deficiencies are dues to factor B, factor D and membrane 
complex attack proteins deficiency.
Disease presentation ACP proteins involved
Immune complex (IC) diseases, SLE with and 
without glomerulonephritis (GN).
Most of ACP proteins trigger tissue injury because 
ACP constitutes the amplification loop of the 
classical pathway
Severe and often repeated pyogenic infections. Deficiency of C3 either primary, or secondary to 
fH or fI deficiency, or the presence of C3 nephritic 
factors. Can also occur with classical component 
deficiency.
Mesangiocapillary glomerulonephritis (MCGN) 
or membranoproliferative glomerulonephritis 
(MPGN)
C3 deficiency classically caused by C3 nephritic 
factors, also fH deficiency
Neisserial infections, usually recurrent 
meningococcal infections.
Occasionally disseminated N. gonorrhea infections.
Terminal component (C5–8) deficiencies; the 
association is less strong in patients with C9 
deficiency. Patients are usually otherwise healthy.
Severe, occasionally repeated, N. meningitidis 
infections in males
Properdin deficiency or Factor D deficiency (very 
rare, not sex linked)
Paroxysmal nocturnal hemoglobinuria Rare acquired clonal disorder of hemopoietic cells 
which lack glycosylphosphatidylinositol (GPI) 
membrane anchored Complement control proteins 
[(DAF) And CD59].
Table 1. 
Clinical presentations of ACP proteins acquired or genetic abnormalities.
105
Semi-Solid Phase Assay for the Alternative Complement Pathway Activity Assessment (AP100)
DOI: http://dx.doi.org/10.5772/intechopen.81743
5. Hypocomplementemic hypersensitivity reactions to synthetic hemodialysis 
membrane at the origin of cardiovascular complication, the most frequent and 
life-threatening complication in hemodialysis [9].
6. Several clinical presentations linked to ACP abnormalities as resumed in 
Table 1 [2].
7. ACP is particularly considered in sepsis, due to its uncontrolled amplification 
in sepsis conditions [10].
2. Protocol
The procedure is essentially the same as for the ACP by kinetic fluid phase assay 
except the concentration of AP buffer and the chicken erythrocyte density used to 
make the gels [11]. A value of 100% of plasma ACP function should be defined by 
the pooled normal human plasmas (NHP standard), prepared from a total of 100 
healthy individuals separate for each sex.
2.1 Samples
Patient serum samples for the functional hemolytic assays need to be fresh, 
that is serum should be separated on the day of venepuncture and used the same 
day, or stored at −80°C. This is probably the single most difficult, yet important, 
step because if the cold chain is broken, the results become impossible to interpret 
correctly [12]. Whole blood, with ethylenediaminetetraacetic acid (EDTA) as the 
anticoagulant can also be used.
Chicken red blood cells (CRBC) was collected in tubes containing Alsever or 
20% (v/v) acid citrate dextrose (ACD) and stored at 4°C.
2.2 Buffers and other reagents
1. Phosphate-buffered saline (PBS) contains: 137 mM NaCl, 2.7 mM KCl, 1.5 mM 
KH2PO4, 8.1 mM Na2HPO. Sodium azide can be added if required.
2. Alternative complement pathway buffer (ACP buffer) is PBS containing 
100 mM ethylene glycol-bis(β-aminoethyl ether)N,N′,N′-tetraacetic acid 
(EGTA) and 7 mM MgCl2; resulting in chelation of Ca2+, but not Mg2+, and 
providing additional Mg2+ [13]. This prevents complement activation via the 
classical pathway and facilitates complement activation via the ACP in aga-
rose gels. ACP buffer/gelatin contains 1 g/L gelatin and is used when protein 
concentrations are low.
3. Agarose: use an agarose that has a low melting point as plates are easier to pour.
2.3 Procedure
1. Before starting, in a sterile tube put 9.8 mL of 1×ACP buffer at 56°C. Also let 
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a. Under aseptic conditions, remove 100  μl packed CE from stock chicken 
blood stored in Alsever’s solution.
b. Wash twice in ACP buffer.
c. Resuspend in the same buffer to the required concentration for assay by 
2.1 mL of ACP buffer and put the cell suspension in a water bath at a tem-
perature of 46°C.  The concentration of CE can be calculated by lysing 
0.1 mL of the stock CE in 2.9 mL H2O and measuring the absorbance of the 
supernatant at 412 nm.
3. Melt 2% agarose stock (most conveniently in a microwave oven although 
immersion in boiling water will suffice) and, using a warm pipet, pipet 
12.25 mL aliquots into universal containers (one for each gel), keep at 56°C.
4. Add the 9.8 mL warmed 1×ACP (56°C) to each bottle of melted agarose. Mix 
well.
Transfer one bottle with diluted agarose to 45°C and allow to cool to this tempe 
rature.
5. To ease pouring the gel, place the warmed Petri dish (or rectangular plate) on 
level tray. Mix carefully and quickly.
6. Pour the mixture evenly onto the level plate. The mixture should go to the mid 
edges of the Petri dish/rectangular plate. Remove bubbles by touching them 
with a pipette tip or gloved finger.
7. Cool plate to 4°C, punch holes using a Pasteur pipette upside down at least 
1 cm apart.
8. Fill wells with a measured serum volumes (30 μL). Include a normal human 
plasma (NHP) standard, and NHP diluted 1/2 and 1/4 on each individual dish/
plate. The size of rings depends on factors such as gel thickness, and NHP 
standards are needed on each dish.
9. Incubate overnight at 4°C, examine Petri dish before transferring to 
37°C. Incubate at 37°C for 1–2 h. Incubate either overnight at 22°C and 2 h at 37°C.
10. Measure the diameters of the rings of lysis and calculate the areas. Areas of 
lysis can be read after photography, or after making direct photographic prints, 
but this is optional.
11. Standard curve: A crude standard curve is drawn by plotting % concentration 
NHP vs. area of lysis (diameter squared can also be used). This allows calcula-
tion of % normal activity in test samples.
3. Representative results
After incubation, the ACP activity is calculated after measuring the diameter 
using the vernier caliper or taking the ACP dish in photo and measure each surface 
well by Image J® (Figure 1). Area surfaces are calculated by the formula S = π*r2, 
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with r = d/2. (r: radius, d: diameter, s: surface). The same procedure is applied to the 
different NHP dilutions included to establish the calibration curve. This is because 
diluting NHP means that all ACP components are diluted equally. As example of 
interpretation, the more the ring is small the more the effectiveness of Eculizumab 
is good. The absence of reaction in a well signifies a complete ACP blockage, either 
by a drug or by a pathological process.
3.1 Materials
1. Chicken erythrocytes (CE) conserved in Alsever’s solution.
2. Phosphate-buffered saline (PBS).
3. Veronal buffered saline (VBS).
4. Gelatin veronal buffer (GVB).
5. AP buffer is GVB containing 5 mM Mg and 5 mM ethylene glycol bis[β-
aminoethylether]N,N′-tetraacetic acid (EGTA, E4378 Sigma).
6. N-saline is 9 g NaCl dissolved in 1 L H2O.
7. Barbitone buffer is made by mixing 0.1 M solutions of sodium barbitone and 
barbituric acid to obtain the target pH and adjusting volume to obtain required 
final molarity.
3.2 Equipment
1. Suitable Petri dishes or glass plates. Size depends on the number of samples. 
Volumes can be adjusted so that the final depth of the gel is ~1–1.5 mm.
2. 56°C incubator and dishes/plate warmer (water bath can also be used).
3. 46°C water bath.
Figure 1. 
ACP dishes for different sera from patients and pooled normal plasmas NHP. (A) Rings size of well 1 and 
9 are found in a complete ACP blockade by Eculizumab or total deficiency of one of the ACP proteins. The 
remaining wells show different plasmatic levels of ACP. (B) Sera tested in this ACP dish are within normal 
range but vary according to the clinical presentation.
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a. Under aseptic conditions, remove 100  μl packed CE from stock chicken 
blood stored in Alsever’s solution.
b. Wash twice in ACP buffer.
c. Resuspend in the same buffer to the required concentration for assay by 
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11. Standard curve: A crude standard curve is drawn by plotting % concentration 
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tion of % normal activity in test samples.
3. Representative results
After incubation, the ACP activity is calculated after measuring the diameter 
using the vernier caliper or taking the ACP dish in photo and measure each surface 
well by Image J® (Figure 1). Area surfaces are calculated by the formula S = π*r2, 
107
Semi-Solid Phase Assay for the Alternative Complement Pathway Activity Assessment (AP100)
DOI: http://dx.doi.org/10.5772/intechopen.81743
with r = d/2. (r: radius, d: diameter, s: surface). The same procedure is applied to the 
different NHP dilutions included to establish the calibration curve. This is because 
diluting NHP means that all ACP components are diluted equally. As example of 
interpretation, the more the ring is small the more the effectiveness of Eculizumab 
is good. The absence of reaction in a well signifies a complete ACP blockage, either 
by a drug or by a pathological process.
3.1 Materials
1. Chicken erythrocytes (CE) conserved in Alsever’s solution.
2. Phosphate-buffered saline (PBS).
3. Veronal buffered saline (VBS).
4. Gelatin veronal buffer (GVB).
5. AP buffer is GVB containing 5 mM Mg and 5 mM ethylene glycol bis[β-
aminoethylether]N,N′-tetraacetic acid (EGTA, E4378 Sigma).
6. N-saline is 9 g NaCl dissolved in 1 L H2O.
7. Barbitone buffer is made by mixing 0.1 M solutions of sodium barbitone and 
barbituric acid to obtain the target pH and adjusting volume to obtain required 
final molarity.
3.2 Equipment
1. Suitable Petri dishes or glass plates. Size depends on the number of samples. 
Volumes can be adjusted so that the final depth of the gel is ~1–1.5 mm.
2. 56°C incubator and dishes/plate warmer (water bath can also be used).
3. 46°C water bath.
Figure 1. 
ACP dishes for different sera from patients and pooled normal plasmas NHP. (A) Rings size of well 1 and 
9 are found in a complete ACP blockade by Eculizumab or total deficiency of one of the ACP proteins. The 
remaining wells show different plasmatic levels of ACP. (B) Sera tested in this ACP dish are within normal 
range but vary according to the clinical presentation.




6. Pasteur pipette as well cutters to produce holes approximately 5 mm diameter. 
If single holes are to be punched, a grid should be placed under the gel so that 
the holes can be distributed evenly.
7. Refrigerated centrifuge.
8. Electronic balance.
9. pH meter/temperature probe.
4. Discussion
Since Thomas A. E. Platts-Mills and Kimishige Ishizaka have discovered that 
fresh normal human serum in EGTA buffer was found to cause >90% hemolysis 
of unsensitized rabbit red blood cells (RaRBC) [11], simple timed lysis assay and 
dilution methods called AP50 (Alternative Pathway 50) was performed to quantify 
hemolytic complement activity in human serum [13–15]. This reaction requires 
C3, factors B and D, and Mg++ ions to form the C3 convertase (C3bBb) [14, 15]. 
In AP50, ACP is activated and measured by virtue of RaRBC decreased sialic acid 
content in addition to the blockade of the classical pathway activation by chelation 
of calcium by EGTA [16]. Nonetheless, AH50 requires a lot of material like spec-
trophotometer and consumable test tubes and highly skillful personal. To adapt 
this assay to simple labs, a semi-solid phase assay was proposed to measure ACP 
activity by using chicken erythrocytes incorporated in agarose gel called AP100. 
Cell membranes of chicken erythrocytes have the same properties as those of the 
Fluid phase assay (AH50) Semi-solid phase assay (AP100)
Number of samples <5 per day Several samples series per day
ACP Activators Red cells Red cells + agarose particles
End point assessment Optical density by 
Spectrophotometer
Diameter measurement directly
Laboratory work flow steps +++ Less
Time consuming +++ Less
Storage No 15–21 days
Transport No Yes (respecting the cold chain)
Global cost +++ Less
Assay related error +++ Less
Manipulator linked error +++ Less
Others • More suitable complement related 
diseases screening
• Do not need a deep immunotechnol-
ogy handling
• Storage of utilized plates for intra and 
inter-laboratory comparisons
Table 2. 
Hemolytic agarose assay features in comparison to tube hemolytic assay.
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rabbit in terms of cell surface charge density of sialic acid whereas they are more 
robust than rabbit because they have nuclei. AP100 assay has many advantages over 
the AH50 one (Table 2). For example, AP100 is more reliable for the eculizumab 
monitoring as shown in the article we have recently reviewed [17]. Moreover, AH50 
still challenging in low incomes country laboratories that cannot equip their hos-
pital and research laboratories to perform this assay. To overcome this roadblock, 
it was proceeded to render this method more practical to each laboratory with a 
purpose to be stored and transported for several weeks. This includes a hemolytic 
agarose dishes/plates; a special adaptation to prevent complement activation via 
the classical pathway and facilitate complement activation via the alternative one 
in agarose gels.
To the best of our knowledge there were no laboratory performing that assays in 
developing countries especially in Africa and no educational chapter is available to 
explain it. Once its optimization in each of these countries laboratories was per-
formed, thanks to ACP dishes/plates, we are expecting to empower doctors’ decision 
making process and improve quality of patients’ management and therapy follow-up. 
Therefore this portable and easy to use device even at the bedside of the patient and 
in the companion do not necessitate any equipped laboratory and may facilitate 
prospective analysis and disease screening in large populations. With enlargement of 
the ACP disease spectrum necessitated complement blockade, AP100 should be con-
sidered by clinical laboratory scientist especially to analyze sets of samples at once.
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Amino Acids Profiling for the 
Diagnosis of Metabolic Disorders
Yana Sandlers
Abstract
Inborn errors of metabolism (IEM) represent a group of inherited diseases in 
which genetic defect leads to the block on a metabolic pathway, resulting in a single 
enzyme dysfunction. As a downstream consequence of the residual or full loss of the 
enzymatic activity, there is an accumulation of toxic metabolites in the proximity of 
the metabolic block and/or a deficiency of an essential metabolic product which leads 
to the clinical presentation of the disease. While individually IEMs are rare, a collec-
tively estimated incidence of metabolic inherited disorders is 1:800. The genetic basis 
of IEMs can involve abnormalities such as point mutations, deletions or insertions, 
or more complex genomic rearrangements. Categorization of IEM can be simply 
made on the basis of the affected metabolic network: fatty acids oxidation disorders, 
protein/amino acids metabolism disorders, disorders of carbohydrate metabolism, 
lysosomal storage diseases, peroxisomal disorders, and mitochondrial diseases. This 
chapter will overview amino acid metabolism-related inherited disorders and amino 
acid analysis for the diagnosis and routine monitoring of this category of IEMs.
Keywords: inborn error of metabolism, amino acids disorders, quantitative amino 
acids analysis, ion exchange chromatography, mass spectrometry
1. Introduction
Amino acids (Figure 1) play multiple important roles in our body: they are basic 
structural protein units and precursors of neurotransmitters, porphyrins, and nitric 
oxide. Furthermore, amino acids derived from the dietary proteins serve as energy 
source since while catabolized in our body, amino acids form organic acids that can 
replenish Krebs cycle and ammonia that eliminates through urea cycle [1].
Amino acids disorders (also called aminoacidopathies) are a group of inborn 
errors of metabolism diseases, caused by the inherited defects in pathways involved 
in amino acids metabolism. All primary amino acids disorders (Table 1) follow an 
autosomal recessive mode of inheritance which means that the mutation caused 
a metabolic block is present in the genetic material of both parents. As a result of 
mutation, the inherited defect is reflected downstream as a lack or a partial biologi-
cal activity of enzymes involved in amino acids metabolism. Consequently, some 
substrates in these pathways accumulate or are diverted into alternative pathways. 
Therefore, amino acids disorders are biochemically characterized by abnormal 
levels of single or several amino acids and their downstream plasma and/or urine 
metabolites (Tables 2–6). Amino acid disorders are presented with variable and 
often nonspecific clinical symptoms. In conjunction with medical support, these 
disorders are managed by nutritional restrictions, supplements and medical 
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foods that limit consumption of an offending amino acid or in some cases protein 
consumption. It is important therefore routinely perform amino acids’ analysis to 
monitor dietary treatment outcomes in already diagnosed individuals. In the next 
chapters, primary amino acids disorders are reviewed and quantitative amino acid 
analysis in clinical settings is discussed.
1.1 Phenylketonuria
Phenylketonuria (commonly known as PKU, incidence 1 in 13,500–19,000 births 
in the United States [2]) is an inherited disorder of phenylalanine metabolism charac-
terized by phenylalanine hydroxylase deficiency (Figure 1). The enzyme catalyzes the 
conversion of phenylalanine to tyrosine in the presence of tetrahydrobiopterin (BH4) 
as a cofactor. Based on plasma phenylalanine level, PKU is categorized by severe 
(Phe > 1200 μmol/L), mild (Phe = 600–1200 μmol/L) and hyperphenylalaninemia 
(above the normal cut off but below 600 μmol/L) phenotypes. Clinically PKU can be 
presented with growth failure, global developmental delay, severe intellectual disabil-
ities and other severe symptoms. During pregnancy, elevated levels of phenylalanine 
have teratogenic effects on the developing fetus [3] and the condition is recognized 
as maternal PKU. Phenylalanine accumulation is also seen in defects of biopterin 
cofactor biosynthesis and regeneration [4] (Table 1). Nutritional management of 
PKU targets excessive accumulation of phenylalanine by restriction of natural protein 
intake in combination with the use of phenylalanine-free protein substitutes.
1.2 Disorders of tyrosine metabolism
Tyrosine metabolic pathway consists of five enzymatic reactions taking place 
mainly in hepatocytes and renal proximal tubules. Tyrosinemia I is the most severe 
inherited disorder of tyrosine metabolism caused by a deficiency of fumarylaceto-
acetate hydrolase, the last enzyme in the tyrosine catabolic pathway. The disorder 
has a high incidence in French Canadian ethnicity [5] and involves hepatorenal 
dysfunction. Tyrosinemia II is caused by a deficiency of the hepatic tyrosine 
aminotransferase and manifested by mental retardation and other severe symptoms 
[6]. A deficiency in the activity of 4-hydroxyphenylpyruvate dioxygenase leads to 
tyrosinemia III, a rare disorder characterized by mild mental retardation and/or 
convulsions [7, 8]. All three disorders biochemically characterized by high levels of 
plasma tyrosine (hypertyrosinemia) and urine excretion of downstream tyrosine 
metabolites (Table 1). Elevated plasma tyrosine can also be seen due to vitamin-C 
responsive transient tyrosinemia during the neonatal period (Figure 2).
Figure 1. 
The general structure of amino acids consist of an amino group, a carboxylic group and a variable R side chain 
that has a major effect on solubility and polarity.
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PAH, phenylalanine hydroxylase; GTPCH, GTP cyclohydrolase; PTPS, 6-pyrovoyltetrahydropterin synthase; PCBD1, 
pterin-4a-carbinolamine dehydratase; DHPR, dihydropterin reductase; FAH, fumarylacetoacetate hydrolase; TAT, 
tyrosine aminotransferase; HPPD, 4-hydroxyphenylpyruvate dioxygenase.
Table 1. 
Laboratory findings in aromatic amino acids disorders.
Figure 2. 
Reaction catalyzed by phenylalanine hydroxylase. Tetrahydrobiopterin (BH4) is a co-factor of PAH. DHPR, 
dihydropteridine reductase; PCBD1, pterin-4-α-carbinolamine dehydratase.
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foods that limit consumption of an offending amino acid or in some cases protein 
consumption. It is important therefore routinely perform amino acids’ analysis to 
monitor dietary treatment outcomes in already diagnosed individuals. In the next 
chapters, primary amino acids disorders are reviewed and quantitative amino acid 
analysis in clinical settings is discussed.
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1.3 Maple syrup urine disease
Maple syrup urine disease is a disorder of branch chain amino acids metabolism 
caused by a deficiency of branched-chain α-keto acid dehydrogenase complex. 
MSUD is presented with five clinical phenotypes on the basis of the age at onset, the 
severity of symptoms and response to thiamine supplementation [9]. MSUD char-
acterized biochemically by elevated plasma branched-chain amino acids (leucine, 
isoleucine, valine, allo-isoleucine) and their abnormal ratio (normal ratio is valine:is
oleucine:leucine/3.5:1:2). The disease is managed by dietary leucine restriction, thus 
all branch chain amino acids and allo-isoleucine are routinely monitored. The classic 
MSUD is the most severe form of the disease characterized by no or very low residual 
enzyme activity and clinically manifested by developmental and neurological delays, 
encephalopathy, feeding problems, and a characteristic maple syrup odor in urine.
1.4 Urea cycle disorders
During protein catabolism, amino acids’ carbon skeleton is metabolized to 
gluconeogenic and/or ketogenic precursors whereas nitrogen group is converted to 
ammonia through the deamination process. Toxic ammonia derived from amino 
acids and other metabolic sources is entering the urea cycle and further is converted 
to the readily excreted and nontoxic urea. The cycle takes place in the liver and a defi-
ciency of any enzymes or transporters involved in the urea cycle can cause ammonia 
accumulation (hyperammonemia) which has a highly toxic effect on the central 
nervous system. The overall estimated incidence of urea cycle disorders is 1:8000. All 
urea cycle disorders have an autosomal recessive inheritance, with the exception of 
ornithine-transcarbamylase deficiency (OTCD), which is X-linked. Plasma citrulline 
is a key amino acid in the biochemical diagnosis of urea cycle defects (Table 3).
Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome 
is caused by the mutations in the SLC25A15 or ORNT1 gene which result in the 
deficiency of ornithine translocase. The protein transports ornithine, lysine, 
and arginine across the inner mitochondrial membrane in peripheral tissues and 
pericentral hepatocytes. ORC1 deficiency reduces the availability of mitochondrial 
ornithine, which leads to the ornithine increase in the cytosol (hyperornithinemia). 
In the liver, since the mitochondrial ornithine is a required substrate for ornithine 
transcarbamylase (OTC), the reduced level of mitochondrial ornithine slows down 
flux through the urea cycle (Figure 3). As a result of the reduced capacity of the 
urea cycle, ammonia and carbamoyl-phosphate levels increase (hyperammonemia). 
At the same time, an excess of carbamoyl-phosphate is diverted to react with lysine 
to form homocitrulline (homocitrullinuria) or enters in the pyrimidine pathway, 
to form orotic acid which is later excreted in urine. Similarly, as for other urea cycle 
disorders, early diagnosis in infancy may improve the clinical outcome of HHH.









MSUD BCAA (B) high, 
allo-Ile (B) high
BCKDC Plasma ratio of Val:Ile:Leu (3.5:1:2), branch chain 
2-ketoacids and 2-hydroxyacids (U)
BCKDC, branched-chain ketoacid dehydrogenase complex.
Table 2. 
Laboratory findings in MSUD.
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Citrullinimia I Cit (B) markedly 
elevated
ASS Hyperammonemia, 
orotic acid (U), can be 
accompanied by high 
glutamine and alanine (B)
Citrullinimia II/citrin 
deficiency
Cit (B) moderate 





acid (U). Citrulline is 
moderately elevated
CPS-I deficiency Cit (B) low CPS1 Can be accompanied 





Cit (B) low OTC Nonspecific amino 
acid profile: increased 
glutamine, alanine and 
decreased ornithine, 




ASA (B), (U) 
elevated
ASL Low citrulline, low 
arginine (B)
Argininemia Arg (B) high Arginase Orotic acid (U), Normal or 
reduced citrulline (B)




Gln (B) high NAGS Cit (B) low, alanine high 
(B)
B, blood; U, urine.
Table 3. 
Laboratory findings in urea cycle disorders.
Figure 3. 
Urea cycle. ARG, arginase; ASS, argininosuccinate synthase; ASL, argininosuccinate lyase; CPS1, 
carbamoylphosphate I synthase; ORNT 1, mitochondrial ornithine transporter; OTC, ornithine 
transcarbamylase.
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1.5 Disorders of sulfur amino acids metabolism
Homocystinuria is a disorder of methionine metabolism (Figure 4). The main 
biochemical finding in homocystinuria is accumulation of a sulfur-containing 
amino acid homocysteine and its metabolites in the blood and urine. Homocysteine 
is formed from methionine via transmethylation. Once generated homocysteine can 
be irreversibly degraded via transsulfuration pathway to cysteine or remethylated 
back to methionine by methionine synthase. Remethylation involves a transfer of 
methyl group from 5-methyltetrahydrofolate to homocysteine via cobalamin (Cbl)-
dependent methionine synthase (MT) and links folate cycle and homocysteine 
pathway. Homocysteine can also be remethylated through an additional pathway 
which involves liver and kidney betaine-homocysteine methyltransferase. Defects 
in any of these steps can result in homocystinuria. The classic homocystinuria is 
caused by cystathionine β-synthase (CBS) deficiency [10], a key enzyme in the 
trans-sulfuration pathway that converts homocysteine into cystathionine. A block 
at cystathionine β-synthase limits transsulfuration to the cysteine and results 
in both increased homocysteine and methionine, the latter caused by enhanced 
remethylation. The remethylation homocystinuria disorders include methylene-
tetrahydrofolate reductase deficiency (MTHFR) and defects of cobalamin (Cbl) 
metabolism [11]. It has to be noted that methionine and not homocysteine is 
analyzed through the newborn screening, thus, MTHFR disorder and the cobala-
min defects may not be detected because methionine level in these disorders can be 
normal. To increase the detection rate in cobalamin related disorders and MTHFR, 
some studies report a benefit of adding total homocysteine analysis to the diagnos-
tic workflow [12]. Total homocysteine is defined as the sum of all homocysteine 
species in plasma/serum, including free and protein-bound forms. The measure-
ment of total homocysteine requires an immediate separation and freezing of the 
collected plasma.
Figure 4. 
Sulfur amino acids metabolism. CBS, cystathionine β synthase; Cbl, cobalamin; SAM, S-adenosyl methionine; 
SAH, S-adenosylhomocysteine; MAT, methionine adenosyltransferase; MS, methionine synthase; MTHFR, 
methylene tetrahydrofolate reductase; THF, tetrahydrofolate.
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1.6 Nonketotic hyperglycemia
Nonketotic hyperglycemia (NKH) is a severe disorder of glycine metabolism. 
Glycine is catabolized through the four-peptide cleavage complex. P-protein, a 
pyridoxal phosphate-containing protein, T-protein, a protein required for the 
tetrahydrofolate-dependent reaction, H-protein, a protein that carries the amino-
methyl intermediate and then hydrogen through the prosthetic lipoyl moiety, and 
L-protein, a lipoamide dehydrogenase. The disorder is so severe, that most of the 
affected individuals die within few months of life or survive with significant intellec-
tual disabilities. Main laboratory findings in NKH is plasma and CSF elevated glycine.
Disorders of amino acids transport
Disorder name Amino acid 
involved
Enzyme/transport defect Additional biomarkers
Cystinuria Cystine (U) 
elevated
Cystine and dibasic amino acids 
in GI tract and renal tubule







Cationic amino acids 
transporter SLC7A7
Arginine, ornithine 




All amino acids 
elevated (U)
Defects in proximal renal tubule
U, urine.
Table 5. 
Laboratory findings in renal aminoacidurias.
Disorders of sulfur amino acids


















SSC* (B, U) high SUOX Taurine, low cystine (B, U)
Molybden cofactor 
deficiency
SSC* (B, U) high SUOX, 
XDH, AO
Taurine, low cystine (B, U), elevated 





Met (B) high GNMT S-adenosylmethionine (B)
Hyper-methioninemia Met (B) high MAT
CBS, cystathionine beta synthase; AdoHcyas, S-adenosylhomocysteine hydroxylase; SUOX, sulfate oxidase; XDH, 
xanthine dehydrogenase; AO, aldehyde oxidase; GNMT, glycine-N-methyltransferase.
*S-sulphocysteine may not be detectable in plasma using routine methods in sulfite oxidase and molybdenum co-factor 
deficiencies.
Table 4. 
Laboratory findings in disorders of sulfur amino acids.
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pyridoxal phosphate-containing protein, T-protein, a protein required for the 
tetrahydrofolate-dependent reaction, H-protein, a protein that carries the amino-
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1.7 Renal aminoacidurias
Renal aminoacidurias are disorders have inherited defects that affect renal 
tubular reabsorption process. Thus these disorders are characterized by abnormal 
urinary amino acids.
2. Newborn screening
Early diagnosis may prevent serious implications of inborn errors of metabolism, 
including amino acids disorders and significantly decrease morbidity and mortality. 
Newborn screening is a public health program that facilities early diagnosis by identi-
fying neonates with potential treatable inborn errors of metabolism at the very early 
stages of their lives [13, 14]. This practice helps to manage the disease even for neonates 
that do not have evident symptoms in the first days of their lives. Amino acids analysis 
has always been an important part of the newborn screening. The first PKU screening 
bacterial inhibition assay was invented by Robert Guthrie in the early '60s [15]. Since 
that time, screening for IEMs is performed worldwide. In the United States, newborn 
screening is a state-mandated public health program ensuring that all newborns are 
screened for certain inherited conditions at birth. The panel of screening conditions 
varies from state to state. The advisory committee on heritable disorders in newborns 
and children advises the Secretary of Health and human services uniform screening 
panel, which currently consist of 34 core disorders and 26 secondary disorders. The 
recommended panel includes multiple amino acids related disorders (Table 7).
3. Quantitative amino acids analysis
Quantitative amino acids analysis is an important tool for diagnosis of amino acids 
disorders and nutritional monitoring of individuals with already established diagno-




Argininosuccinate aciduria, citrullinemia type I homocystinuria 




Nonketotic hyperglycinemia (NKH), prolinemia, hyperammonemia/ornithinemia/
citrullinemia (HHH)
Secondary Defects of biopterin cofactor biosynthesis and regeneration, citrullinemia II, 
hypermethioninemia, tyrosinemia II, tyrosinemia III
Table 7. 
List of amino acids disorders that are recommended by the Secretary of the Department of Health and Human 
Services (HHS) as a part of state universal newborn screening (NBS) program effective July 2018.
Disorder of glycine metabolism
Disorder name Amino acid 
involved









B, blood; CSF, cerebrospinal fluid.
Table 6. 
Laboratory findings in NKH.
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fluids for inborn errors of metabolism diagnostics and monitoring are blood, plasma, 
and urine. In some cases, cerebrospinal fluid (CSF) amino acid levels are also diag-
nostic (Table 5). Although each disorder is biochemically characterized by abnormal 
levels of a single or a few amino acids, quantitative a non-screening analysis, and 
interpretation is not restricted to those metabolites and consist from a panel of nearly 
40 amino acids and specific ratios. For example, along with plasma phenylalanine 
level, it is important also to assess plasma phenylalanine/tyrosine ratio that can be 
used to differentiate between PKU and non-PKU hyperphenylalaninemia [16].
3.1 Factors affecting amino acid analysis
The different chemical characteristics, a wide range of normal physiological 
levels [17–19], age groups variability and other factors detailed below represent a 
significant analytical challenge for the amino acid analysis. Diet is one of the  
significant factors that can highly affect amino acids levels [20, 21]. For example, 
meat and poultry consumption leads to increased excretion of β alanine and 
1-methylhistidine. Thus blood collection intended for amino acids analysis is 
recommended after overnight fasting. Other factors such as urinary bacterial 
contamination can significantly alter urinary amino acids profile [22]. Some drugs 
interfere with amino acids metabolism [23] or cause signal artifacts. Valproic acid, 
for example, can cause an increase in plasma glycine. Anticoagulants used dur-
ing sample collection also can contain interfering constituents [24]. For example, 
blood collection tubes containing sodium bisulfate in addition to heparin can 
yield a peak of S-sulfocysteine, falsely suggesting sulfite oxidase deficiency. 
Ethylenediaminetetraacetic acid (EDTA) additive in collection tube can produce 
ninhydrin-positive peaks, therefore lithium-heparin coated tubes are strongly 
preferred for the blood collection. An additional interfering factor to the amino acid 
analysis is a hemolysis as it may lead to the decrease of arginine with simultaneous 
increase of ornithine due to red blood cells arginase activity, and an increase in 
taurine that released from leukocytes and platelets. Serum is usually not a choice for 
the amino acids analysis, because blood needs to clot at room temperature during 
which asparagine is converted to aspartic acid and glutamine to glutamic acid.
For the urine analysis, a 24-h urine collection is preferred, alternatively, an 
overnight collection can be sufficient for the diagnostic purposes. In order to avoid 
artifacts, no preservatives are added to the urine sample.
Overall, during a prolong sample storage glutamine and asparagine decrease 
whereas glutamic and aspartic acids increase simultaneously. Additional markers 
of prolong storage are an increase of ethanolamine derived from phosphoethanol-
amine decomposition, increased tryptophan, GABA and taurine.
When cerebrospinal fluid is used for the analysis, it must be not contaminated 
with blood, as it leads to the nonspecific increase of multiple amino acids and can 
mask diagnostic findings.
Quantitative amino acids analysis implies in a variety of nonclinical fields such 
as biomedical research, bioengineering, food science, and agriculture. Multiple 
analytical methods have been developed over the years, however, some of these 
methods are not cost effective and labor intensive and thus are not applicable in 
clinical settings. The aim of next paragraphs is to describe the most common and 
widely used platforms in laboratory medicine field.
3.2 Ion exchange chromatography coupled with optical detection
In early 50s, diagnostic quantitative amino acid analysis became feasible with 
Moore and Stein publication on plasma amino acids separation with polystyrene 
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recommended panel includes multiple amino acids related disorders (Table 7).
3. Quantitative amino acids analysis
Quantitative amino acids analysis is an important tool for diagnosis of amino acids 
disorders and nutritional monitoring of individuals with already established diagno-




Argininosuccinate aciduria, citrullinemia type I homocystinuria 




Nonketotic hyperglycinemia (NKH), prolinemia, hyperammonemia/ornithinemia/
citrullinemia (HHH)
Secondary Defects of biopterin cofactor biosynthesis and regeneration, citrullinemia II, 
hypermethioninemia, tyrosinemia II, tyrosinemia III
Table 7. 
List of amino acids disorders that are recommended by the Secretary of the Department of Health and Human 
Services (HHS) as a part of state universal newborn screening (NBS) program effective July 2018.
Disorder of glycine metabolism
Disorder name Amino acid 
involved









B, blood; CSF, cerebrospinal fluid.
Table 6. 
Laboratory findings in NKH.
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fluids for inborn errors of metabolism diagnostics and monitoring are blood, plasma, 
and urine. In some cases, cerebrospinal fluid (CSF) amino acid levels are also diag-
nostic (Table 5). Although each disorder is biochemically characterized by abnormal 
levels of a single or a few amino acids, quantitative a non-screening analysis, and 
interpretation is not restricted to those metabolites and consist from a panel of nearly 
40 amino acids and specific ratios. For example, along with plasma phenylalanine 
level, it is important also to assess plasma phenylalanine/tyrosine ratio that can be 
used to differentiate between PKU and non-PKU hyperphenylalaninemia [16].
3.1 Factors affecting amino acid analysis
The different chemical characteristics, a wide range of normal physiological 
levels [17–19], age groups variability and other factors detailed below represent a 
significant analytical challenge for the amino acid analysis. Diet is one of the  
significant factors that can highly affect amino acids levels [20, 21]. For example, 
meat and poultry consumption leads to increased excretion of β alanine and 
1-methylhistidine. Thus blood collection intended for amino acids analysis is 
recommended after overnight fasting. Other factors such as urinary bacterial 
contamination can significantly alter urinary amino acids profile [22]. Some drugs 
interfere with amino acids metabolism [23] or cause signal artifacts. Valproic acid, 
for example, can cause an increase in plasma glycine. Anticoagulants used dur-
ing sample collection also can contain interfering constituents [24]. For example, 
blood collection tubes containing sodium bisulfate in addition to heparin can 
yield a peak of S-sulfocysteine, falsely suggesting sulfite oxidase deficiency. 
Ethylenediaminetetraacetic acid (EDTA) additive in collection tube can produce 
ninhydrin-positive peaks, therefore lithium-heparin coated tubes are strongly 
preferred for the blood collection. An additional interfering factor to the amino acid 
analysis is a hemolysis as it may lead to the decrease of arginine with simultaneous 
increase of ornithine due to red blood cells arginase activity, and an increase in 
taurine that released from leukocytes and platelets. Serum is usually not a choice for 
the amino acids analysis, because blood needs to clot at room temperature during 
which asparagine is converted to aspartic acid and glutamine to glutamic acid.
For the urine analysis, a 24-h urine collection is preferred, alternatively, an 
overnight collection can be sufficient for the diagnostic purposes. In order to avoid 
artifacts, no preservatives are added to the urine sample.
Overall, during a prolong sample storage glutamine and asparagine decrease 
whereas glutamic and aspartic acids increase simultaneously. Additional markers 
of prolong storage are an increase of ethanolamine derived from phosphoethanol-
amine decomposition, increased tryptophan, GABA and taurine.
When cerebrospinal fluid is used for the analysis, it must be not contaminated 
with blood, as it leads to the nonspecific increase of multiple amino acids and can 
mask diagnostic findings.
Quantitative amino acids analysis implies in a variety of nonclinical fields such 
as biomedical research, bioengineering, food science, and agriculture. Multiple 
analytical methods have been developed over the years, however, some of these 
methods are not cost effective and labor intensive and thus are not applicable in 
clinical settings. The aim of next paragraphs is to describe the most common and 
widely used platforms in laboratory medicine field.
3.2 Ion exchange chromatography coupled with optical detection
In early 50s, diagnostic quantitative amino acid analysis became feasible with 
Moore and Stein publication on plasma amino acids separation with polystyrene 
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resin column [25] and the subsequent automatization of the technique [26]. 
The principle, called ion exchange chromatography (IEC) with a post-column 
derivatization, for a long time remained a gold standard for the clinical amino 
acids analysis. Nowadays, despite the methodological advancements, the ion 
exchange chromatography using a lithium buffer system, followed the post-column 
derivatization with ninhydrin and UV detection is still widely used in clinical 
setting.
Standard sample preparation for IEC amino acid analysis involves deproteiniza-
tion with 35% (w/v) sulfosalicylic acid (SSA) added to the biological fluid. It is 
recommended to use one volume of SSA to 10 volumes of plasma. A fixed amount 
of non-physiological amino acid as an internal standard is added to all samples. 
Commonly used internal standards are d-glucosaminic acid, S-2-aminoethyl-
1-cysteine, norvaline, and norleucine, however, norleucine can interfere with 
argininosuccinic acid peak. After a short incubation, centrifugation and filtration, 
the sample is ready for the injection and separation.
In IEC, the separation is driven by the ionic interactions between the amino acid 
and functional ligands linked to the stationary phase of the column. The chromato-
graphic column is filled with negatively charged resins. The sample is loaded on the 
column in low acidic pH and at this point, all amino acids bear a positive charge and 
strongly interact with the column. Manipulation with a lithium buffer composition 
during the run alters pH and salt composition, and as a result, there is a change in 
amino acid charge status (Figure 5). As the isoelectric point is reached amino acid is 
not charged anymore and has weak interactions with the charged column.
The complex separation of multiple amino acids is achieved based on ionic 
interactions strength. Amino acids with the weakest ionic interactions to the 
column start to elute first. After column elution, amino acids are mixed with a 
post-column reagent and are optically detected. The most common and well-
established post-column derivatization is reaction with ninhydrin that produces a 
purple Ruhemann’s chromophore (λmax = 570 nm, Figure 6) for α-amino acids and 
yellow product with secondary amines (λmax = 440 nm) for such as proline and 
 hydroxyproline [27].
The absorbance intensity of the produced colorful analyte originated from 
every eluted amino acid is proportional to the amino acid’s concentration in 
the examined biological fluid. Despite the fact that IEC amino acids technique 
is highly reproducible with a good linearity over a broad range, it suffers from 
a long run time for the full amino acids profile (about 150 min), and a lack 
of specificity as amino acids identification is based solely on retention time. 
Furthermore, co-elution of some amino acids on standard IEC method is 
Figure 5. 
Aspartic acid charge in different pH.
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observed. For example, homocitrulline co-elutes with methionine and make 
challenging HHH syndrome. Moreover, allo-isoleucine, a diagnostic market for 
MSUD co-elutes with cystathionine. Argininosuccinic acid that accumulates in 
patients with argininosuccinate lyase deficiency has the same retention time as 
leucine. Additional drawback of the methodology is a limited stability of ninhy-
drin (recommended storage of the working solution ≤1 month) which adds up to 
the cost of the analysis.
3.3 RP-HPLC and RP-UPLC techniques
In recent years, reverse-phase high-performance liquid chromatography 
(RP-HPLC) and ultra-high performance liquid chromatography (UPLC) meth-
ods emerged as an alternative to the ion exchange chromatography. In RP-HPLC 
methods, the separation is based on hydrophobic interactions between the 
analyzed amino acid in the mobile phase and the immobilized hydrophobic 
ligands attached to the nonpolar column stationary phase. RP-HPLC offers 
a great resolution of very closely related molecules under a wide range of 
chromatographic conditions. For the optical detection, derivatization with 
o-phthalaldehyde (OPA) can be used as a pre-column or a post-column reaction. 
During the reaction, in the presence of thiol such as 2-mercaptoethanol, a stable 
fluorescent product is produced and can be detected by fluorimetry (excitation 
340 nm and emission 410 nm) or UV (340 nm) [28, 29]. Although reproducible 
and automated [30], OPA derivatization method is not a good choice for pro-
line/hydroxyproline and sulfur-containing amino acids detection. Alternative 
reagents for RP-HPLC with pre-column derivatization are phenylisothiocyanate 
(PITC, Pico-Tag commercialized by Waters) [31], dimethylamino-azoben-
zenesulfonyl-chloride (DABS-Cl) [32] and 9-fluorenylmethylchloroformate 
(FMOC-Cl) [33].
More advanced UPLC systems employ a small particle size (typically 1.7 μM) and 
a high pH range stable columns. These systems use less solvent and are operated in a 
high pressure which allows an excellent resolution achieved in a short time frame and 
thus potentially decreases turnaround time per sample. Narayan et al. analyzed 170 
patient samples by pre-column 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate 
(AQC) derivatization (Figure 7) followed by reverse phase UPLC [34] and com-
pared amino acids data to the traditional amino acids analyzer operated through ion 
Figure 6. 
Ninhydrin reaction with amino acid to produce Ruhemann’s purple.
Figure 7. 
AQC reaction with amino acid.
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resin column [25] and the subsequent automatization of the technique [26]. 
The principle, called ion exchange chromatography (IEC) with a post-column 
derivatization, for a long time remained a gold standard for the clinical amino 
acids analysis. Nowadays, despite the methodological advancements, the ion 
exchange chromatography using a lithium buffer system, followed the post-column 
derivatization with ninhydrin and UV detection is still widely used in clinical 
setting.
Standard sample preparation for IEC amino acid analysis involves deproteiniza-
tion with 35% (w/v) sulfosalicylic acid (SSA) added to the biological fluid. It is 
recommended to use one volume of SSA to 10 volumes of plasma. A fixed amount 
of non-physiological amino acid as an internal standard is added to all samples. 
Commonly used internal standards are d-glucosaminic acid, S-2-aminoethyl-
1-cysteine, norvaline, and norleucine, however, norleucine can interfere with 
argininosuccinic acid peak. After a short incubation, centrifugation and filtration, 
the sample is ready for the injection and separation.
In IEC, the separation is driven by the ionic interactions between the amino acid 
and functional ligands linked to the stationary phase of the column. The chromato-
graphic column is filled with negatively charged resins. The sample is loaded on the 
column in low acidic pH and at this point, all amino acids bear a positive charge and 
strongly interact with the column. Manipulation with a lithium buffer composition 
during the run alters pH and salt composition, and as a result, there is a change in 
amino acid charge status (Figure 5). As the isoelectric point is reached amino acid is 
not charged anymore and has weak interactions with the charged column.
The complex separation of multiple amino acids is achieved based on ionic 
interactions strength. Amino acids with the weakest ionic interactions to the 
column start to elute first. After column elution, amino acids are mixed with a 
post-column reagent and are optically detected. The most common and well-
established post-column derivatization is reaction with ninhydrin that produces a 
purple Ruhemann’s chromophore (λmax = 570 nm, Figure 6) for α-amino acids and 
yellow product with secondary amines (λmax = 440 nm) for such as proline and 
 hydroxyproline [27].
The absorbance intensity of the produced colorful analyte originated from 
every eluted amino acid is proportional to the amino acid’s concentration in 
the examined biological fluid. Despite the fact that IEC amino acids technique 
is highly reproducible with a good linearity over a broad range, it suffers from 
a long run time for the full amino acids profile (about 150 min), and a lack 
of specificity as amino acids identification is based solely on retention time. 
Furthermore, co-elution of some amino acids on standard IEC method is 
Figure 5. 
Aspartic acid charge in different pH.
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observed. For example, homocitrulline co-elutes with methionine and make 
challenging HHH syndrome. Moreover, allo-isoleucine, a diagnostic market for 
MSUD co-elutes with cystathionine. Argininosuccinic acid that accumulates in 
patients with argininosuccinate lyase deficiency has the same retention time as 
leucine. Additional drawback of the methodology is a limited stability of ninhy-
drin (recommended storage of the working solution ≤1 month) which adds up to 
the cost of the analysis.
3.3 RP-HPLC and RP-UPLC techniques
In recent years, reverse-phase high-performance liquid chromatography 
(RP-HPLC) and ultra-high performance liquid chromatography (UPLC) meth-
ods emerged as an alternative to the ion exchange chromatography. In RP-HPLC 
methods, the separation is based on hydrophobic interactions between the 
analyzed amino acid in the mobile phase and the immobilized hydrophobic 
ligands attached to the nonpolar column stationary phase. RP-HPLC offers 
a great resolution of very closely related molecules under a wide range of 
chromatographic conditions. For the optical detection, derivatization with 
o-phthalaldehyde (OPA) can be used as a pre-column or a post-column reaction. 
During the reaction, in the presence of thiol such as 2-mercaptoethanol, a stable 
fluorescent product is produced and can be detected by fluorimetry (excitation 
340 nm and emission 410 nm) or UV (340 nm) [28, 29]. Although reproducible 
and automated [30], OPA derivatization method is not a good choice for pro-
line/hydroxyproline and sulfur-containing amino acids detection. Alternative 
reagents for RP-HPLC with pre-column derivatization are phenylisothiocyanate 
(PITC, Pico-Tag commercialized by Waters) [31], dimethylamino-azoben-
zenesulfonyl-chloride (DABS-Cl) [32] and 9-fluorenylmethylchloroformate 
(FMOC-Cl) [33].
More advanced UPLC systems employ a small particle size (typically 1.7 μM) and 
a high pH range stable columns. These systems use less solvent and are operated in a 
high pressure which allows an excellent resolution achieved in a short time frame and 
thus potentially decreases turnaround time per sample. Narayan et al. analyzed 170 
patient samples by pre-column 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate 
(AQC) derivatization (Figure 7) followed by reverse phase UPLC [34] and com-
pared amino acids data to the traditional amino acids analyzer operated through ion 
Figure 6. 
Ninhydrin reaction with amino acid to produce Ruhemann’s purple.
Figure 7. 
AQC reaction with amino acid.
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exchange chromatography method. The study found that UPLC method is compa-
rable to the reference IEC and thus adaptable to the clinical laboratory.
Peake et al. developed a modified RP-UPLC method and achieved a better reso-
lution for tyrosine, glycine, arginine and homocitrulline peaks [35]. The improved 
method also provides enhanced resolution to separate ornithine from mesocys-
tathionine. There is a high clinical significance to accurate ornithine analysis as 
ornithine’s levels are diagnostic for hyperornithinemia-hyperammonemia- 
homocitrullinemia (HHH) syndrome. The developed UPLC method has several 
advantages. Due to the short analysis time, it is feasible to include calibration 
prior to the analysis of urgent samples with a special turnaround times. Overall, 
RP-UPLC decreases turnaround time per sample, however, commercial kit com-
ponents have a very limited shelf life and thus the method is not cost effective for 
clinical laboratories with a small samples volume.
Overall, ion exchange chromatography, RP-HPLC, and RP-UPLC techniques 
have a good reproducibility and a high sensitivity in the low picomole range, how-
ever, they all are carried out with optical detection. The main drawback of this type 
of detection is a lack of specificity as amino acids identification is solely based on 
the retention time. This can potentially cause to the false findings. For example, in a 
standard ion exchange chromatography method, ampicillin and amoxicillin co-elute 
with phenylalanine and it can be reported as falsely elevated.
3.4 Flow infusion tandem mass spectrometry (FIA-MS/MS)
More recently, developments and advancements in mass spectrometry field 
led to the inclusion of tandem mass spectrometry (MS/MS) as an alternative high 
throughput and specific technique for the amino acids analysis. It is also feasible 
to separate amino acids by liquid chromatography prior to the mass spectrometry 
analysis, however, it is time-consuming in clinical settings. Instead, tandem mass 
spectrometry scans are used for the high throughput, cost-effective amino acids 
analysis. It has to be noted, that FIA-MS/MS is a screening analysis that widely 
implemented through the newborn screening initiative.
For the newborn screening, blood samples are typically collected on filter paper 
and a defined size (typically 3 mm) disks are punched out of the paper and are 
extracted. The early assays required derivatization by butylation (Figure 8) in order 
to improve detection limits and minimize ion suppression effects in a complex bio-
logical matrix. Currently, to increase a throughput, some clinical laboratories skip 
on the derivatization step. Extracted and derivatized samples are directly intro-
duced by injection to the mass spectrometer instrument with no chromatographic 
separation. Usually, 5–10 μl of a sample is injected into a flowing solvent at a very 
low (20–50 μl) flow rate. All screened amino acids (Table 8) are eluting at the same 
time whereas a typical run time is 1.5–2 min per sample. Every analyzed amino acid 
is assayed with the corresponding stable isotopic labeled standard.
The isotopic-labeled standards are closely related to the structure of the ana-
lyzed amino acids and have similar physicochemical properties to the target amino 
acids, but can be distinguished by mass spectrometry as they have a different 
Figure 8. 
Derivatization of alanine with n-butanol.
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mass to charge ratio (m/z) (Table 8). They are added at a known quantity, and the 
response of each analyzed amino acid is normalized by the response of the match-
ing internal standard. This type of normalization reduces a systematic error due to 
the poor recovery and decreases multiple matrix effects. The inclusion of internal 
standards also corrects a batch to batch variability due to the sample preparation 
and overall raises the accuracy and precision of the assay.
The tandem mass spectrometer has five basic components: the ion source 
where all molecules are a subject to the soft ionization, a mass analyzer that 
separates analytes based on their mass to charge ratio (Q1), a collision cell where 
molecular ions encounter an inert gas and undergo fragmentation (Q2), a second 
mass analyzer to separate fragments produced in the collision cell (Q3), and a 
detector. In collision cell, most of the screened butylated α-amino acids form a 
common and a very specific fragment of 102 Da (Figure 9). The tandem mass 
spectrometer then can be set to scan a constant mass difference of 102 Da and to 
produce a spectrum of the molecular ions derived from those amino acids that lost 
102 Da in the collision cell (Q2) (Figure 9). Butylated amino acids with a basic 
side chains such as ornithine, citrulline loose ammonia and butyl formate in the 
Target amino acid m/z Internal standard m/z
Alanine 146.1 2H4 alanine 150.1
Arginine 231.2 13C,2H4 arginine 236.2
Aspartic acid 246.2 2H3 aspartic acid 249.2
Citrulline 232.2 2H2 citrulline 234.2
Glutamic acid 260.2 2H3 glutamic acid 263.2
Glycine 132.1 15N,13C glycine 134.1
Leucine/isoleucine 188.2 2h3 leucine 191.2
Methionine 206.2 2H3 methionine 209.2
Ornithine 189.2 2H2 ornithine 191.2
Phenylalanine 222.2 13C6 phenylalanine 228.2
Tyrosine 238.2 13C6 tyrosine 244.2
Valine 174.2 2H8 valine 182.2
Table 8. 
Amino acids analyzed by FIA-MS/MS for the standard newborn screening panel and their stable isotopic 
labeled internal standards.
Figure 9. 
Schematic presentation of tandem mass spectrometer. Phenylalanine (as butyl ester) looses 106 Da in the 
collision cell. When mass spectrometer operates in neutral loss scanning mode, it scans Q1 and Q3 in a 
synchronized manner. The mass difference of 102 Da (corresponds to a neutral fragment common to the most 
amino acids) passing through Q2 remains constant.
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exchange chromatography method. The study found that UPLC method is compa-
rable to the reference IEC and thus adaptable to the clinical laboratory.
Peake et al. developed a modified RP-UPLC method and achieved a better reso-
lution for tyrosine, glycine, arginine and homocitrulline peaks [35]. The improved 
method also provides enhanced resolution to separate ornithine from mesocys-
tathionine. There is a high clinical significance to accurate ornithine analysis as 
ornithine’s levels are diagnostic for hyperornithinemia-hyperammonemia- 
homocitrullinemia (HHH) syndrome. The developed UPLC method has several 
advantages. Due to the short analysis time, it is feasible to include calibration 
prior to the analysis of urgent samples with a special turnaround times. Overall, 
RP-UPLC decreases turnaround time per sample, however, commercial kit com-
ponents have a very limited shelf life and thus the method is not cost effective for 
clinical laboratories with a small samples volume.
Overall, ion exchange chromatography, RP-HPLC, and RP-UPLC techniques 
have a good reproducibility and a high sensitivity in the low picomole range, how-
ever, they all are carried out with optical detection. The main drawback of this type 
of detection is a lack of specificity as amino acids identification is solely based on 
the retention time. This can potentially cause to the false findings. For example, in a 
standard ion exchange chromatography method, ampicillin and amoxicillin co-elute 
with phenylalanine and it can be reported as falsely elevated.
3.4 Flow infusion tandem mass spectrometry (FIA-MS/MS)
More recently, developments and advancements in mass spectrometry field 
led to the inclusion of tandem mass spectrometry (MS/MS) as an alternative high 
throughput and specific technique for the amino acids analysis. It is also feasible 
to separate amino acids by liquid chromatography prior to the mass spectrometry 
analysis, however, it is time-consuming in clinical settings. Instead, tandem mass 
spectrometry scans are used for the high throughput, cost-effective amino acids 
analysis. It has to be noted, that FIA-MS/MS is a screening analysis that widely 
implemented through the newborn screening initiative.
For the newborn screening, blood samples are typically collected on filter paper 
and a defined size (typically 3 mm) disks are punched out of the paper and are 
extracted. The early assays required derivatization by butylation (Figure 8) in order 
to improve detection limits and minimize ion suppression effects in a complex bio-
logical matrix. Currently, to increase a throughput, some clinical laboratories skip 
on the derivatization step. Extracted and derivatized samples are directly intro-
duced by injection to the mass spectrometer instrument with no chromatographic 
separation. Usually, 5–10 μl of a sample is injected into a flowing solvent at a very 
low (20–50 μl) flow rate. All screened amino acids (Table 8) are eluting at the same 
time whereas a typical run time is 1.5–2 min per sample. Every analyzed amino acid 
is assayed with the corresponding stable isotopic labeled standard.
The isotopic-labeled standards are closely related to the structure of the ana-
lyzed amino acids and have similar physicochemical properties to the target amino 
acids, but can be distinguished by mass spectrometry as they have a different 
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mass to charge ratio (m/z) (Table 8). They are added at a known quantity, and the 
response of each analyzed amino acid is normalized by the response of the match-
ing internal standard. This type of normalization reduces a systematic error due to 
the poor recovery and decreases multiple matrix effects. The inclusion of internal 
standards also corrects a batch to batch variability due to the sample preparation 
and overall raises the accuracy and precision of the assay.
The tandem mass spectrometer has five basic components: the ion source 
where all molecules are a subject to the soft ionization, a mass analyzer that 
separates analytes based on their mass to charge ratio (Q1), a collision cell where 
molecular ions encounter an inert gas and undergo fragmentation (Q2), a second 
mass analyzer to separate fragments produced in the collision cell (Q3), and a 
detector. In collision cell, most of the screened butylated α-amino acids form a 
common and a very specific fragment of 102 Da (Figure 9). The tandem mass 
spectrometer then can be set to scan a constant mass difference of 102 Da and to 
produce a spectrum of the molecular ions derived from those amino acids that lost 
102 Da in the collision cell (Q2) (Figure 9). Butylated amino acids with a basic 
side chains such as ornithine, citrulline loose ammonia and butyl formate in the 
Target amino acid m/z Internal standard m/z
Alanine 146.1 2H4 alanine 150.1
Arginine 231.2 13C,2H4 arginine 236.2
Aspartic acid 246.2 2H3 aspartic acid 249.2
Citrulline 232.2 2H2 citrulline 234.2
Glutamic acid 260.2 2H3 glutamic acid 263.2
Glycine 132.1 15N,13C glycine 134.1
Leucine/isoleucine 188.2 2h3 leucine 191.2
Methionine 206.2 2H3 methionine 209.2
Ornithine 189.2 2H2 ornithine 191.2
Phenylalanine 222.2 13C6 phenylalanine 228.2
Tyrosine 238.2 13C6 tyrosine 244.2
Valine 174.2 2H8 valine 182.2
Table 8. 
Amino acids analyzed by FIA-MS/MS for the standard newborn screening panel and their stable isotopic 
labeled internal standards.
Figure 9. 
Schematic presentation of tandem mass spectrometer. Phenylalanine (as butyl ester) looses 106 Da in the 
collision cell. When mass spectrometer operates in neutral loss scanning mode, it scans Q1 and Q3 in a 
synchronized manner. The mass difference of 102 Da (corresponds to a neutral fragment common to the most 
amino acids) passing through Q2 remains constant.
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collision cell (m/z 119). For glycine and arginine, the most intensive signal corre-
sponds to the loss of 56 and 161 Da, respectively. All these specific losses or transi-
tions can be detected by different and highly specific tandem mass spectrometer’s 
scans in the single analysis.
The main limitation of the FIA-MS/MS is inability to differentiate amino acids 
that share the same m/z such as leucine/isoleucine and hydroxyproline (butylated 
derivatives m/z 188), alanine/sarcosine (butylated derivatives m/z 146) and in a 
more extended profiles glutamine/lysine (butylated derivatives m/z 186), proline/
asparagine (butylated derivatives m/z 172). Also, FIA-MS/MS is not applicable 
for cysteine and homocysteine analysis since these amino acids are not stable and 
react to form cystine and homocystine (Figure 10). During the ionization process, 
cystine and homocystine produce double charged molecules and it complicates the 
analysis.
Due to the high sensitivity and selectivity, there are more mass spectrometry-
based techniques are available for the amino acids analysis, although because of 
extensive sample preparation or limited number of amino acids covered, these 
methods are not widely used in clinical laboratories. Gas chromatography mass 
spectrometry (GCMS) [36], capillary electrophoresis mass spectrometry (CEMS) 
[37], ion pairing (IP)-LC-MS/MS, HILIC-LC-mass spectrometry [38] and two 
column LC-MS/MS methods [39], ion pairing (IP)-LC-HRMS (TOF) [40] can be 
successfully applied for the physiological amino acids analysis although with some 
limitations.
4. Diagnosis of amino acids related disorders
The initial diagnosis of amino acids disorders is based on clinical presentation and 
biochemical findings such as abnormal levels of specific amino acids (Tables 1–6) 
or accumulation of the downstream metabolites in biological fluids, however, these 
characteristics are very heterogenic and often nonspecific. The most common clinical 
indications for the quantitative amino acid analysis in neonates and pediatric patients 
are coma, lethargy, seizures and vomiting, unexplained developmental delay and sib-
lings with similar symptoms. Plasma amino acids analysis is also ordered as a confor-
mational test to follow up abnormal newborn screening results. Hyperammonemia 
is characteristic to the most urea cycle disorders (Table 3) and therefore is another 
Figure 10. 
Sulfur amino acids and their disulfides.
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strong indication for plasma amino acids analysis. Additional general biochemical 
indicators of follow up quantitative amino acids analysis are ketosis (high blood 
and urine ketones), acidosis (blood pH below 7.35) and lactic acidemia (high lactate 
excretion), alkalosis (blood pH above 7.45), polyuria, polydipsia (extreme thirsti-
ness), and dehydration. Amino acids analysis is also an important tool in the diagno-
sis of muscle and liver diseases, neurological disorders, renal failure, autism spectrum 
disorders and nutritional disturbances. Interpretation of amino acids profile is not 
just based on the abnormal level of a single amino acid, but rather involves pattern 
recognition, diagnostic ratios (Tables 1 and 2) and correlation to the patient’s clinical 
history. It is recommended to confirm the diagnosis by molecular analysis or in vitro 
enzymatic assay (usually skin or tissue biopsy sample or blood cells).
5. Treatment options
Currently, there are numbers of available therapeutic approaches that aim in 
a substrate and downstream products restoration balance (Figure 11). One of the 
Figure 11. 
Treatment strategies in amino acids disorders.
Figure 12. 
Removal of toxic ammonia. In urea cycle disorders ammonia cannot be converted to urea, but alternatively 
can be converted to glutamine and glycine. Ammonia scavengers phenylbutyrate and sodium benzoate react 
with glutamine and glycine and consequently remove excess of ammonia. Phenylglutamine and hippurate are 
excreted in urine.
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collision cell (m/z 119). For glycine and arginine, the most intensive signal corre-
sponds to the loss of 56 and 161 Da, respectively. All these specific losses or transi-
tions can be detected by different and highly specific tandem mass spectrometer’s 
scans in the single analysis.
The main limitation of the FIA-MS/MS is inability to differentiate amino acids 
that share the same m/z such as leucine/isoleucine and hydroxyproline (butylated 
derivatives m/z 188), alanine/sarcosine (butylated derivatives m/z 146) and in a 
more extended profiles glutamine/lysine (butylated derivatives m/z 186), proline/
asparagine (butylated derivatives m/z 172). Also, FIA-MS/MS is not applicable 
for cysteine and homocysteine analysis since these amino acids are not stable and 
react to form cystine and homocystine (Figure 10). During the ionization process, 
cystine and homocystine produce double charged molecules and it complicates the 
analysis.
Due to the high sensitivity and selectivity, there are more mass spectrometry-
based techniques are available for the amino acids analysis, although because of 
extensive sample preparation or limited number of amino acids covered, these 
methods are not widely used in clinical laboratories. Gas chromatography mass 
spectrometry (GCMS) [36], capillary electrophoresis mass spectrometry (CEMS) 
[37], ion pairing (IP)-LC-MS/MS, HILIC-LC-mass spectrometry [38] and two 
column LC-MS/MS methods [39], ion pairing (IP)-LC-HRMS (TOF) [40] can be 
successfully applied for the physiological amino acids analysis although with some 
limitations.
4. Diagnosis of amino acids related disorders
The initial diagnosis of amino acids disorders is based on clinical presentation and 
biochemical findings such as abnormal levels of specific amino acids (Tables 1–6) 
or accumulation of the downstream metabolites in biological fluids, however, these 
characteristics are very heterogenic and often nonspecific. The most common clinical 
indications for the quantitative amino acid analysis in neonates and pediatric patients 
are coma, lethargy, seizures and vomiting, unexplained developmental delay and sib-
lings with similar symptoms. Plasma amino acids analysis is also ordered as a confor-
mational test to follow up abnormal newborn screening results. Hyperammonemia 
is characteristic to the most urea cycle disorders (Table 3) and therefore is another 
Figure 10. 
Sulfur amino acids and their disulfides.
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strong indication for plasma amino acids analysis. Additional general biochemical 
indicators of follow up quantitative amino acids analysis are ketosis (high blood 
and urine ketones), acidosis (blood pH below 7.35) and lactic acidemia (high lactate 
excretion), alkalosis (blood pH above 7.45), polyuria, polydipsia (extreme thirsti-
ness), and dehydration. Amino acids analysis is also an important tool in the diagno-
sis of muscle and liver diseases, neurological disorders, renal failure, autism spectrum 
disorders and nutritional disturbances. Interpretation of amino acids profile is not 
just based on the abnormal level of a single amino acid, but rather involves pattern 
recognition, diagnostic ratios (Tables 1 and 2) and correlation to the patient’s clinical 
history. It is recommended to confirm the diagnosis by molecular analysis or in vitro 
enzymatic assay (usually skin or tissue biopsy sample or blood cells).
5. Treatment options
Currently, there are numbers of available therapeutic approaches that aim in 
a substrate and downstream products restoration balance (Figure 11). One of the 
Figure 11. 
Treatment strategies in amino acids disorders.
Figure 12. 
Removal of toxic ammonia. In urea cycle disorders ammonia cannot be converted to urea, but alternatively 
can be converted to glutamine and glycine. Ammonia scavengers phenylbutyrate and sodium benzoate react 
with glutamine and glycine and consequently remove excess of ammonia. Phenylglutamine and hippurate are 
excreted in urine.
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approaches in this direction is to reduce substrate accumulation by dietary restric-
tions. Nutritional therapies restrict offending amino acid or often total protein 
consumption through provision and monitoring of all essential components to 
meet dietary requirements. For example, special medical foods for PKU affected 
individuals have a very negligible amount of phenylalanine, but supplement the 
total protein required for the normal growth, development and nutritional status. 
Another example is MSUD nutritional management that restricts intake of the 
branch chain amino acids [41], but supplies the majority of the protein required in 
the standard diet.
Amino acids disorders are often manifested by the accumulation of toxic 
downstream metabolites. For example, urea acid disorders are characterized by 
life-threatening hyperammonemia (ammonia accumulation). Toxic metabolites 
removal treatment aims at reducing production or increasing excretion of these 
metabolites. To reduce hyperammonemia, sodium benzoate and phenylbutyrate 
are used to increased ammonia excretion (Figure 12) and to bypass the urea cycle 
metabolic block [42, 43]. Another example is an approach to reduce the produc-
tion of succinylacetone, a neurological toxin that accumulates in tyrosinaemia 
I. Nitisinone (NTBC) treatment blocks a formation of fumarylacetoacetate and its 
subsequent conversion to the succinylacetone [44, 45].
If as a result of mutation, a specific enzyme still retains its residual activity, it 
can be stimulated by a co-factor or a co-factor precursor supplementation. This 
concept applies in treating tetrahydrobiopterin deficiency (Figure 2) [46, 47], 
remethylation defects (Figure 4) [48] and cystathionine beta-synthase deficiency 
(Figure 4) [10]. In some amino acids disorders, even partial metabolic block 
prevents from synthesizing an essential downstream metabolite to meet metabolic 
requirements. In these cases, essential product supplementation is required. For 
example, as a part of urea cycle disorders management, l-arginine and l-citrulline 
are administered [43]. This helps to reduce excessive protein catabolism, due to the 
low arginine levels.
6. Conclusion
In conclusion, amino acids disorders are a group of inborn errors of metabolism 
with highly variable clinical and biochemical presentations. Clinical manifestation 
often comprises severe neurological symptoms, growth and developmental delays. 
Most of the amino acids disorders related conditions are included in the newborn 
screening program to facilitate early diagnosis and early disease treatment. The 
analysis of physiological amino acids levels is a key tool in the diagnosis and clinical 
management of inborn errors of amino acids metabolism. A small subset of amino 
acids is analyzed in newborn screening by tandem mass spectrometry and leads to 
the detection of affected neonates even when they do not have a symptomatic dis-
ease manifestation. A more comprehensive, quantitative amino acids analysis covers 
analysis of nearly 40 amino acids. Prior to the analysis and results interpretation, 
pre-analytical variables such as a fasting status and medication treatments should 
be taken into account in order to avoid false reported findings. A most common 
sample preparation method for the quantitative amino acids analysis is acidification 
of specimen with a known small volume of concentrated acid, such as sulfosali-
cylic acid to precipitate proteins and large molecules, followed by centrifugation, 
leaving the water-soluble amino acids in the supernatant for the analysis. A variety 
of analytical methods have been developed over the past 60 years, and scientists 
have made significant achievements in the fields of derivatization, chromatography 
and mass spectrometry, however, the ion exchange chromatography method still 
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remains the gold standard technique in the field. It is expected that more advanced 
techniques will be developed targeting important clinical laboratories requirements 
such as reduced samples pretreatment, linearity over the large concentration range 
for over the 40 amino acids, increased automation, high sensitivity, shorter run 
time and improved specificity. These methodological improvements will facilitate 
the diagnostic process and therapy monitoring for amino acids disorders. The 
field is also expending to the more exploratory platforms such as a whole-genome 
sequencing and untargeted metabolomics. Although these modalities have some 
restrictions in clinical settings [1, 49], they facilitate novel genes identification, 
novel biomarkers discovery and disease associations and thus strongly advancing 
the field [50, 51].
The major treatment goal for amino acids disorders is to normalize imbalance 
between the substrate and its downstream products and to avoid accumulation of 
the toxic substances. At the same time, nutritional management must meet basic 
dietary requirements for growth and normal development. Even though for many 
amino acids disorders current treatments do not offer a cure, they significantly 
improve the quality of life. It is expected over the upcoming years, that method-
ological advances will lead to a greater understanding of the IEM and in particular 
amino acids related disorders which will help further to improve disease outcomes.
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Abstract
Modern health care organizations, e.g., tissue banks, require a resource-based 
view (RBV) for an efficient stimulation of innovation, productivity, and per-
formance, especially in the context of laboratory management and new product 
development. High quality advanced therapy medicinal products (ATMPs) are 
expected to bring important health benefits; therefore, their production has to be 
performed in accordance with good manufacturing practice (GMP). Although there 
are no precisely defined criteria for quality control/evaluation methods of obtained 
ATMPs, all aspects of pharmaceutical quality of ATMPs’ development, manufactur-
ing, distribution, inspection, and review processes ought to be strictly fulfilled. 
Explicit performance management and production regimes in accordance with 
pharmacopeia and RBV philosophy have been proposed in this chapter.
Keywords: resource-based view, advanced therapy medicinal products, tissue bank, 
good manufacturing practice, lean management
1. The change of paradigm
An innovative way of hospital management appeared in the 1990s. Methods 
originating from the industry and known as lean management and Theory of 
Constraints (TOC) have proven surprisingly adequate in health care environment. 
These helped to overcome the problems of many hospitals facing severe issues and 
as a result requiring turnaround.
Effective management of the organization has to be holistic in nature and focus 
exclusively on the point of view of client/patient instead of unit managers. The 
effectiveness and process synchronization have to be also looked upon from the same 
perspective. Management approach aiming at local optimizations traps the manag-
ers ultimately leading to underperformance of the organization as a whole, witch 
hunt and frustration from the very bottom to the top of the organizational ladder. 
Moreover, most of the employees including top managers are not fully aware of the 
structure of processes in their company. These processes do not fit the most com-
monly applied management practices. In their nature, these are horizontal and not 
vertical like the structures of most of the organizations [1].
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The term “lean management” has been first formulated by the American 
researcher John Krafcik who has been investigating the reasons behind competitive 
advantage of Japanese automobile industry over its American counterpart. Krafcik 
has been particularly impressed by the Toyota Production System (TPS), which has 
been developing in Japan from mid-1940s.
Essentially, lean system could be defined as an elimination of waste and respect 
to all of the employees organization-wide. The goal of the organization is to deliver 
added value to the patient/client/payer. Added value is generated when any activ-
ity that delivers tangible results in the process is performed correctly the first time 
and for which the patient/client/payer is ready to pay. All the rest is regarded as 
waste. There are seven types of waste defined by the TPS originator—Taiichi Ohno. 
Detailed description is outside the scope of this book, but an interested reader will 
easily find it outlined in many available resources [2].
The set of tools and techniques applied in lean is usually presented as the so-
called Toyota House or Lean House. The fundaments of the house comprise 5S—the 
system of creating and maintaining a neat and clean work environment, continuous 
improvement, standard work, balanced distribution of the job, and visual controls. 
All of these elements are crucial; nevertheless, 5S and standardized work require 
closer explanation.
The majority of organizations do not realize how much waste is hidden in their 
current processes. There is an abundance of unnecessary tools, equipment, excess 
inventory, documentation, etc., in any hospital. All these obscure the real problems. 
Any attempt to optimize the processes without launching 5S at the very beginning is 
doomed to fail as the main issues will stay hidden behind the visible surface.
Standard work in lean is different from what is usually meant by the notion. 
Standardization is the best presently known way of performing a certain task. If 
the employees develop a better, safer way, the standard work can be changed almost 
immediately. This is different from the traditional approach relying on rigid rules, 
which are almost impossible to change. Actually, lean is a scientific method based 
on continuous experiments, which make it extremely flexible, and ensures involve-
ment of the employees on all the levels.
Two walls of the Toyota House can be distinguished. The first one is continu-
ous flow, which concentrates on elimination of delays as well as right care in the 
right time in the right place. The second one is a quality approach, focusing on 
error detection, preventing errors at the very source, and involving the employees 
in problem-solving. The most important rule is to ensure that no witch hunt takes 
place. Instead, employees providing information about the existing and possible 
issues and implementations of related solutions should be rewarded.
Finally, the roof comprises the ultimate goals: health, safety, staff morale, and 
patient satisfaction.
Unfortunately, the term “lean” has been misinterpreted, mainly in the USA, and 
used in the form of practices involving layoffs and increased work burden. As a 
result, it has lead to pathologies that are in no way connected to the Japanese ideas. 
The authors would like to stress that the aforementioned mismanagement has noth-
ing in common with genuine lean, which is based directly on TPS.
Theory of Constraints emerged at the beginning of the 1980s, when the Israeli 
physicist, Dr. Eliyahu Goldratt who became interested in the production planning 
processes, published his first book on the subject in the form of a bestselling busi-
ness novel The Goal [3]. Goldratt claimed that every organization has its own main 
constraint, either internal or external, and proposed a set of five steps called the 
Process of Ongoing Improvement (POOGI) to handle these issues accordingly. The 
aforementioned steps are:
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• Identify the constraint,
• Exploit the constraint—ensure that the constraint is operational all the avail-
able time,
• Subordinate all the resources within the organization to the requirements of 
the constraint,
• Elevate the constraint, i.e., widen it, and
• If the constraint has been broken, identify the new one and start the process all 
over again, but be aware of the inertia.
Over the following years, Goldratt developed the applications of the TOC in 
various areas like project management, sales, marketing, and people management. 
In the 1990s, he introduced the TOC thinking processes—a set of tools aimed at 
enhancing the analysis of the problems and building solid, logical, time-proven 
solutions. Today, TOC has found its applications in many different areas both in 
manufacturing and in services like logistics, strategy, health care, education, and 
resocialization [4].
It has to be stressed that both lean and TOC—if they are to be implemented 
the proper way—have to be a company-wide effort closely supervised and led by 
the top management. Both clinical and nonclinical departments must be taken 
into account. Obviously, the positive cultural change of the organization will 
follow as an ultimate result of the implementation. The task is by no means easy, 
but the payoffs are well worth it. Potential benefits include 20–80% of produc-
tivity improvement, reduction of unnecessary length of stay, and significant 
reduction in inventory and space, and savings counted in millions of  
local currency are not uncommon if the methods are applied properly and  
given sufficient time [5]. One has to remember that both methods advocate  
continuous and growing improvement and are therefore not a one-time 
initiative.
Neither lean nor TOC is meant to replace the golden medical standards or the 
standards of pharmaceutical production like GMP. They are rather complementary 
tools and techniques, paving the way for the existing standards to rise to new 
levels.
Dr. Stanislaw Sakiel Burn Treatment Centre (CLO) based in Siemianowice 
Śląskie, Poland, is a top hospital specializing primarily in the treatment of 
burns and chronic wounds. CLO has been a pioneer in application of TOC and 
lean in hospital management since early 2016. According to the knowledge of 
the authors, it is the only hospital in Poland where the system not only is still 
functioning but also delivers constantly better results. The Bank of Tissues has 
been among the first units where the approach has been applied. The project 
was initiated in 2016. Despite the fact that GMP was already in place, it soon 
became apparent that there is still a huge room for improvement. The decision 
to implement 5S quickly delivered results. Process mapping followed, together 
with visible changes in the flow in local production site. Today, the flow is faster, 
job is better organized, and the breaks are sporadic instead of being a norm. 
Improved communication with the operating theater resulted in more on-time 
deliveries and less unnecessary additional transports. This in turn contributed to 
shorter surgical procedures and better overall conditions for patients and medi-
cal personnel alike.
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• Identify the constraint,
• Exploit the constraint—ensure that the constraint is operational all the avail-
able time,
• Subordinate all the resources within the organization to the requirements of 
the constraint,
• Elevate the constraint, i.e., widen it, and
• If the constraint has been broken, identify the new one and start the process all 
over again, but be aware of the inertia.
Over the following years, Goldratt developed the applications of the TOC in 
various areas like project management, sales, marketing, and people management. 
In the 1990s, he introduced the TOC thinking processes—a set of tools aimed at 
enhancing the analysis of the problems and building solid, logical, time-proven 
solutions. Today, TOC has found its applications in many different areas both in 
manufacturing and in services like logistics, strategy, health care, education, and 
resocialization [4].
It has to be stressed that both lean and TOC—if they are to be implemented 
the proper way—have to be a company-wide effort closely supervised and led by 
the top management. Both clinical and nonclinical departments must be taken 
into account. Obviously, the positive cultural change of the organization will 
follow as an ultimate result of the implementation. The task is by no means easy, 
but the payoffs are well worth it. Potential benefits include 20–80% of produc-
tivity improvement, reduction of unnecessary length of stay, and significant 
reduction in inventory and space, and savings counted in millions of  
local currency are not uncommon if the methods are applied properly and  
given sufficient time [5]. One has to remember that both methods advocate  
continuous and growing improvement and are therefore not a one-time 
initiative.
Neither lean nor TOC is meant to replace the golden medical standards or the 
standards of pharmaceutical production like GMP. They are rather complementary 
tools and techniques, paving the way for the existing standards to rise to new 
levels.
Dr. Stanislaw Sakiel Burn Treatment Centre (CLO) based in Siemianowice 
Śląskie, Poland, is a top hospital specializing primarily in the treatment of 
burns and chronic wounds. CLO has been a pioneer in application of TOC and 
lean in hospital management since early 2016. According to the knowledge of 
the authors, it is the only hospital in Poland where the system not only is still 
functioning but also delivers constantly better results. The Bank of Tissues has 
been among the first units where the approach has been applied. The project 
was initiated in 2016. Despite the fact that GMP was already in place, it soon 
became apparent that there is still a huge room for improvement. The decision 
to implement 5S quickly delivered results. Process mapping followed, together 
with visible changes in the flow in local production site. Today, the flow is faster, 
job is better organized, and the breaks are sporadic instead of being a norm. 
Improved communication with the operating theater resulted in more on-time 
deliveries and less unnecessary additional transports. This in turn contributed to 
shorter surgical procedures and better overall conditions for patients and medi-
cal personnel alike.
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2.  Resource-based view (RBV) approach in health care organizations 
and tissue bank laboratory management
2.1 Resource-based view framework for health care organizations
The resource-based view (RBV) is a theoretical framework used to study and 
explain the competitive behavior of organizations [6, 7] that emerged in 1980s 
and 1990s, after the major works published by Barney, J. Firm Resources and 
Sustained Competitive Advantage, Prahalad and Hamel The Core Competence of the 
Corporation, and Wernerfelt, B. The Resource-Based View of the Firm. Since then, 
RBV approach has been widely used and appreciated in the management of pri-
vate organizations. However, it may also bring a promising framework to imple-
ment in the context of large-scale quality improvement within the public health 
care entities. Although these theories may be novel for the health management 
field, including models of strategic management originally developed for private 
sector firms, their application within publicly funded settings may be problematic 
or require customization, but nevertheless provide interesting insights [8]. It 
may provide a sustainable solution to manage quality driven, highly complex, 
and environmentally turbulenced settings such as tissue bank laboratories. RBV 
approach may be the answer to maximize growth, quality, and performance in a 
way to cope with modern, rapid technological changes and competitive medical 
environments.
The tissue banking sector quality improvement efforts take place in interor-
ganizational networks rather than in a large, vertically integrated organization. 
Therefore, tissue bank managers encounter significant difficulties in understand-
ing high organizational complexity that cannot be reduced to simple cause-effect 
relations or one variable [8]. The challenge is not only to be in compliance with 
applicable codes and quality regulations of good manufacturing practice (GMP), 
state regulatory agency, or pharmaceutical regulatory requirements, but also at 
the same time to optimize your business operations and standardize workflows in 
processing laboratories. Navigating through this complicated regulatory milieu and 
at the same ensuring efficient manufacturing process along with sensible business 
cost balance may require a RBV theoretical framework. Resource-based view and 
regulatory compliance are not mutually exclusive but should be combined to deliver 
excellent performance improvements and complex approach to stimulate organiza-
tion’s competitiveness, productivity, and innovation.
2.2 RBV model
The RBV resource approach assumes that the success of the organization lies 
within the organization itself, or to be exact, in its valuable, intangible, and not 
perfectly imitable resources (VRIO condition) allowing it to achieve a sustainable 
competitive advantage [9]. Resource-based view (RBV) analyzes and interprets 
resources of the organizations to understand how organizations achieve sustain-
able competitive advantage. The RBV focuses on the concept of difficult-to-imitate 
attributes of the firm as sources of superior performance and competitive advantage 
[10, 11]. It takes an ‘inside-out’ view of firm-specific perspective on why organiza-
tions succeed or fail in the market place [12]. According to this approach, resources 
are given the superior role in achieving higher organizational performance. The RBV 
model presents some critical assumptions regarding resources, which are about to be 
met, in order to obtain efficient manufacturing process in line with regulatory com-
pliance. The first stage of the RBV model categorizes resources within the organiza-
tion into two basic types: tangible and intangible resources. The literature categorizes 
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resources also into three main categories: tangible resources, intangible resources, 
and capabilities [13]. Capabilities refer to the skills organization possesses to coordi-
nate the resources (i.a., teamwork, organizational culture, and trust); however, they 
are not clearly owned and difficult to measure. For the purpose of the RBV model 
in this paper, the author included capabilities into tangible and intangible resource 
category (Table 1).
Tangible resources belong to the organization and can be divided into fixed 
assets (i.e., tissue bank facilities, land, laboratory machinery, clean room systems, 
and furniture) and current assets including, i.a., capital equipment, laboratory 
equipment, inventory, and financial means. Such assets are also referred to as 
property-based resources [6]. Other divisions of tangible resources include also 
categories of physical and financial assets [14].
Intangible resources, also referred to as knowledge-based resources [15], consist 
of intellectual property and include, i.a., operational knowledge of the laboratory 
employees, process knowledge, procedures, accumulated experience, patents, tissue 
bank brand recognition, community relationship, trademark, and legal agreements. 
They can be further divided into infinite and finite intangible assets (Figure 1).
Tangible and intangible resources can be further grouped into various sub-
categories. One of them was first presented by Barney [13] and included physical 
resources (physical, technological, plant, and equipment), human capital resources 
(training, experience, and insights), and organizational capital resources (formal 
structure). An example of broader classification of resources and capabilities of a 
tissue bank can be found in Table 1.
According to RBV, not all resources of the firm will be strategic and, hence, 
sources of competitive advantage. Competitive advantage occurs only when there is 
a situation of resource heterogeneity and immobility [16]. The resource heterogene-
ity implies that organizations have varying capabilities and possess unique bunch 
of resources allowing them to design different strategies to obtain competitive 
advantage. Resource immobility may be understood as inability of competing firms 
to obtain resources from other firms. If the resource is not perfectly mobile  
Table 1. 
Examples of tissue bank tangible and intangible resources and capabilities.
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structure). An example of broader classification of resources and capabilities of a 
tissue bank can be found in Table 1.
According to RBV, not all resources of the firm will be strategic and, hence, 
sources of competitive advantage. Competitive advantage occurs only when there is 
a situation of resource heterogeneity and immobility [16]. The resource heterogene-
ity implies that organizations have varying capabilities and possess unique bunch 
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(i.e., the resource is not free to move between firms, or if a firm without a resource 
faces a considerable cost burden in developing, acquiring, or using it that a firm 
already using it does not), then the resource is likely to be a source of sustained 
competitive advantage [16].
In order for the resource to provide sustainable and desirable performance, 
VRIO framework criteria must be fulfilled. The original tool VRIN was described by 
Barney [10] in his work Firm Resources and Sustained Competitive Advantage and was 
later improved by Barney to VRIO in Looking Inside for Competitive Advantage (1995).
1. Valuable (V): a resource is considered valuable when it provides strategic 
value to organization, enabling it to exploit opportunities or defend against 
threats. The resource that is unable to meet this criterion leads to competitive 
disadvantage.
2. Rare (R): rare resources, hard to obtain by competitors, grant temporary 
competitive advantage. The resource must be rare enough to design and 
execute unique business strategy in comparison with other organizations on 
the market.
3. Imperfect imitability (I): the resource leading to competitive advantage must 
be costly to imitate for other organizations that do not have it. The resource 
may also be hard to imitate not only because of financial reasons but also 
because of difficulties in acquiring it, its complexity, causal ambiguity, or even 
historical conditions.
4. Non-Substitutability (N): it is impossible for a competitor to substitute 
or replace a certain resource by other or alternative resource/Organized to 
Capture Value (O): it is the task of the organization to be able to organize its 
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potential of its unique resources. Therefore, the resource itself does not confer 
any value to the company; it is crucial to organize the company allowing it to 
achieve not only temporary but also sustained competitive advantage.
The VRIO framework may therefore be a crucial strategic analysis tool uncov-
ering resources and capabilities that give organizations a long-term competitive 
advantage. An example of VRIO analysis for tissue bank can be found in Table 2.
2.3 Summary
Internal resources and capabilities determine strategic choices made by firms 
while competing in their external business environment [15]. As resource require-
ments in health care organizations must be carefully managed due to cost con-
straints, RBV approach along with VRIO resource analysis adaptation to tissue bank 
not-for-profit settings seems intuitively sound. Resource-based view can ensure 
sensible balance between complying quality regulations that govern tissue banks 
and optimizing processing practices. Examining and identifying unique (valu-
able, rare, and costly to imitate) organizational resources through RBV and VRIO 
framework may deliver simple but excellent performance improvements. Finding 
out if the entity is organized to exploit the resources and protecting them may lead 
to better financial results as control of superior and unique resources is necessary to 
establish a cost advantage, which leads to profitability [14]. Finally, constant review 
of VRIO resources and capabilities enables organizations to establish clear-cut 
sustainable competitive advantage and growth.
3. Activity and documentation of a tissue bank
The activity of a tissue bank may be limited to the preparation of biostatic (radia-
tion sterilized) and biovital (living) grafts using documented and proven procedures. 
In this regard, a tissue bank operates under a Ministry of Health License and must 
demonstrate the implementation of a quality assurance system that meets the require-
ments of the Law of July 1, 2005, on the collection, storage, and transplantation of 
cells, tissues, and organs as amended (Journal of Laws 2017 item 1000). The regulation 
Table 2. 
Examples of VRIO analysis: ADM patent.
Biochemical Testing - Clinical correlation and Diagnosis
140
(i.e., the resource is not free to move between firms, or if a firm without a resource 
faces a considerable cost burden in developing, acquiring, or using it that a firm 
already using it does not), then the resource is likely to be a source of sustained 
competitive advantage [16].
In order for the resource to provide sustainable and desirable performance, 
VRIO framework criteria must be fulfilled. The original tool VRIN was described by 
Barney [10] in his work Firm Resources and Sustained Competitive Advantage and was 
later improved by Barney to VRIO in Looking Inside for Competitive Advantage (1995).
1. Valuable (V): a resource is considered valuable when it provides strategic 
value to organization, enabling it to exploit opportunities or defend against 
threats. The resource that is unable to meet this criterion leads to competitive 
disadvantage.
2. Rare (R): rare resources, hard to obtain by competitors, grant temporary 
competitive advantage. The resource must be rare enough to design and 
execute unique business strategy in comparison with other organizations on 
the market.
3. Imperfect imitability (I): the resource leading to competitive advantage must 
be costly to imitate for other organizations that do not have it. The resource 
may also be hard to imitate not only because of financial reasons but also 
because of difficulties in acquiring it, its complexity, causal ambiguity, or even 
historical conditions.
4. Non-Substitutability (N): it is impossible for a competitor to substitute 
or replace a certain resource by other or alternative resource/Organized to 
Capture Value (O): it is the task of the organization to be able to organize its 




Resource-Based View of Laboratory Management: Tissue Bank ATMP Production as a Model
DOI: http://dx.doi.org/10.5772/intechopen.86561
potential of its unique resources. Therefore, the resource itself does not confer 
any value to the company; it is crucial to organize the company allowing it to 
achieve not only temporary but also sustained competitive advantage.
The VRIO framework may therefore be a crucial strategic analysis tool uncov-
ering resources and capabilities that give organizations a long-term competitive 
advantage. An example of VRIO analysis for tissue bank can be found in Table 2.
2.3 Summary
Internal resources and capabilities determine strategic choices made by firms 
while competing in their external business environment [15]. As resource require-
ments in health care organizations must be carefully managed due to cost con-
straints, RBV approach along with VRIO resource analysis adaptation to tissue bank 
not-for-profit settings seems intuitively sound. Resource-based view can ensure 
sensible balance between complying quality regulations that govern tissue banks 
and optimizing processing practices. Examining and identifying unique (valu-
able, rare, and costly to imitate) organizational resources through RBV and VRIO 
framework may deliver simple but excellent performance improvements. Finding 
out if the entity is organized to exploit the resources and protecting them may lead 
to better financial results as control of superior and unique resources is necessary to 
establish a cost advantage, which leads to profitability [14]. Finally, constant review 
of VRIO resources and capabilities enables organizations to establish clear-cut 
sustainable competitive advantage and growth.
3. Activity and documentation of a tissue bank
The activity of a tissue bank may be limited to the preparation of biostatic (radia-
tion sterilized) and biovital (living) grafts using documented and proven procedures. 
In this regard, a tissue bank operates under a Ministry of Health License and must 
demonstrate the implementation of a quality assurance system that meets the require-
ments of the Law of July 1, 2005, on the collection, storage, and transplantation of 
cells, tissues, and organs as amended (Journal of Laws 2017 item 1000). The regulation 
Table 2. 
Examples of VRIO analysis: ADM patent.
Biochemical Testing - Clinical correlation and Diagnosis
142
contains the basic documents that a tissue bank quality system must include; however, 
some of the mentioned documents seem to be obsolete. The basic documents used 
in a tissue bank are standard operating procedures (SOPs). SOPs must describe the 
requirements regarding primarily the processes and activities related to the collection 
of cells or tissues, their acceptance, processing, storage, distribution, transport, as 
well as monitoring the condition of cells or tissues on their way from the donor to 
the recipient. Standard operating procedures should specify the medical devices and 
materials that have direct contact with cells or tissues. The criteria for the qualification 
and selection of the cell or tissue donor and the criteria for excluding the deceased 
donor, including the objection against the collection of tissues, must be clearly 
defined. Standard operating procedures should describe the method of cell or tissue 
collection, detailing the data necessary for the identification of the entity arranging 
the tissue collection and the data regarding the collection itself so as to ensure full 
traceability of the collected cells or tissues. The procedures must specify the means of 
transporting the collected cells or tissues and their acceptance into the tissue and cell 
bank. The quality system procedures in a tissue bank must specify how to identify and 
secure cells or tissues during transport, and describe the stage of acceptance of tissue 
and cellular material into the bank, specifying the information on:
The way in which cells or tissues are accepted into a tissue and cell bank, taking the 
following into account:
a. The common understanding of the purpose of the collected cells or tissues
b. Results of medical examinations, specialist examinations, and laboratory tests
c. Documented criteria of donor selection performed by an authorized person
d. Documented transport, packaging, and labeling conditions
e. The assessment of the quality of the cells or tissues accepted into the  
tissue and cell bank
f. The method of dealing with cell or tissue transplants that do not conform 
with the specification and have incomplete test results and unacceptable 
quality or defects
g. The course of quarantine from the time of acceptance of cells or tissues into 
the tissue and cell bank until they are released for processing or withdrawn
The next step, which must be included in standard operating procedures, is the 
processing of cells or tissues. These procedures must take into account the 
requirements regarding the following elements of all cell or tissue type process-
ing: labeling, processing conditions, and ongoing evaluation of the processing 
operations in order to ensure the safety and quality of the cells or tissues being 
processed. The SOPs must describe the manner of approval and documentation 
of the changes in the processing operations. A cell or tissue identification system 
must be developed and described at every stage of the processing to distinguish 
between authorized products and unauthorized products. The infected cell or 
tissue removal or withdrawal procedures must be developed and described to 
prevent infection of other processed cells or tissues, the processing products, 
environment, or personnel.
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The SOPs must include the following:
• The grace period conditions after the processing of cells or tissues
• The method of cell or tissue sterilization
• The grace period conditions after the sterilization of cells or tissues
• The manner of storing the processed cells or tissues and releasing them for 
distribution after the grace period
Another stage that must be included in the quality system is the storage of cells 
or tissues after processing. Procedures in this regard must specify the requirements 
for the following:
• Separate storage conditions and maximum storage time for each cell or tissue 
type, taking into account the possibility of deterioration of the cell or tissue 
properties in the course of storage
• Separate storage conditions and maximum storage time for each type of 
product derived from the processed cells or tissues, taking into account the 
possibility of deterioration of the product properties
• The development of a cell or tissue inventory and identification system at each 
storage stage
Standard operating procedures for the distribution of cells or tissues determine 
the requirements regarding labeling of materials intended for distribution as well as 
transport criteria and conditions. The scope of standard operating procedures must 
also include the monitoring of the quality of cells or tissues on their way from the 
donor to the recipient.
A very important aspect is to define the manner of recording significant adverse 
events and significant adverse reactions associated with the collection, testing, pro-
cessing, storage, distribution and transplantation of cells or tissues, their reporting, 
and elimination of the reasons for their occurrence.
The documentation of the quality system must also contain the operating 
manuals specifying the applicable documentation, including types of documents, 
their keeping and circulation in the tissue and cell bank, and the manner of keeping 
records of specific activities performed in a tissue bank. The documentation must 
also contain reporting forms and donor cards.
The described quality system concerns procedures regarding tissue and cell 
banking. If a tissue bank additionally produces advanced therapy medicinal 
products (ATMPs) using the hospital-exemption advanced therapy medicinal 
product (HE-ATMP) production procedure, two complementary systems must 
be developed. Becoming a producer of hospital-exemption advanced therapy 
medicinal products, the tissue bank must additionally implement the good man-
ufacturing practice (GMP) quality system certified by the Main Pharmaceutical 
Inspectorate.
The system requires the development of documentation necessary to meet the 
requirements of the GMP quality system. The basic document containing the pro-
ducer’s characteristics is the site master file describing the activities of the production 
authorization holder related to the good manufacturing practice.
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requirements of the GMP quality system. The basic document containing the pro-
ducer’s characteristics is the site master file describing the activities of the production 
authorization holder related to the good manufacturing practice.
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The GMP documentation must also include the following manuals:
• Specifications describing in detail the requirements for a medicinal product or 
material used or obtained in the production process. They constitute the basis 
for quality assessment.
• Production recipes, processing and packaging instructions, and testing 
manuals. This documentation must provide details of all the output materi-
als, devices, and computer systems used. All instructions regarding the 
processing, packaging, sampling, and sample testing must also be specified 
in detail.
In-process control and process control in real time (PAT—process analytical 
technologies) that are used in the process must be specified along with the accep-
tance criteria:
• Procedures: standard operating procedures (SOP) determining the manner of 
operation execution
• Protocols presenting the manuals and records of the concerned operation 
execution
• Contractual agreements referring to arrangements between the client and the 
contractor for commissioned activities
The GMP system defines the types of records and reports:
• The records provide evidence of actions taken to demonstrate compliance 
with the manual, e.g., activities, events, tests, and, in the case of batch 
production, the history of each batch of a medicinal product, including its 
distribution. Records contain raw data that are used to create other entries. All 
data used as the basis for quality activities should be defined as raw data.
• The analytical certificates provide a summary of the medicinal product 
sample or material test results including the assessment of compliance with 
a given specification. Alternatively, the certification can be based entirely 
or in part on real-time process control (summaries and deviation reports) 
for a batch associated with real-time batch control (PAT—process analytical 
technologies), with parameters and measurements that must comply with the 
approved documentation attached to the marketing authorization.
• The reports document the execution of individual tests, projects, or studies as 
well as results, conclusions, and recommendations.
In the GMP quality system, it is necessary to develop and supervise the docu-
mentation, which is defined in the good documentation practice.
It includes the following recommendations:
• The manually entered data must be clear, legible, and impossible to delete.
• The records must be made or supplemented in the course of execution of each 
activity in such a way that all important activities related to the production of 
medicinal products are reproducible.
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• Every change of a record in a document should be signed and dated, and the 
means of introducing the change must enable the original information to be 
read. The reason for the change must be provided in justified cases.
In order to properly archive documents, the relationship between the record 
and the production activity should be clearly defined as well as the place where the 
record has been entered.
It is also necessary to have the properly approved and dated specifications of 
starting and packaging materials as well as the finished products.
The following documents should also be developed:
• Production recipes and production manuals
• Packaging instructions
• Batch production records
• Batch packaging records
The acceptance of each delivery of any starting material (including bulk prod-
ucts, intermediate products, and finished products) of any direct, external, and 
printed packaging material requires written procedures and records. It is necessary 
to develop written procedures for material and product testing at various stages of 
production, describing the methods and equipment used. The executed tests should 
be documented.
As part of the GMP system, written procedures for releasing or rejecting 
materials and products, including the certification of the finished products by the 
qualified person, must be developed. All entries must be available to the quali-
fied person. The developed system must immediately identify deviations and any 
changes implemented in the critical data.
The distribution records of each manufactured batch of medicinal product must 
be kept and stored in order to withdraw a series from the market if necessary.
The system also requires the development of written procedures, programs, 
protocols, reports, and related records regarding undertaken actions or final 
conclusions. These procedures should include the following:
• Process, equipment, and system validation and qualification
• Device assembly and calibration
• Technology
• Maintenance, cleaning, and disinfection
• Personnel issues, including a list of specimen signatures, and training in 
respect to the requirements
• Technical issues, protective clothing and hygiene, as well as the verification of 
the effectiveness of the training sessions conducted
• Environmental monitoring
• Pest control
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• Every change of a record in a document should be signed and dated, and the 
means of introducing the change must enable the original information to be 
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ucts, intermediate products, and finished products) of any direct, external, and 
printed packaging material requires written procedures and records. It is necessary 
to develop written procedures for material and product testing at various stages of 
production, describing the methods and equipment used. The executed tests should 
be documented.
As part of the GMP system, written procedures for releasing or rejecting 
materials and products, including the certification of the finished products by the 
qualified person, must be developed. All entries must be available to the quali-
fied person. The developed system must immediately identify deviations and any 
changes implemented in the critical data.
The distribution records of each manufactured batch of medicinal product must 
be kept and stored in order to withdraw a series from the market if necessary.
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protocols, reports, and related records regarding undertaken actions or final 
conclusions. These procedures should include the following:
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the effectiveness of the training sessions conducted
• Environmental monitoring
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• Complaints
• Withdrawal from the market
• Returns
• Change control
• Explanatory proceedings regarding deviations and nonconformities
• Internal audits regarding the quality and observing the good manufacturing 
practice
• Record summaries
• Audits at suppliers
The producers must provide clear and understandable operating instructions for 
the main production and control equipment. They must keep logs of the master and 
critical control equipment, production equipment, and areas in which production 
processes take place. There must be records regarding each area, device, method, 
calibration, maintenance, cleaning, or repair introduced in chronological order, 
dated and signed by the personnel performing these activities. A list of quality 
management system documents should be kept.
4.  Quality and risk management in compliance with GMP and with 
reference to RBV
As described above, the cells were qualified by the European Medicines Agency 
as advanced therapy medicinal products (ATMPs), so their production is subject to 
good manufacturing practice (GMP) [17]. The ATMP implementation is therefore 
not only technologically complex but also strictly regulated by national and 
European laws. GMP, although it is the legal basis, is only a part of quality manage-
ment at tissue banks [18]. By definition, resource-based view contains all the 
principles of good manufacturing practice. If the quality of the delivered product is 
defined by us as meeting the requirements and expectations of patients, simple 
observation of the GMP does not guarantee that these requirements will be met 
[18]. It seems that only the combination of GMP with the ISO 9001 standard, the 
RBV approach, and lean management enables a comprehensive approach to man-
agement, including quality and risk management. ATMP production is special and 
requires a rigorous and carefully monitored bioprocess to control the intrinsically 
complex and variable nature of the substance, especially since some ATMPs can be 
combined with medical devices, such as biodegradable matrices or scaffolds [19]. It 
should also be mentioned that material collection from a patient takes place in a 
hospital that is not a GMP-controlled environment, which additionally contributes 
to the increased variability of this stage [20] and leaves room for other management 
techniques, such as RBV and lean. A better understanding of graft production 
management requires risk analysis, including its identification, assessment, and 
control. The risk is determined by the likelihood of damage and the consequences of 
this damage. The risk associated with the quality of the advanced therapy medicinal 
product/tissue is one of the components of the total risk arising from the produc-
tion and use of the graft. This indicates the need to extend quality management 
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with a resource approach. Product quality must be maintained throughout the 
entire production cycle and must allow identification and control of potential risks 
associated with development, production, and transplantation. The quality risk 
management principles include development, production, distribution, process 
reviews, and validations. An important element of the quality system resulting 
from GMP is the process of corrective and preventive actions (CAPA), which refers 
to deviations, i.e., events departing from the approved procedures or instructions. 
An example would be a change of the culture incubator during the process or 
allowing the tissue to be packaged without obtaining the results of quality control 
analyses. These types of activities are sometimes undertaken to rescue the medicinal 
product (graft) or to maintain the continuity of cell culture; however, the area of 
their application ends at the stage of production of the medicinal product. The 
initial stage in the CAPA process is to clearly define the problem, i.e., register  
the deviation and provide its short description containing the scope and area of the 
occurrence of the irregularity and to indicate the leader of the explanatory actions, 
who will be responsible for carrying out the entire explanatory procedure. At this 
stage, it must be added that the idea of corrective and preventive action implemen-
tation is not to blame anyone but to continuously improve the production process 
and the quality of grafts. In determining the actual or most probable cause of an 
adverse event, the following elements should be taken into account: the equipment 
and materials used, validity, feasibility and comprehensibility of procedures, the 
design of the entire process (including its bottlenecks), the level employee qualifi-
cations, software, and external factors. Any additional resources that may poten-
tially have an impact on the adverse event that has occurred are also identified and 
documented. After preparing a list of probable causes, the information and data 
collection must ensue to be used to draw conclusions about the possible cause of the 
event. Then, the explanatory actions are implemented and the reasons for the 
deviation are identified. Repair/corrective actions and their implementation are also 
specified, and all these actions should be described in order to later verify the 
effectiveness of the steps taken. Then, there is risk communication, which is a 
process of sharing risk information and risk management methods between deci-
sion-makers and other parties. The parties exchange information at each stage of 
the risk management process. If the explanatory actions do not show the reason for 
the deviation, a quality risk assessment should be performed. A number of com-
monly accepted and well-defined methods and processes of risk analysis and 
quality risk management have been developed. Risk control in turn involves actions 
that introduce decisions in the area of risk management. The purpose of risk control 
is to make decisions, which lead to risk reduction to an acceptable level. The contri-
bution of work devoted to risk management should be proportional to the risk 
weight. Preliminary hazard analysis (PHA) is an analytic tool based on the applica-
tion of previous experience or knowledge about the threat or failure to identify 
future threats (Annex 20 GMP). One of the PHA variations is brainstorming, 
during which the expert group asks “what if” questions to identify the impact of 
individual elements on the production process and formulate recommendations for 
the actions to be taken. The quality of the results obtained using this method 
depends to a large extent on the experience and knowledge of the participants [20]. 
The hazard and operability studies (HAZOP) method of analysis was developed in 
the 1960s. Like the PHA, it is a systematic method; however, it requires more 
detailed information. The HAZOP method uses a predefined set of guiding words to 
describe the parameters, which leads to the creation of a pair of words that is 
referenced to a point in the process that can potentially fail. As a result of using this 
method, a table is created that includes situations, which can cause a failure, 
together with its consequences and specific causes. However, this is a 
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from GMP is the process of corrective and preventive actions (CAPA), which refers 
to deviations, i.e., events departing from the approved procedures or instructions. 
An example would be a change of the culture incubator during the process or 
allowing the tissue to be packaged without obtaining the results of quality control 
analyses. These types of activities are sometimes undertaken to rescue the medicinal 
product (graft) or to maintain the continuity of cell culture; however, the area of 
their application ends at the stage of production of the medicinal product. The 
initial stage in the CAPA process is to clearly define the problem, i.e., register  
the deviation and provide its short description containing the scope and area of the 
occurrence of the irregularity and to indicate the leader of the explanatory actions, 
who will be responsible for carrying out the entire explanatory procedure. At this 
stage, it must be added that the idea of corrective and preventive action implemen-
tation is not to blame anyone but to continuously improve the production process 
and the quality of grafts. In determining the actual or most probable cause of an 
adverse event, the following elements should be taken into account: the equipment 
and materials used, validity, feasibility and comprehensibility of procedures, the 
design of the entire process (including its bottlenecks), the level employee qualifi-
cations, software, and external factors. Any additional resources that may poten-
tially have an impact on the adverse event that has occurred are also identified and 
documented. After preparing a list of probable causes, the information and data 
collection must ensue to be used to draw conclusions about the possible cause of the 
event. Then, the explanatory actions are implemented and the reasons for the 
deviation are identified. Repair/corrective actions and their implementation are also 
specified, and all these actions should be described in order to later verify the 
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sion-makers and other parties. The parties exchange information at each stage of 
the risk management process. If the explanatory actions do not show the reason for 
the deviation, a quality risk assessment should be performed. A number of com-
monly accepted and well-defined methods and processes of risk analysis and 
quality risk management have been developed. Risk control in turn involves actions 
that introduce decisions in the area of risk management. The purpose of risk control 
is to make decisions, which lead to risk reduction to an acceptable level. The contri-
bution of work devoted to risk management should be proportional to the risk 
weight. Preliminary hazard analysis (PHA) is an analytic tool based on the applica-
tion of previous experience or knowledge about the threat or failure to identify 
future threats (Annex 20 GMP). One of the PHA variations is brainstorming, 
during which the expert group asks “what if” questions to identify the impact of 
individual elements on the production process and formulate recommendations for 
the actions to be taken. The quality of the results obtained using this method 
depends to a large extent on the experience and knowledge of the participants [20]. 
The hazard and operability studies (HAZOP) method of analysis was developed in 
the 1960s. Like the PHA, it is a systematic method; however, it requires more 
detailed information. The HAZOP method uses a predefined set of guiding words to 
describe the parameters, which leads to the creation of a pair of words that is 
referenced to a point in the process that can potentially fail. As a result of using this 
method, a table is created that includes situations, which can cause a failure, 
together with its consequences and specific causes. However, this is a 
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time-consuming and labor-intensive method and as such it generates considerable 
costs [20]. The process map is a technique based on a graphical representation of the 
functioning of a set of processes and their mutual relationships. The fault tree 
analysis (FTA) has been developed for the aviation industry and is a deductive 
method that assumes the occurrence of a defect in process functionality and can 
link multiple causes to identify the cause-and-effect chain. Failure mode and effects 
analysis (FMEA) is mainly focused on the optimization of the product and is 
particularly recommended in the situation of new product introduction because it 
allows for the recognition of the potential interfering factors. As a result of this 
quantitative method, we obtain the so-called risk priority number (RPN) and 
information about strong and weak points of production. The criticality of the 
defect is calculated, and the higher the calculated parameter, the greater the risk 
associated with the defect. After identifying the risks and weaknesses of the process 
and their characterization, decisions should be made on which risks should be 
reduced and which should be observed or eliminated. Controlling risks is a techno-
logical and economic challenge. Before making any changes, an assessment must be 
performed to ensure that the proposed change will not cause any new or unex-
pected risks. The fact that a change is inevitable makes it a critical factor, especially 
in GMP and ISO environments, where inappropriate or “uncontrolled” changes can 
affect patient safety and public health. For this reason, the concept of change 
control is closely related to compliance with GMP and ISO, where any changes in 
production and processes must be controlled. Change control procedures must be 
recorded in order to standardize the workflow, especially at key stages such as 
collecting material outside the production environment. The “uncontrolled” change 
refers to modifications made without verification and approval by the quality 
control manager and in special cases also the hospital management. In GMP and 
ISO environments, strict adherence to approved policies and procedures is a key 
factor in maintaining production efficiency in a controlled state, and change control 
is critical. Changes are subject to review and approval by the quality control unit. To 
summarize, GMP is a formalized procedure and imposes a heavy burden on the 
producer of transplants, and while compliance is a required minimum, it is not 
enough to ensure the right quality of using the manufactured products [18]. The 
specificity of risk management in the aspect of GMP consists in focusing on poten-
tial failures in the production of transplants and their safety for the patient. RBV 
refers to a broader management area including risk management at the time of 
collecting cellular material and its transplantation as well as the patient’s fate. 
However, some authors point to limitations in the application of resource manage-
ment in the public health service [8] due to the complex nature of such entities. 
Lean management possesses tools that are able to systematize it [21].
5. Production management
The tissue bank is the place for graft preparation for the treatment of patients 
with severe burns and chronic wounds. As already mentioned, the preparations 
produced in our bank are biostatic grafts, which are subject to radiation sterilization 
and live cell transplants, produced under sterile conditions. Due to the specificity 
of the products manufactured in the laboratories, appropriate, supervised envi-
ronmental conditions must be ensured. For this purpose, we use “clean rooms,” in 
which, thanks to the use of special HEPA filters and laminar air vents, it is possible 
to obtain the appropriate class of air purity. The highest class achieved in our bank 
is air purity class A achieved under the laminar chamber, where the amount of 
particles and microorganisms generated during operation should be zero. In order 
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to provide such sterile and dust-free conditions in air purity class A, the rooms 
located on the way to a class A clean room must meet a series of criteria. The main 
one is the maintenance of a pressure cascade, which means that in order to get to 
a class A clean room, you have to go through several airlocks separating neighbor-
ing rooms of the following purity class: gray (of the least air purity) D, C, and 
B. Positive pressure is maintained in each airlock in relation to the previous lock, 
employees wear dust-free and sterile clothes and gloves, and, finally, in the class B 
air purity room, they put on a sterile dust-free clean room suit covering their entire 
body. All these precautions are necessary because we want to protect the product we 
manufacture, i.e., the advanced therapy medicinal product in the form of cultured 
skin cells. The cultures that we prepare are supervised by the Main Pharmaceutical 
Inspector; therefore, as mentioned above, they must be prepared in accordance 
with good manufacturing practice (GMP). The requirements that we must meet 
in order to culture cells for a burn patient make all the preparations leading to 
the process initiation strategic. It should be noted that employees and resources 
(reagents and consumables) in the laboratory are in a constant state of readiness. 
At the same time, we are not able to estimate with 100% certainty whether, at a 
given time, we are going to culture cells at all and, if so, for how many patients. The 
unpredictability of the production process (cell culture) in the face of the risk of 
expiry of reagents necessary for maintaining production continuity means that a 
compromise must be found consisting in the continuous maintenance of small-scale 
stock of culture materials. The greater part of consumables used in the preparation 
of medicinal products is highly specialized and is not widely available, and the 
delivery of a larger quantity often takes a long time. Therefore, ensuring constant 
availability of materials seems to be one of the solutions enabling continuity of pro-
duction. However, lean management requires keeping losses to a minimum, which 
is, in a way, contrary to the GMP assumptions making production halt risk minimi-
zation a priority. A common-sense approach should therefore be applied translating 
into ensuring the minimum amount of reagents that is sufficient to maintain the 
continuity of production, even in the case of mass events, such as an explosion in a 
coal mine, when mass production of cellular grafts must be available immediately.
In the case of maintaining sterile environmental conditions, it is also important 
to systematically and periodically perform cleaning and disinfection of rooms 
according to the adopted schedule. It is also necessary to permanently perform 
environmental monitoring: continuous monitoring of the amount of particles in 
class B rooms, as well as microbiological tests of air and clean room surfaces, carried 
out according to schedule. Control and supervision are also applied to devices used 
for cell culture and the conditions prevailing in them, e.g., the devices that are 
critical in the production process—incubators. A monitoring system is installed 
in the rooms. It monitors the environment and notifies employees supervising cell 
cultures about the occurrence of errors in the culture process. Such monitoring is 
necessary because it allows for quick response and taking action in the event of a 
risk of culture loss.
Highly specialized persons who have acquired appropriate skills in numer-
ous training sessions are assigned to work in the clean rooms. Their professional 
experience and the ability to organize and manage their working time are also 
important. Due to the specifics of the work—a sterile, monitored and supervised 
environment in a clean room—each entrance to such rooms generates additional 
costs. That is why, employees working with cell cultures must carefully consider, 
plan, and organize all elements of their work in the laboratory before it begins. 
Employees involved in the preparation of cell cultures follow the applicable, written 
procedures and validated processes. Most processes should be validated based on 
reference reagents; however, the tissue material from which the cells are isolated 
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to provide such sterile and dust-free conditions in air purity class A, the rooms 
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(reagents and consumables) in the laboratory are in a constant state of readiness. 
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duction. However, lean management requires keeping losses to a minimum, which 
is, in a way, contrary to the GMP assumptions making production halt risk minimi-
zation a priority. A common-sense approach should therefore be applied translating 
into ensuring the minimum amount of reagents that is sufficient to maintain the 
continuity of production, even in the case of mass events, such as an explosion in a 
coal mine, when mass production of cellular grafts must be available immediately.
In the case of maintaining sterile environmental conditions, it is also important 
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environmental monitoring: continuous monitoring of the amount of particles in 
class B rooms, as well as microbiological tests of air and clean room surfaces, carried 
out according to schedule. Control and supervision are also applied to devices used 
for cell culture and the conditions prevailing in them, e.g., the devices that are 
critical in the production process—incubators. A monitoring system is installed 
in the rooms. It monitors the environment and notifies employees supervising cell 
cultures about the occurrence of errors in the culture process. Such monitoring is 
necessary because it allows for quick response and taking action in the event of a 
risk of culture loss.
Highly specialized persons who have acquired appropriate skills in numer-
ous training sessions are assigned to work in the clean rooms. Their professional 
experience and the ability to organize and manage their working time are also 
important. Due to the specifics of the work—a sterile, monitored and supervised 
environment in a clean room—each entrance to such rooms generates additional 
costs. That is why, employees working with cell cultures must carefully consider, 
plan, and organize all elements of their work in the laboratory before it begins. 
Employees involved in the preparation of cell cultures follow the applicable, written 
procedures and validated processes. Most processes should be validated based on 
reference reagents; however, the tissue material from which the cells are isolated 
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and the culture is established is so unique that it is not possible to replace it with 
the reference material. Therefore, all employees must comply with specific require-
ments. In standard work, it is important not only to maintain the purity and sterility 
of the cell culture and the rooms but also to ensure that all necessary reagents and 
materials are available in the laboratory. The duty of employees leaving the labora-
tory is to supplement, prepare, or provide information on missing items to all 
persons involved in the cell culture process. Each employee entering the laboratory 
studio must be sure that he or she will be able to perform all the tasks without any 
problems. Due to the need to monitor and maintain room sterility, any unneces-
sary entering and exiting the clean room creates a risk of pollution and generates 
costs of, among other things, used protective clothing and cleaning agents. All 
these activities are aimed at ensuring the sterility of the advanced therapy medici-
nal product manufactured in the tissue bank. Figure 2 shows the increase in the 
number of cultures and autologous skin cell transplantations. This increase has 
been possible thanks to the standardization of production processes that has been 
achieved by minimizing material losses. The lean and TOC management methods 
contributed to the increase in the number of cultures, which made better manage-
ment of laboratory resources possible.
As mentioned above, cell cultures can be established after the occurrence of a 
mass event, e.g., an explosion in a coal mine or a large fire, in which more people 
suffer burns. In such a situation, our only safeguard that makes it possible to take 
appropriate action is to keep reagents and consumables in the laboratory. In such 
cases, the experience of employees and cooperation with other hospital depart-
ments are very important. This allows for the planning of a strategic approach to the 
problem, which goes beyond the GMP management area, and still requires manage-
ment and control. Establishing a cell culture is conditioned not only by securing the 
necessary reagents and materials but also by providing care for the most disadvan-
taged patients, which results from the efficient operation of the hospital, reinforced 
by the management system. In such cases, it is also important to adopt the right 
approach and plan the work of all personnel to avoid unwanted cross-infection or 
contamination, which could result in the loss of valuable cell culture. The resource-
based view (RBV) approach seems to be necessary to manage the aspects that are 
not covered by the GMP procedures.
The preparation of biostatic skin and human amnion grafts is much less 
restrictive. These are grafts, in which the final stage of preparation is radiation 
Figure 2. 
Number of cultured and transplanted autologous skin cell cultures in years 2008–2018.
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sterilization. This means that these transplants are not live and constitute only a 
temporary dressing. Due to the fact of sterilization, the grafts are also prepared 
in clean rooms, under the laminar chamber of class A air purity, but in the class 
C environment. When preparing tissue transplants, employees also use their 
experience in managing their working time, maintaining cleanliness and order 
in the laboratory and good manufacturing practice. These skills are very useful 
and promote continuous improvement of the produced grafts and production 
efficiency. The chart in Figure 3 shows the increase in the surface area of biostatic 
amniotic and dermal grafts prepared in particular years. The use of a resource 
management approach, among others, has enabled the increase in productivity, 
which translates into the surface area (cm2) of the prepared tissue and cellular 
grafts. The increasing number of donors, and hence the amount of documenta-
tion to complete, makes it necessary to adopt a strategic approach to the work so 
that as much work as possible can be performed at the same time, thus generating 
added value.
6.  Strategic potential of a tissue bank in terms of validation of processes 
and qualification of equipment and rooms
Tissue bank management requires well-established, thorough knowledge of the 
processes occurring in the area of clean room production. In this respect, the key 
issue for a tissue bank, as mentioned above, is to have adequately qualified person-
nel and therefore human resources possessing the required education, experi-
ence, competences, and abilities. The second important element in the process of 
managing a tissue bank is the possession of appropriate devices and rooms, i.e., 
the hardware and accommodation resources. User requirements for hardware and 
accommodation resources should be characterized and defined in detail. These 
elements, in the RBV approach, can be collectively referred to as strategic potential. 
In general terms, the strategic potential is a factor influencing the tissue bank’s 
achievement of the expected results. The key effects include the ability to use 
resources to achieve the intended targets and, therefore, obtain the highest quality 
product according to the tested, repeatable, and effective production methodology 
using adequately verified equipment and rooms.
Figure 3. 
The surface area of prepared skin and amniotic grafts in years 2009–2018.
Biochemical Testing - Clinical correlation and Diagnosis
150
and the culture is established is so unique that it is not possible to replace it with 
the reference material. Therefore, all employees must comply with specific require-
ments. In standard work, it is important not only to maintain the purity and sterility 
of the cell culture and the rooms but also to ensure that all necessary reagents and 
materials are available in the laboratory. The duty of employees leaving the labora-
tory is to supplement, prepare, or provide information on missing items to all 
persons involved in the cell culture process. Each employee entering the laboratory 
studio must be sure that he or she will be able to perform all the tasks without any 
problems. Due to the need to monitor and maintain room sterility, any unneces-
sary entering and exiting the clean room creates a risk of pollution and generates 
costs of, among other things, used protective clothing and cleaning agents. All 
these activities are aimed at ensuring the sterility of the advanced therapy medici-
nal product manufactured in the tissue bank. Figure 2 shows the increase in the 
number of cultures and autologous skin cell transplantations. This increase has 
been possible thanks to the standardization of production processes that has been 
achieved by minimizing material losses. The lean and TOC management methods 
contributed to the increase in the number of cultures, which made better manage-
ment of laboratory resources possible.
As mentioned above, cell cultures can be established after the occurrence of a 
mass event, e.g., an explosion in a coal mine or a large fire, in which more people 
suffer burns. In such a situation, our only safeguard that makes it possible to take 
appropriate action is to keep reagents and consumables in the laboratory. In such 
cases, the experience of employees and cooperation with other hospital depart-
ments are very important. This allows for the planning of a strategic approach to the 
problem, which goes beyond the GMP management area, and still requires manage-
ment and control. Establishing a cell culture is conditioned not only by securing the 
necessary reagents and materials but also by providing care for the most disadvan-
taged patients, which results from the efficient operation of the hospital, reinforced 
by the management system. In such cases, it is also important to adopt the right 
approach and plan the work of all personnel to avoid unwanted cross-infection or 
contamination, which could result in the loss of valuable cell culture. The resource-
based view (RBV) approach seems to be necessary to manage the aspects that are 
not covered by the GMP procedures.
The preparation of biostatic skin and human amnion grafts is much less 
restrictive. These are grafts, in which the final stage of preparation is radiation 
Figure 2. 
Number of cultured and transplanted autologous skin cell cultures in years 2008–2018.
151
Resource-Based View of Laboratory Management: Tissue Bank ATMP Production as a Model
DOI: http://dx.doi.org/10.5772/intechopen.86561
sterilization. This means that these transplants are not live and constitute only a 
temporary dressing. Due to the fact of sterilization, the grafts are also prepared 
in clean rooms, under the laminar chamber of class A air purity, but in the class 
C environment. When preparing tissue transplants, employees also use their 
experience in managing their working time, maintaining cleanliness and order 
in the laboratory and good manufacturing practice. These skills are very useful 
and promote continuous improvement of the produced grafts and production 
efficiency. The chart in Figure 3 shows the increase in the surface area of biostatic 
amniotic and dermal grafts prepared in particular years. The use of a resource 
management approach, among others, has enabled the increase in productivity, 
which translates into the surface area (cm2) of the prepared tissue and cellular 
grafts. The increasing number of donors, and hence the amount of documenta-
tion to complete, makes it necessary to adopt a strategic approach to the work so 
that as much work as possible can be performed at the same time, thus generating 
added value.
6.  Strategic potential of a tissue bank in terms of validation of processes 
and qualification of equipment and rooms
Tissue bank management requires well-established, thorough knowledge of the 
processes occurring in the area of clean room production. In this respect, the key 
issue for a tissue bank, as mentioned above, is to have adequately qualified person-
nel and therefore human resources possessing the required education, experi-
ence, competences, and abilities. The second important element in the process of 
managing a tissue bank is the possession of appropriate devices and rooms, i.e., 
the hardware and accommodation resources. User requirements for hardware and 
accommodation resources should be characterized and defined in detail. These 
elements, in the RBV approach, can be collectively referred to as strategic potential. 
In general terms, the strategic potential is a factor influencing the tissue bank’s 
achievement of the expected results. The key effects include the ability to use 
resources to achieve the intended targets and, therefore, obtain the highest quality 
product according to the tested, repeatable, and effective production methodology 
using adequately verified equipment and rooms.
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The expected effects are, therefore, the result of the tissue bank’s implementation 
of adequately planned tasks. These tasks are directly related to the achievement of 
the intended objective. In this respect, the achieved production effects are the so-
called determinants of a tissue bank success. We use this expression to appropriately 
define the ranges and criteria of acceptance that a given tissue bank product must 
meet before a batch is released to distribution. These criteria must be strictly defined 
in the production specification. Moreover, in addition to the so-called determinants 
of success, so-called success factors must also be defined. These factors result from 
adequately defined and purposefully adopted strategic potentials of the tissue bank. 
The strategic potentials include in particular the professional experience of human 
resources. Based on specific experience and “know-how,” appropriate operational 
procedures should be created for all activities performed in the tissue bank. However, 
the final adoption of all the proposed solutions (e.g., methodological, analytical, 
and technological) requires evaluation that is very carefully planned and analyzed in 
terms of the correctness of the adopted assumptions. This means that each parameter 
that constitutes a specific stage or the whole of a given process must be subject to con-
trol in terms of meeting the expected assumptions. In case of changes in the specified 
parameter or parameters, a whole evaluation of the process must be repeated.
Procedures related to the evaluation of processes executed in the tissue bank are 
called validation procedures. In this respect, special consideration should be given 
to the validation of the manufacturing process of the hospital-exemption advanced 
therapy medicinal product (HE-ATMP), the process of manufacturing medical 
devices, tissue transplants, transport of these products, cleaning, and disinfection, 
including employee clothing. However, by contrast, the evaluation procedures 
related to the correct functioning of devices and rooms are called qualification 
procedures. In this respect, it should be clearly emphasized that the qualification 
of devices and rooms covers the entirety of undertakings related to the purchase, 
installation, and operation of a given device or room, starting from specifying the 
user’s specific requirements to determining the conformity of the proposed prelimi-
nary design with the requirements, to subsequent processes confirming the compli-
ance regarding the installation and proper functioning.
6.1 Main validation plan
The main validation plan (MVP) defines the approach to the qualification/valida-
tion of GMP areas for all validation activities carried out in the existing or newly 
designed premises of a tissue bank. It is aimed at ensuring that the expectations have 
been clearly communicated to all participants implementing the validation program. 
The MVP clearly and comprehensively defines the requirements and scope of responsi-
bility in the validation process. The main objectives and tasks of the MVP are as follows:
1. Presentation of policy, requirements, and expectations regarding the valida-
tion activities in laboratory rooms where the tasks related to the production of 
advanced therapy medicinal products, HE-ATMP, analysis and quality control, 
as well as research and development work are performed
2. Defining the organizational structure of validation activities
3. A brief description of the installations, systems, and devices that will be 
validated with reference to the existing documents
4. Specification of the format of the validation documentation used in the 
protocols and reports
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5. Outlining the validation strategy and indicating the documents defining the 
task and scope of responsibility for the tissue bank, contractors and suppliers 
of particular systems, installations, and process equipment
6. Presentation of the approach to change control
7. Drawing up a plan and scheduling validation activities
8. Ensuring consistent application of the terms in accordance with their estab-
lished definitions (in documents such as the standard operating procedures 
(SOPs), validation protocols, etc.)
The MPV contains general guidelines for the preparation of other validation 
documents. Rational principles and a rational approach when using the MPV are 
recommended. In the event of circumstances unforeseen in the plan, the rationale 
and assessment of the deviation must be documented.
Validation/qualification activities will be carried out depending on the subject of 
validation/qualification and on the nature of the activities performed by the valida-
tion team appointed by the qualified/competent/responsible person to perform spe-
cific tasks. The validation team may consist of representatives of quality assurance, 
tissue bank user/manager, technical and technological experts, and quality control.
This approach to validation and carrying out validation work fulfills the regula-
tions and guidelines specified in the European Commission Directive 2003/94/
EC and the Regulation of the Minister of Health of October 1, 2008, on the 
requirements of good manufacturing practice (Journal of Laws 2008.184.1143) as 
amended. Validation is an action aimed at confirming, in a documented manner and 
in accordance with the principles of RBV and good manufacturing practice, those 
procedures, processes, devices, materials, activities, systems, and installations truly 
lead to planned results. This is achieved through the development of test plans, 
protocols, and procedures, as well as the implementation of the records made in the 
protocols and the documentation of the results obtained in the intermediate and 
final reports. The report is an approved written plan of the measurement, control, 
and methodology of testing and result documentation. The verification and valida-
tion of the qualification and validation documentation are performed in accordance 
with the internal procedure prior to the initiation of the qualification/validation 
activities. In any case, the validation activities performed by external companies 
must be supervised by an appropriate employee of the tissue bank and are subject 
to acceptance and approval by tissue bank employees. The same persons and the 
persons performing the tests (other than those included in the validation team) also 
check and approve the reports from a given qualification/validation phase following 
the tests, in order to confirm that the production environment, devices, and the 
process are indeed suitable for the production of HE-ATMP, medical devices, tissue 
grafts, etc., in the tissue bank and that they meet the requirements of good manu-
facturing practice. The full set of qualification and validation documents consists of 
protocols and test cards.
The installation qualification (IQ ) protocols pertaining to the equipment, instal-
lations, and clean rooms, similar to the operational qualification (OQ ) protocols of 
these systems, are developed for all critical modules of systems, installations, and 
devices.
The process qualification (PQ ) protocols are developed only for those systems, 
installations, or devices for which their operation data are necessary to verify the 
correctness of the process and for which long-term monitoring of their perfor-
mance is recommended (e.g., laminar chamber, CO2 incubator, bioreactor, and 
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lished definitions (in documents such as the standard operating procedures 
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documents. Rational principles and a rational approach when using the MPV are 
recommended. In the event of circumstances unforeseen in the plan, the rationale 
and assessment of the deviation must be documented.
Validation/qualification activities will be carried out depending on the subject of 
validation/qualification and on the nature of the activities performed by the valida-
tion team appointed by the qualified/competent/responsible person to perform spe-
cific tasks. The validation team may consist of representatives of quality assurance, 
tissue bank user/manager, technical and technological experts, and quality control.
This approach to validation and carrying out validation work fulfills the regula-
tions and guidelines specified in the European Commission Directive 2003/94/
EC and the Regulation of the Minister of Health of October 1, 2008, on the 
requirements of good manufacturing practice (Journal of Laws 2008.184.1143) as 
amended. Validation is an action aimed at confirming, in a documented manner and 
in accordance with the principles of RBV and good manufacturing practice, those 
procedures, processes, devices, materials, activities, systems, and installations truly 
lead to planned results. This is achieved through the development of test plans, 
protocols, and procedures, as well as the implementation of the records made in the 
protocols and the documentation of the results obtained in the intermediate and 
final reports. The report is an approved written plan of the measurement, control, 
and methodology of testing and result documentation. The verification and valida-
tion of the qualification and validation documentation are performed in accordance 
with the internal procedure prior to the initiation of the qualification/validation 
activities. In any case, the validation activities performed by external companies 
must be supervised by an appropriate employee of the tissue bank and are subject 
to acceptance and approval by tissue bank employees. The same persons and the 
persons performing the tests (other than those included in the validation team) also 
check and approve the reports from a given qualification/validation phase following 
the tests, in order to confirm that the production environment, devices, and the 
process are indeed suitable for the production of HE-ATMP, medical devices, tissue 
grafts, etc., in the tissue bank and that they meet the requirements of good manu-
facturing practice. The full set of qualification and validation documents consists of 
protocols and test cards.
The installation qualification (IQ ) protocols pertaining to the equipment, instal-
lations, and clean rooms, similar to the operational qualification (OQ ) protocols of 
these systems, are developed for all critical modules of systems, installations, and 
devices.
The process qualification (PQ ) protocols are developed only for those systems, 
installations, or devices for which their operation data are necessary to verify the 
correctness of the process and for which long-term monitoring of their perfor-
mance is recommended (e.g., laminar chamber, CO2 incubator, bioreactor, and 
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refrigerator-freezer). Systems, installations, or devices for which PQ activities are 
necessary will be selected at the risk analysis (RA) stage. Any noncompliance with 
the conditions set out in the protocols encountered during the validation process 
will be recorded and evaluated. The registered nonconformities will be analyzed, 
and then the actions regarding the manner of further dealing with the noncon-
formities (e.g., the development of justification/explanation, making corrections, 
and then carrying out reclassification tests) will be defined. All such data will be 
documented and saved. The obtained results will be collected and presented in 
relevant reports after the completion of each qualification stage.
6.2 Approach to validation
Validation of rooms, devices, systems, and installations used in production 
carried out in the tissue bank constitutes a part of the quality assurance policy of 
the entire enterprise (tissue bank, hospital, and biotechnological or pharmaceuti-
cal company). Qualification/validation activities and the creation of appropriate 
documentation must be carried out in accordance with the qualification/validation 
schedule by tissue bank representatives, suppliers of installations, systems, process 
equipment, and/or contractors providing validation services. Supervision and coor-
dination of qualification/validation activities should be carried out by a tissue bank 
representative. Validation teams and validation contractors are required to develop 
a series of protocols to check all critical parameters of rooms, systems, installations, 
and devices in the tissue bank. The protocols will be implemented in accordance 
with the test methods presented in the protocols. Each protocol will be used to 
obtain documentation that will confirm the compliance of the system, installation, 
or device with the GMP guidelines. To qualify equipment, rooms, and installations, 
the documents obtained after carrying out the service activities can be used. All 
protocols and reports will be archived after their final approval.
It should be emphasized that conducting validation cannot negatively affect the 
production process. In addition, special attention should be paid to the timely per-
formance of validation work, and subsequent planned validation activities related 
to a given device, room, etc., should be carried out within the prescribed time 
limit. However, it is possible that the deadline of the next validation is not met. This 
disadvantageous situation may occur due to a number of possible occurrences that 
may affect the feasibility of performing validation work. The factors affecting the 
performed validation work time shift include, among others, production, sickness 
of the person performing the validation, mechanical failure, etc. The information 
about the validation time shift must be included in the validation protocol.
In order to summarize and approve the completion of individual stages of quali-
fication/validation activities, appropriate reports are prepared, which are checked 
and approved by appropriate persons. The report must include a summary of the 
qualification/validation course, a description of test results, and documented, 
explained, and evaluated nonconformities. After the approval of the report, if no 
critical nonconformities were found or all critical nonconformities were resolved, 
you are allowed to proceed to the next qualification/validation phase.
6.3 Summary
The activities related to the performance of validation/qualification activities are 
aimed at ensuring the highest quality of the tissue bank products being developed. 
They take place in accordance with RBV and with the optimal use of the strate-
gic potential of the laboratory. The approach to validation is part of the broadly 
understood RBV, which results from the conscious management of the unit using 
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knowledge and science. The validation and qualification activities are necessary to 
verify the adopted methods and the continuous improvement of processes. This, in 
turn, fits into modern management systems using the PDCA or DMAIC approach, 
based on a thorough analysis of a given process and a thorough problem solution. It 
should also be emphasized that the validation activities require the involvement of 
appropriately qualified personnel, which will contribute to ensuring high quality 
and safety of the obtained products.
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equipment, and/or contractors providing validation services. Supervision and coor-
dination of qualification/validation activities should be carried out by a tissue bank 
representative. Validation teams and validation contractors are required to develop 
a series of protocols to check all critical parameters of rooms, systems, installations, 
and devices in the tissue bank. The protocols will be implemented in accordance 
with the test methods presented in the protocols. Each protocol will be used to 
obtain documentation that will confirm the compliance of the system, installation, 
or device with the GMP guidelines. To qualify equipment, rooms, and installations, 
the documents obtained after carrying out the service activities can be used. All 
protocols and reports will be archived after their final approval.
It should be emphasized that conducting validation cannot negatively affect the 
production process. In addition, special attention should be paid to the timely per-
formance of validation work, and subsequent planned validation activities related 
to a given device, room, etc., should be carried out within the prescribed time 
limit. However, it is possible that the deadline of the next validation is not met. This 
disadvantageous situation may occur due to a number of possible occurrences that 
may affect the feasibility of performing validation work. The factors affecting the 
performed validation work time shift include, among others, production, sickness 
of the person performing the validation, mechanical failure, etc. The information 
about the validation time shift must be included in the validation protocol.
In order to summarize and approve the completion of individual stages of quali-
fication/validation activities, appropriate reports are prepared, which are checked 
and approved by appropriate persons. The report must include a summary of the 
qualification/validation course, a description of test results, and documented, 
explained, and evaluated nonconformities. After the approval of the report, if no 
critical nonconformities were found or all critical nonconformities were resolved, 
you are allowed to proceed to the next qualification/validation phase.
6.3 Summary
The activities related to the performance of validation/qualification activities are 
aimed at ensuring the highest quality of the tissue bank products being developed. 
They take place in accordance with RBV and with the optimal use of the strate-
gic potential of the laboratory. The approach to validation is part of the broadly 
understood RBV, which results from the conscious management of the unit using 
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knowledge and science. The validation and qualification activities are necessary to 
verify the adopted methods and the continuous improvement of processes. This, in 
turn, fits into modern management systems using the PDCA or DMAIC approach, 
based on a thorough analysis of a given process and a thorough problem solution. It 
should also be emphasized that the validation activities require the involvement of 
appropriately qualified personnel, which will contribute to ensuring high quality 
and safety of the obtained products.
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